**NRG ONCOLOGY**

**RTOG 0924**

**ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL**

This trial is part of the National Clinical Trials Network (NCTN) program, which is sponsored by the National Cancer Institute (NCI). The trial will be led by NRG Oncology with the participation of the network of NCTN researchers: the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and SWOG.

**Study Team (4/27/15)**

<table>
<thead>
<tr>
<th><strong>Principal Investigator/Radiation Oncology</strong></th>
<th><strong>High Dose Rate Brachytherapy Co-Chair</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mack Roach III, MD</td>
<td>I-Chow Hsu, MD</td>
</tr>
<tr>
<td>UCSF, Department of Radiation Oncology</td>
<td>UCSF, Department of Radiation Oncology</td>
</tr>
<tr>
<td>1600 Divisadero Street</td>
<td>1600 Divisadero Street Suite H1031</td>
</tr>
<tr>
<td>San Francisco, CA 94143-1708</td>
<td>San Francisco, CA 94143-1708</td>
</tr>
<tr>
<td>Phone: 415-353-7181/Fax: 415-353-7182</td>
<td>Phone: 415-353-7175/Fax: 415-353-9883</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:mroach@radonc.ucsf.edu">mroach@radonc.ucsf.edu</a></td>
<td>E-mail: <a href="mailto:ihsu@radonc.ucsf.edu">ihsu@radonc.ucsf.edu</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Intensity Modulated Radiotherapy Co-Chair</strong></th>
<th><strong>Low Dose Rate Brachytherapy Co-Chair</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hans Chung, MD</td>
<td>Gerard Morton, MD</td>
</tr>
<tr>
<td>Toronto-Sunnybrook Regional Cancer Center</td>
<td>Toronto-Sunnybrook Regional Cancer Center</td>
</tr>
<tr>
<td>Department of Radiation Oncology</td>
<td>Department of Radiation Oncology</td>
</tr>
<tr>
<td>2075 Bayview Avenue</td>
<td>2075 Bayview Ave.</td>
</tr>
<tr>
<td>Toronto, ON M4N 3M5 CANADA</td>
<td>Toronto, ON M4N 3M5 CANADA</td>
</tr>
<tr>
<td>Phone: 416-480-4834/Fax: 416-480-6002</td>
<td>Phone: 416-480-6165/Fax: 416-480-6002</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:hans.chung@sunnybrook.ca">hans.chung@sunnybrook.ca</a></td>
<td>E-mail: <a href="mailto:gerard.morton@sunnybrook.ca">gerard.morton@sunnybrook.ca</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Intensity Modulated Radiotherapy Co-Chair</strong></th>
<th><strong>Medical Physics Co-Chair</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Albert J. Chang, M.D., Ph.D.</td>
<td>Robert E. Wallace, PhD</td>
</tr>
<tr>
<td>University of California, San Francisco</td>
<td>Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>Department of Radiation Oncology</td>
<td>Department of Radiation Oncology</td>
</tr>
<tr>
<td>1600 Divisadero St. Suite H-1031</td>
<td>8700 Beverly Boulevard, AC1085A</td>
</tr>
<tr>
<td>San Francisco, CA 94115</td>
<td>Los Angeles, CA 90048</td>
</tr>
<tr>
<td>Phone: 415-353-9895/Fax: 415-353-9883</td>
<td>Phone: 310-423-6649/Fax: 310-659-3332</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:ChangAJ@radonc.ucsf.edu">ChangAJ@radonc.ucsf.edu</a></td>
<td>E-mail: <a href="mailto:robert.wallace@cshs.org">robert.wallace@cshs.org</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Urology Co-Chair</strong></th>
<th><strong>Outcomes/Quality of Life Co-Chair</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonard G. Gomella, MD, FACS</td>
<td>Ben Movsas, MD</td>
</tr>
<tr>
<td>Department of Urology</td>
<td>Henry Ford Health System</td>
</tr>
<tr>
<td>Kimmel Cancer Center</td>
<td>2799 W. Grand Boulevard</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td>Detroit, MI 48202</td>
</tr>
<tr>
<td>1025 Walnut Street, 1102</td>
<td>Phone: 313-916-5188/Fax: 313-916-3235</td>
</tr>
<tr>
<td>Philadelphia, PA 19107</td>
<td>E-mail: <a href="mailto:bmovsas1@hfhs.org">bmovsas1@hfhs.org</a></td>
</tr>
<tr>
<td>Phone: 215-955-1702/Fax: 215-923-1884</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:leonard.gomella@jefferson.edu">leonard.gomella@jefferson.edu</a></td>
<td></td>
</tr>
</tbody>
</table>

Study Team continued on next page
NRG ONCOLOGY
RTOG 0924

ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL

RTOG 0924 Study Team continued (4/27/15)

<table>
<thead>
<tr>
<th>Outcomes/Utilities Co-Chair</th>
<th>Correlative Science Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah Watkins Bruner, RN, PhD, FAAN</td>
<td>Jeffry P. Simko, MD, PhD</td>
</tr>
<tr>
<td>Nell Hodgson Woodruff School of Nursing</td>
<td>NRG Oncology Biospecimen Bank</td>
</tr>
<tr>
<td>Emory University</td>
<td>2340 Sutter Street, Room S341</td>
</tr>
<tr>
<td>1520 Clifton Road, Room 232</td>
<td>UCSF Helen Diller Family Comprehensive</td>
</tr>
<tr>
<td>Atlanta, GA 30322</td>
<td>Cancer Center, San Francisco, CA 94115</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:deborah.w.bruner@emory.edu">deborah.w.bruner@emory.edu</a></td>
<td>Fax: 415-476-5271</td>
</tr>
<tr>
<td></td>
<td>E-mail: <a href="mailto:Jeff.Simko@ucsf.edu">Jeff.Simko@ucsf.edu</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes/Fatigue Co-Chair</th>
<th>Correlative Science Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea M. Barsevick, PhD, RN, FAAN</td>
<td>Barry S. Rosenstein, PhD</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td>Department of Radiation Oncology, Box 1236</td>
</tr>
<tr>
<td>Department of Medical Oncology</td>
<td>Mount Sinai School of Medicine</td>
</tr>
<tr>
<td>Population Science Division</td>
<td>One Gustave Levy Place</td>
</tr>
<tr>
<td>834 Chestnut Street, Suite 314</td>
<td>New York, NY 10029</td>
</tr>
<tr>
<td>Philadelphia PA 19107</td>
<td>Phone: 212-241-9408/Fax: 212-996-8927</td>
</tr>
<tr>
<td>Phone: 215-503-4623/Fax: 503-9506</td>
<td>E-mail: <a href="mailto:barry.rosenstein@mssm.edu">barry.rosenstein@mssm.edu</a></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:Andrea.Barsevick@jefferson.edu">Andrea.Barsevick@jefferson.edu</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes/Translational Co-Chair</th>
<th>Senior Statistician</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah Citrin, MD</td>
<td>Qiang Zhang, PhD</td>
</tr>
<tr>
<td>Radiation Oncology Branch</td>
<td>NRG Oncology</td>
</tr>
<tr>
<td>National Cancer Institute</td>
<td>1818 Market Street, Suite 1720</td>
</tr>
<tr>
<td>10 CRC, B2-3500</td>
<td>Philadelphia, PA 19103</td>
</tr>
<tr>
<td>10 Center Drive</td>
<td>Phone: 215-574-3197/Fax: 215-928-0153</td>
</tr>
<tr>
<td>Bethesda, MD 20892</td>
<td>E-mail: <a href="mailto:ZhangQ@nrgoncology.org">ZhangQ@nrgoncology.org</a></td>
</tr>
<tr>
<td>Phone: 301-496-5457/Fax: 301-480-5439</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:citrind@mail.nih.gov">citrind@mail.nih.gov</a></td>
<td></td>
</tr>
</tbody>
</table>

### Protocol Agents

<table>
<thead>
<tr>
<th>Agent</th>
<th>Supply</th>
<th>NSC #</th>
<th>IND #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bicalutamide, Flutamide, Leuprolide, Goserelin, Buserelin, Triptorelin Degarelix</td>
<td>Commercial</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

RTOG 0924, Version Date: 4/20/16
NRG ONCOLOGY

RTOG 0924

ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL

Participating Sites

☑️ U.S. and Canada
☑️ Approved International Member Sites

Document History

<table>
<thead>
<tr>
<th>Amendment/Update</th>
<th>Version/Update Date</th>
<th>Broadcast Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment 3</td>
<td>April 20, 2016</td>
<td>May 16, 2016</td>
</tr>
<tr>
<td>Amendment 2</td>
<td>April 27, 2015</td>
<td>May 26, 2015</td>
</tr>
<tr>
<td>Amendment 1</td>
<td>February 26, 2014</td>
<td>April 22, 2014</td>
</tr>
<tr>
<td>Update</td>
<td>February 11, 2014</td>
<td>February 11, 2014</td>
</tr>
<tr>
<td>Activation</td>
<td>June 16, 2011</td>
<td>July 7, 2011</td>
</tr>
</tbody>
</table>

NRG Oncology
1-800-227-5463, ext. 4189

This protocol was designed and developed by NRG Oncology. It is intended to be used only in conjunction with institution-specific IRB approval for study entry. No other use or reproduction is authorized by NRG Oncology nor does NRG Oncology assume any responsibility for unauthorized use of this protocol.
NRG ONCOLOGY
RTOG 0924

ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL

<table>
<thead>
<tr>
<th>CANCER TRIALS SUPPORT UNIT (CTSU) CONTACT INFORMATION (4/27/15)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>To submit site registration documents:</strong></td>
</tr>
<tr>
<td>CTSU Regulatory Office</td>
</tr>
<tr>
<td>1818 Market Street, Suite 1100</td>
</tr>
<tr>
<td>Philadelphia, PA 19103</td>
</tr>
<tr>
<td>Phone: 1-866-651-CTSU</td>
</tr>
<tr>
<td>Fax: 215-569-0206</td>
</tr>
<tr>
<td>Email: <a href="mailto:CTSURegulatory@ctsu.coccg.org">CTSURegulatory@ctsu.coccg.org</a> for submitting regulatory documents only</td>
</tr>
<tr>
<td>For patient enrollments:</td>
</tr>
<tr>
<td>Please refer to the patient enrollment section for instructions on using the OPEN system.</td>
</tr>
<tr>
<td>Contact the CTSU Help Desk with any OPEN-related questions at <a href="mailto:ctsucontact@westat.com">ctsucontact@westat.com</a></td>
</tr>
<tr>
<td>Submit study data directly to the Lead Cooperative Group unless otherwise specified in the protocol:</td>
</tr>
<tr>
<td>NRG Oncology</td>
</tr>
<tr>
<td>1818 Market Street</td>
</tr>
<tr>
<td>Suite 1720</td>
</tr>
<tr>
<td>Philadelphia, PA 19103</td>
</tr>
<tr>
<td>Submit data electronically via the NRG Oncology/RTOG web site, <a href="http://www.rtog.org">www.rtog.org</a></td>
</tr>
<tr>
<td>Do not submit study data or forms to CTSU Data Operations. Do not copy the CTSU on data submissions.</td>
</tr>
</tbody>
</table>

The most current version of the **study protocol and all supporting documents** must be downloaded from the protocol-specific Web page of the CTSU Member Web site located at [https://www.ctsu.org](http://www.ctsu.org). Access to the CTSU members’ web site is managed through the Cancer Therapy and Evaluation Program - Identity and Access Management (CTEP-IAM) registration system and requires user log on with CTEP-IAM username and password.

**For patient eligibility or treatment-related questions** Contact the Study PI of the Lead Protocol Organization.

**For questions unrelated to patient eligibility, treatment, or data submission** contact the CTSU Help Desk by phone or e-mail: CTSU General Information Line – 1-888-823-5923, or [ctsucontact@westat.com](mailto:ctsucontact@westat.com). All calls and correspondence will be triaged to the appropriate CTSU representative.

**For detailed information on the regulatory and monitoring procedures for CTSU sites** please review the CTSU Regulatory and Monitoring Procedures policy located on the CTSU members’ web site [https://www.ctsu.org > education and resources tab > CTSU Operations Information >CTSU Regulatory and Monitoring Policy](https://www.ctsu.org).

**The CTSU Web site is located at** [https://www.ctsu.org](http://www.ctsu.org)
Table of Contents (4/20/16)

NRG ONCOLOGY ................................................................................................................................. 1
RTOG 0924 ........................................................................................................................................... 1
SCHEMA .................................................................................................................................................. 7
ELIGIBILITY CHECKLIST ....................................................................................................................... 8
1.0 INTRODUCTION ............................................................................................................................. 13
1.1 Rationale for Selected Approach and Trial Design ........................................................................ 13
1.2 The Relevance of RTOG 0924 to Phase III Trials Completed to Date ......................................... 13
1.3 Decision to allow option for treating patients with 4 months (versus 6 months) of ADT .............. 13
1.4 Principles and Supporting Data for a Phase III Trial Evaluating Whole-Pelvic Radiotherapy ... 14
1.5 Health-Related Quality of Life (HRQOL), Fatigue, and Quality-Adjusted Survival (QAS) ........ 14
1.6 Correlation of Circulating Proinflammatory Cytokines to Fatigue .............................................. 20
1.7 Genetic Predictors of Fatigue ......................................................................................................... 21
1.8 Expression Signature to Predict Lymph Node Status ..................................................................... 22
2.0 OBJECTIVES ................................................................................................................................... 22
2.1 Primary Objective .......................................................................................................................... 22
2.2 Secondary Objectives ..................................................................................................................... 22
3.0 PATIENT SELECTION .................................................................................................................... 23
3.1 Conditions for Patient Eligibility .................................................................................................. 23
3.2 Conditions for Patient Ineligibility ............................................................................................... 23
4.0 PRETREATMENT EVALUATIONS/MANAGEMENT .................................................................. 24
4.1 Required Evaluations/Management ............................................................................................... 24
4.2 Highly Recommended Evaluations/Management .......................................................................... 24
4.3 Optional Online Completion of Patient Reported Outcome (PRO) Assessments ...................... 24
5.0 REGISTRATION PROCEDURES ................................................................................................. 26
5.1 Pre-Registration Requirements for Intensity Modulated Radiation Therapy (IMRT) Treatment Approach ................................................................................................................................. 26
5.2 Pre-Registration Requirements for 3-D Conformal Radiation Therapy (3DCRT) Treatment Approach .................................................................................................................................................. 26
5.3 Pre-Registration Requirements for Brachytherapy Treatment Approach ...................................... 26
5.4 Digital RT Data Submission Using TRIAD ................................................................................... 27
5.5 Regulatory Pre-Registration Requirements ................................................................................... 28
5.6 Registration .................................................................................................................................... 29
6.0 RADIATION THERAPY .................................................................................................................. 30
6.1 Dose Specifications ......................................................................................................................... 31
6.2 Technical Factors ........................................................................................................................... 33
6.3 EBRT Localization, Simulation, and Immobilization .................................................................... 33
6.4 Treatment Planning/Target Volumes ............................................................................................... 33
6.5 Critical Structures .......................................................................................................................... 36
6.6 Treatment Verification .................................................................................................................... 37
6.7 Quality Assurance .......................................................................................................................... 37
6.8 Dose Specifications/Technical Considerations: LDR Brachytherapy Boost ............................... 38
6.9 Dose Specifications/Technical Considerations: HDR Brachytherapy Boost ................................. 39
6.10 R.T. Quality Assurance Reviews .................................................................................................. 42
6.11 Radiation Therapy Adverse Events ............................................................................................... 42
6.12 Radiation Therapy Adverse Event Reporting .............................................................................. 42
7.0 DRUG THERAPY ............................................................................................................................. 42
7.1 Anti-Androgen Therapy: Casodex (Bicalutamide) ......................................................................... 42
7.2 Anti-Androgen Therapy: Eulexin (Flutamide) ................................................................................. 43
7.3 LHRH Agonist/Antagonist Therapy (leuprolide, goserelin, buserelin, triptorelin/degarelix) ......... 44
7.4 Adverse Events (2/26/14) ............................................................................................................. 44
7.5 CTEP-AERS Adverse Event Reporting Requirements ................................................................... 45
8.0 SURGERY ......................................................................................................................................... 47
9.0 OTHER THERAPY ........................................................................................................................... 47
### Risk Group

1. GS 7-10 + T1c-T2b + PSA < 50 ng/ml
2. GS 6 + T2c-T4 or ≥ 50% biopsies + PSA < 50 ng/ml
3. GS 6 + T1c-T2b + PSA > 20 ng/ml

### Type of RT Boost

1. IMRT
2. Brachytherapy (LDR using PPI or HDR)

### Duration of Androgen Deprivation Therapy**

1. Short Term (6 months)
2. Long Term (32 months)*
3. Short term (4 months)

**LHRH duration is per physician discretion to be declared at registration as 4 months, 6 months or 32 months

### Arm 1:

- Neoadjuvant androgen deprivation therapy
- Neoadjuvant prostate & seminal vesicle RT
- Boost to prostate & proximal seminal vesicles

### Arm 2:

- Neoadjuvant Androgen Deprivation Therapy
- Whole-pelvic RT
- Boost to prostate & proximal seminal vesicles

* 32 months chosen because RTOG 9202 used 28 months and EORTC used 36 months = avg 32 months

(2/26/14) **Note:** As this protocol allows for treatment with exclusively EBRT or EBRT + brachytherapy (at the discretion of the treating physician), this must be specified at the time of study enrollment. Should a patient who was originally intended to receive brachytherapy be found, post enrollment, to be a poor brachytherapy candidate based on transrectal ultrasound examination, he may be switched to external beam radiotherapy administered per protocol guidelines, but this will result in a protocol deviation. Therefore, it is strongly recommended to obtain ultrasound assessment of prospective brachytherapy patients before enrollment on this study.

### Patient Population:

(See Section 3.0 for Eligibility) (2/26/14)

Patients who are most likely to benefit from androgen deprivation therapy and whole-pelvic radiotherapy, defined as:

- a) Having a significant risk of lymph node involvement (e.g. >15%, based on the Roach formula);
- b) Being in one of the following risk groups:
  - GS 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
  - GS 6 + T2c-T4 (palpation) + PSA < 50 ng/ml **Gleason score 6 + ≥ 50% biopsies + PSA < 50 ng/ml**;
  - GS 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.
Institution #
RTOG 0924

ELIGIBILITY CHECKLIST (4/27/15)

Case #

1 ________ (Y) Does the patient have histologic proven diagnosis of adenocarcinoma of the prostate within 180 days of registration?

2 ________ (Y) Is the patient at moderate to high risk for recurrence as determined by one of the following combinations?
   - Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (this includes both intermediate and high risk patients);
   - Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/ml OR Gleason score 6 + ≥ 50% positive biopsies + PSA < 50 ng/ml;
   - Gleason score 6 + T1c-T2b (palpation) + PSA > 20ng/ml

3 ________ What is the Gleason score?

4 ________ What is the T-stage?

5 ________ What is the PSA?

6 ________ (N/Y) Are 50% or more of the core biopsies positive?

7 ________ (Y) Has a history and physical examination (including a digital rectal exam) been done within 90 days prior to registration?

8 ________ (Y) Are the lymph nodes negative via imaging (CT/MR of pelvis + or – abdomen) and not by nodal sampling/dissection within 90 days prior to registration or are they considered to be equivocal or questionable but < 1.5 cm?

9 ________ (N/Y) Was a bone scan done within 120 days prior to registration showing no evidence of bone metastases (Na F PET/CT is an acceptable substitute)?
   ________ (Y) If no, was the bone scan considered to be equivocal and plain films were read as negative for metastases?

10 ________ (Y) Was the baseline PSA (study entry) performed with an FDA approved assay within 120 days prior to registration?

11 ________ (N) Was the study entry (baseline) PSA obtained during any of the following time frames?
   - The 10 day period following the prostate biopsy
   - After the initiation of hormonal therapy
   - Within 30 days after the discontinuation of finasteride
   - Within 90 days after the discontinuation of dutasteride

12 ________ (Y) Is the Zubrod performance status 0 or 1?

13 ________ (Y) Is the patient > to 18 years old?
14 __________(Y) Was a CBC with differential done within 60 days prior to registration with adequate bone marrow function as described below?
   • Absolute neutrophil count (ANC) ≥ 1500 cell/mm³
   • Platelets ≥ 100,000 cells/mm³
   • Hemoglobin ≥ 8.0 g/dl

15 _______(N/Y) Was this patient diagnosed with a prior invasive (except for non-melanoma skin cancer) malignancy?
   _______(Y) If yes, has the patient been considered to be disease-free for 3 or more years (1095 days)?

16 _______(Y) Is the patient able to provide study specific informed consent prior to registration?

17 _______(N) Has the patient had previous radical surgery (prostatectomy) or cryosurgery for prostate cancer?

18 _______(N) Has the patient had previous pelvic irradiation, prostate brachytherapy or bilateral orchiectomy?

19 _______(N/Y) Has the patient had previous hormonal therapy such as LHRH agonists, anti-androgens, estrogens or surgical castration?
   _______(Y) If yes, did the patient begin protocol specified androgen deprivation therapy 45 days or less prior to registration? Refer to Section 7.1.1 for timing of oral anti-androgen administration with the LHRH agonist.

20 _______(N) Has this patient had previous or concurrent cytotoxic chemotherapy for prostate cancer (prior chemotherapy for different cancer is allowed)?

21 _______(N) Has this patient used finasteride within 30 days prior to registration?

22 _______(N) Has this patient used dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration?

23 _______(N) Has this patient had prior radiotherapy, including brachytherapy, to the region of this study cancer that would result in overlap of radiation therapy fields?
24 ________ (N) Does this patient have any severe or active co-morbidities as defined by the following?
   • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months (180 days)
   • Transmural myocardial infarction within the last 6 months (180 days)
   • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
   • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
   • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction
   • Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.

25 ________ (N) Has this patient had any prior allergic reaction to the study drug(s) involved in this protocol?

26 ________ (N/Y) Will this patient be receiving brachytherapy (if no skip to Q 27)?

27 ________ (Y/N/A) Is the patient sexually active and willing/able to use medically acceptable forms of contraception?

The following questions will be asked at Study Registration:
IMRT/BRACHYTHERAPY CREDENTIALING IS REQUIRED BEFORE REGISTRATION (4/20/16)

_______ 1. Institutional person randomizing case.
_______ (Y) 2. Has the Eligibility Checklist been completed?
_______ (Y) 3. In the opinion of the investigator, is the patient eligible?
_______ 4. Date informed consent signed
_______ 5. Patient initials (LFM)
_______ 6. Verifying Physician
_______ 7. Patient ID
_______ 8. Date of Birth
_______ 9. Race
_______ 10. Ethnicity
_______ 11. Gender
__12. Country of Residence\n
__13. Zip Code (U.S. Residents)\n
__14. Method of Payment\n
__15. Any care at a VA or Military Hospital?\n
__16. Calendar Base Date (start of hormone treatment—if hormones have started prior to registration use today’s date)\n
__17. Randomization date\n
(Y/N) 18. Have you obtained the patient's consent for his or her tissue to be kept for use in research to learn about, prevent, treat, or cure cancer?\n
(Y/N) 19. Have you obtained the patient's consent for his or her blood to be kept for use in research to learn about, prevent, treat, or cure cancer? Blood collection is mandatory for patients who provided consent for the QOL portion of this study. Note: The QOL component closed to new patient accrual on 3/9/15.\n
(Y/N) 20. Have you obtained the patient's consent for his or her urine to be kept for use in research to learn about, prevent, treat, or cure cancer?\n
(Y/N) 21. Have you obtained the patient's consent for his or her tissue to be kept for use in research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)?\n
(Y/N) 22. Have you obtained the patient's consent for his or her blood to be kept for use in research about other health problems (for example: diabetes, Alzheimer's disease, or heart disease). Blood collection is mandatory for patients who provided consent for the QOL portion of this study. Note: The QOL component closed to new patient accrual on 3/9/15.\n
(Y/N) 23. Have you obtained the patient's consent for his or her urine to be kept for use in research about other health problems (for example: causes of diabetes, Alzheimer's disease, and heart disease)?\n
(Y/N) 24. Have you obtained the patient's consent to allow someone from this institution to contact him or her in the future to take part in more research?
**Risk group:**
1. Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk)
2. Gleason score 6 + T2c-T4 (palpation) or ≥ 50% (positive) biopsies + PSA < 50 ng/ml
3. Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/ml

**RT Modality for Boost**
1. IMRT
2. LDR Permanent Prostate Implant (PPI) Boost
3. HDR Boost

**Specify duration of ADT:**
1. Short term (6 months)
2. Long term (32 months)
3. Short term (4 months)

**Specify use of IMRT.**

**Email address of RA following the patient**

The Eligibility Checklist must be completed in its entirety prior to web registration. The completed, signed, and dated checklist used at study entry must be retained in the patient’s study file and will be evaluated during an institutional NCI/NRG Oncology audit.

**Completed by** ____________________________  **Date** ____________________________
1.0 INTRODUCTION

1.1 Rationale for Selected Approach and Trial Design

The term “intermediate risk” is frequently applied to prostate cancer patients whose biochemical control rates are not as favorable as low risk patients but not as poor as that of high risk patients. Usually such patients have any one of the following features: (1) Gleason’s scores of 7; or (2) a serum prostate specific antigen (PSA) of 10 to 20 ng/ml; or (3) clinical T stage of T2b-T2c on digital rectal exam. However, this “intermediate risk” group encompasses a broad range of patients with heterogeneous outcomes. For example, patients with one of the adverse factors have a more favorable outcome than those with two, and those with all three do worse than those with two (Zelesky 1998; Chism 2004; Le 2000). Furthermore, regardless of whether managed by external beam radiotherapy (EBRT), permanent prostate implant (PPI), or EBRT combined with high dose rate (HDR) brachytherapy intermediate patients with 50% or more of their biopsies positive have a prognosis comparable to high-risk patients (D’Amico 2002; Wong 2004; Rossi 2006; Kestin 2002). Recent data from NRG Oncology suggest that age < 70 years of age is associated with a higher rate of biochemical failure, DM, and a decreased CSS (Roach et al. unpublished data). Age less than 70 years of age was associated with a lower risk of death from other causes. However, for simplicity, our study population will not use age as a part of our selection criteria. This study will include patients who can be considered to have “unfavorable” intermediate risk prostate cancer and “favorable” high risk prostate cancer (See Eligibility, Section 3.0).

During the past decade, three strategies: (1) dose-escalation; (2) androgen deprivation therapy (ADT); and (3) whole-pelvic radiotherapy (WPRT), have independently emerged in the treatment of intermediate- and high-risk prostate cancer. No clear consensus on the optimal management of intermediate risk patients with multiple adverse features or “favorable” high-risk patients has been reached. RTOG 9413 demonstrated that patients with a risk of lymph node involvement >15% have an improvement in progression free survival (PFS) with neoadjuvant hormonal therapy combined with WPRT compared to prostate-only (PO) radiotherapy (total prostate dose in both arms of 70.2 Gy) [Roach 2003]. However, roughly half of all patients in this study had a pretreatment PSA > 20 ng/ml and roughly 70% were clinical T2c to T3. Thus, many of these patients were unfavorable intermediate or high risk and might have been better served with higher doses to their prostates and with a longer duration of ADT.

The proposed study will determine whether when higher doses of radiation is given there is a benefit to WPRT when treating unfavorable-intermediate to favorable high-risk patients. It is estimated that such patients have a risk of lymph node involvement > 15% but are not as likely to harbor occult distant metastasis as unfavorable high risk men (GS=8-10 and T3 and PSA >20) [Kattan 2003]. In addition, such patients are more likely to sustain long-term local control with high dose radiotherapy using IMRT, PPI, or boost. A subset analysis of RTOG 9413 supports the notion that patients in this type of intermediate subgroup might in fact benefit the most from WPRT (Roach 2003). Additional support for the use of whole pelvic radiotherapy can be found in retrospective data from UCSF and Stanford, Yale, University of Michigan, Italy, and Poland (as described above) [Seaward 1998; Spiotto 2007; Aizer 2009; Pan 2002; Da Pozzo 2009; Milecki 2009]. Other retrospective data question the value of NADT and WPRT when using high dose EBRT or HDR boost (Jacob 2005; Nguyen 2008).

1.2 The Relevance of RTOG 0924 to Phase III Trials Completed to Date

High doses of radiation reduce PSA failure rates (compared to lower doses) but have not been shown to improve survival rates or reduce the rate of metastasis (Mets). The lack of a benefit to date may be secondary to the presence of occult disease in regional disease not included in the radiation fields. Our current study would address this issue.

Phase III Trials including intermediate and high risk patients treated with EBRT combined with short term androgen deprivation therapy (ADT) (4 to 6 months) have demonstrated a reduction in PSA failure, the rate of distant metastasis, cause specific survival and possibly overall survival (Roach 2008; D’Amico 2004). Patients who undergo dose escalated EBRT in addition to ADT also seem to benefit (Dearnaley 2007). RTOG 0924 will build on these studies by allowing patients with “unfavorable” intermediate and “favorable” high risk disease to receive either short term (ST) ADT or long term (LT) and dose escalated radiotherapy while testing the value of WPRT.

1.3 Decision to allow option for treating patients with 4 months (versus 6 months) of ADT (4/20/16)

The option for treating patients with 4 months (versus 6 months) of androgen deprivation therapy (ADT) was added because RTOG 9910 (n~1500), which compared 4 versus 9 months of ADT, found no
difference in the 10-year survival or any other major endpoint, with the exception of more toxicity in the latter (Pisansky 2015). In addition, four other phase III randomized studies support this finding: a subset analysis of RTOG 9202 (n=1500) of 4 versus 28 months (Hanks 2003); a Canadian trial of 3 versus 8 months (Crook 2004); an Irish trial of 4 versus 8 months (Armstrong 2010); and a Canadian trial of 5 versus 10 months (Laverdiere 2004). Thus, there is no justification for continuing to require the more expensive and morbid 6 months course of ADT on this trial.

1.4 Principles and Supporting Data for a Phase III Trial Evaluating Whole-Pelvic Radiotherapy

1.4.1 Only patients with a significant risk of lymph node involvement can possibly benefit from WPRT.
1.4.2 Data based on extended lymph node dissections are likely to be more accurate than those based on nodal sampling or limited dissections. Based on Briganti’s (2007) nomogram a patient with a T1c and 50% of cores positive and a Gleason score of 7, the PSA=10 has a ~18% of positive nodes. With a Gleason score of 8-10 it goes up to 25%. Heidenreich, et al. (2007) also concluded 20 to 25% in intermediate risk patients and 30 to 40% of high-risk patients had lymph node involvement when an extended lymph node dissection was performed. Thus, the role of WPRT needs to be defined for intermediate risk patients with multiple adverse features and “favorable” high-risk patients.
1.4.3 Retrospective data and RTOG 9413 support WPRT as a means of reducing recurrence:
   - Retrospective data from UCSF suggest that patients with a risk of 15 to 35% benefit the most from WPRT (Seaward 1998).
   - Retrospective data from Stanford involving the treatment of patients in the post-operative setting supports WPRT (Spitto 2007).
   - Retrospective data from Yale supports WPRT in patients with high-risk prostate cancer (Aizer 2009);
   - Retrospective data from University of Michigan supports WPRT for men with a Partin Table risk of 5 to 15% (Pan 2002).
   - Retrospective data from Italy demonstrated an improvement in cause specific survival (CSS) in post operative patients with positive lymph nodes treated with RT +ADT (75% WPRT) compared to ADT alone (Da Pozzo 2009).
1.4.4 RTOG 9413 demonstrated an increase in progression with hazard of 1.52 if only the prostate was irradiated in conjunction with short term neoadjuvant ADT (Roach 2003).
1.4.5 Subset analysis from RTOG 9413 suggests that the patients with the greatest benefit had a PSA< 30 and GS=7-10 or PSA >30 ng/ml and GS< 7 (Roach 2003). Thus, high-risk patients appear to benefit.
1.4.6 Higher doses of radiation to the prostate should allow the benefits to be more obvious because fewer failures will be local. With a dose of 70 Gy many of the failures may have been local even if pelvic nodes were controlled.
1.4.7 The use of IMRT should result in better results than RTOG 9413 by providing better coverage of nodes and better control (Roach 2006; Wang-Chesebro 2006) and less toxicity (Chan 2008; Chung 2009).
1.4.8 Only an adequately powered study with patients at risk for death from prostate cancer can answer this question. In order to demonstrate a survival advantage the patients at risk must be at significant risk of death within 10 years.
1.4.9 The short term ADT arm of RTOG 9202 revealed CSS 85% at 10 years, despite a median PSA> 20 ng/ml, T2c-T3 and GS 8-10. A 40% reduction in mortality would yield a CSS of ~ 93 for an absolute difference of <10%. The same arm of RTOG 9413 was associated with a 10-year CSS of 90%. Assuming fewer deaths due to local failure the goal of a 10% reduction should be achievable (Lawton 2007).

1.5 Health-Related Quality of Life (HRQOL), Fatigue, and Quality-Adjusted Survival (QAS)

Several studies indicate a higher rate of symptomatic toxicity (mostly GI and GU) in men with prostate cancer who have received whole pelvic radiation therapy (WPRT) versus prostate-only radiation therapy (PORT). For example, in RTOG 9413, the rate of acute grade 2 or higher GI toxicity was significantly higher in patients receiving WPRT (47%) versus PORT (20%), p<0.001. Similarly, the rate of grade 2+ acute GU toxicity was also higher in patients receiving pelvic radiation (>30%) than those receiving PORT (22%), p=0.016 (Pommier 2007). These significant differences were present whether or not one compared the PORT group to the whole-pelvis group or the mini-pelvis group. Overall, the acute grade 2+ RT-related GU and GI toxicities significantly correlated with the radiation field size. Similarly, there was a
significant increase in grade 2+ late GU toxicity for patients who received WPRT (15%) versus those that received PORT (5.6%), p=0.03. There was also a significant difference in late grade 2+ GI toxicity between those who received WPRT (15%) versus those that received mini-pelvis (8.5%) or PORT (7%), p=0.002. Moreover, the incidence of late grade 3+ GI toxicity in this study also correlated with field size (4.3% were WPRT versus 0% for PORT, p=0.006). While, in general, the rates of grade 3+ toxicities are low, the rates of grade 2 toxicities are quite prominent and these symptoms (e.g. urinary frequency, dysuria, rectal pain, diarrhea, etc) can certainly affect quality of life, particularly the GI and GU domains of QOL.

Similarly, in a recent analysis comparing a consecutive sample of 277 patients with prostate cancer who received either WPRT or PORT, Aizer, et al. (2009), reported a significantly higher rate of acute GI toxicity in the patients receiving WPRT (p=0.048), as well as a trend toward an increase in acute GU toxicity in this group (p=0.09). Interestingly, they reported a higher rate of biochemical control in the patients that received WPRT (86%) versus those who received PORT (69%), p=0.002. They conclude that while WPRT may yield improvement in biochemical control, it results in a greater incidence of acute toxicity.

Not all studies, however, have shown a significant increase in toxicity from pelvic radiation to prostate-only radiation. In a randomized trial reported by Pommier, et al. (2007), comparing WPRT to PORT, they found no significant differences in acute or late digestive toxicities based upon the treatment field. However, they did note a non-significant increase in grade 2+ acute digestive toxicities on the pelvic arm (which was approximately 7% higher). They explain part of this lower rate of increased GI toxicity in this study (compared to RTOG 9413) based upon the lower pelvic volume and lower RT dose used in this study. They also found that pelvic radiation was associated with an increase in grade 2+ late GU toxicity (43.3% versus 36.9%, p=0.17). Of note, a significant, unexpected, increase of grade 2+ urinary acute toxicities was noted in the prostate-only group, which they felt was possibly explained by the more frequent use of >2Gy per fraction in this group (versus 1.8Gy per fraction in the pelvic group).

Some have argued that the application of intensity modulated radiation therapy (IMRT) for prostate cancer has essentially prevented the development of significant toxicity from radiation. However, several studies indicate that this is not the case. In one study of >100 patients treated with IMRT to the prostate and/or seminal vesicles, grade 2 GI toxicities were observed in approximately 30% of the patients. Grade 2 acute GU toxicities were observed in 36% of the patients, in addition to 7% grade 3 GU toxicities (De Meerleer 2004).

Indeed, a recent study carefully compared the toxicity rates in patients receiving IMRT to the whole pelvis versus the prostate. In this study, all patients received IMRT to 79.2Gy with concurrent androgen deprivation with a minimum follow-up of 12 months. Thirty patients received initial whole pelvic IMRT to 45Gy in 25 fractions and 30 patients received prostate-only IMRT. Careful bladder and rectal dose volume histogram constraints were utilized. Interestingly, the rate of acute grade 2 GI toxicity was significantly increased in the pelvic radiation group at 50% versus 13% in the prostate only group (p=0.006). They concluded that whole pelvic IMRT results in clinically significant increases in GU toxicity in comparison to prostate-only IMRT (Deville 2010).

The influence of hormone therapy on toxicity rates in patients receiving radiation on prostate cancer have shown mixed findings. In a single institutional review of over 1,000 patients all treated with 3-D conformal RT, the use of long-term androgen deprivation therapy (ADT) significantly increased the risk of both GU and GI morbidity compared to patients treated with 3-D conformal RT alone (Feigenberg 2005). They found that the 5-year risk of grade 2+ GU morbidity was 8% with no ADT versus 14% with long-term ADT (p=0.02). The 5-year actuarial risk of grade 2+ GI morbidity was 17% for no ADT and 26% for long-term ADT (p=0.017). However, in a secondary analysis of several NRG Oncology studies, Lawton, et al, found that patients treated with RT and short-term ADT had a lower probability of grade 3+ GI and GU toxicities compared with patients treated with RT alone (Lawton 2008). Of note, in RTOG 0924 patients on both arms will similarly receive at least six months of ADT.

Prior studies have demonstrated a disconnect between physician-derived toxicity scores and patient reported outcomes (PRO), such as quality of life. Indeed, there is generally an underreporting of clinically relevant symptoms based upon the toxicity scoring, as compared to the PRO information. NRG Oncology demonstrated this “disconnect” between toxicity scores and PRO data in a lung cancer study, RTOG
9801. While there were no significant differences in the rates of esophagitis toxicity in this randomized trial testing a radiation protector, amifostine, there were some improvements noted with amifostine based upon patient reported outcomes, such as the level of pain (Sarna 2008). In the context of prostate radiation, a similar phenomenon has been noted. Over 300 prostate cancer patients participated in the Dutch randomized trial comparing 68Gy to 78Gy (Al-Mamgani 2010). This study showed no significant differences in the rates of late GU and GI toxicity at 3 years. Yet, in both randomized arms, statistically significant decreases in QOL scores over time were seen in six scales. Moreover, the deterioration over time was only clinically relevant in the role-physical and physical-functioning scales in the patients treated in the high-dose arm. Of importance, late GU and GI toxicities showed a trend toward significant correlation with quality of life changes over time. Thus, as several studies in the past have shown an increased level of GI and GU toxicity in patients receiving whole-pelvic radiation versus prostate-only radiation, it is important to study these effects directly from the patient perspective.

There are limited data regarding quality of life studies comparing patients treated with WPRT versus PORT. In a long-term study of quality of life in men treated for prostate cancer, Hanlon, et al. (2001), reported significant differences based on field size. In particular, patients treated with pelvic radiation had significantly higher rates of self-reported rectal urgency (40% versus 22%, $p=0.03$), an increased use of pads for protection against bowel incontinence (10% versus 0%, $p=0.01$) and lower overall bowel satisfaction (72% versus 88%, $p=0.03$). Men treated with larger fields sizes reported more problems with getting up at night to urinate than men treated with smaller field sizes. In the words of the authors, “clearly, large field irradiation contributes to the late bowel dysfunction”. In this study, comparing WPRT to radiation focused on the prostate area, the key QOL domains expected to be affected are GI and GU, due to an increase in the dose/volume of radiation to the bowel and bladder from whole pelvic radiation. These side effects need more systematic study in clinical trials. Such studies would provide well-defined side effect profiles for better informing physicians and patients of the full consequences of WPRT and improve the awareness that they should incorporate into routine practice strategies for preventing and managing toxicities (Higano 2003). To address HRQOL, RTOG 0924 will compare the treatment arms for differences in prostate cancer HRQOL outcomes, particularly the GI and GU domains (as measured by change over time in the Expanded Prostate Cancer Index Composite [EPIC])-26 (van Andel 2003).

### 1.5.1 Fatigue

Fatigue has been described as the most frequent and distressing symptom related to cancer and its treatment (Bower 2005). Radiotherapy-induced fatigue is a common early side effect reported by 80% of patients during treatment (Jereczek-Fossa 2001). There is evidence that cancer-related fatigue (CRF) has profound effects on ability to function in usual roles and activities and can linger for months or years after treatment completion (Lilleby 1999; Monga 1999; Monga 2005; Truong 2006). The high prevalence of this symptom in persons treated with radiotherapy, as well as its association with poor quality of life, mark it as a significant problem that requires further scientific study.

Fatigue has been found to increase significantly during the course of RT (Jereczek-Fossa 2001; Truong 2006; Beard 1997; Danjoux 2007; Prue 2006). A few reports that consider dose-volume related factors (such as small-field or conformal RT vs. whole-pelvic-field RT) support the hypothesis that higher volumes of RT may be a key factor in treatment-induced fatigue.

Danjoux, et al., (2007) prospectively evaluated fatigue in a cohort of prostate cancer patients. Patients were categorized as having conformal RT ($n=50$), prostate-boost-only RT ($n=33$), or larger field whole pelvis plus prostate boost, RT ($n=46$). Fatigue severity increased more during therapy for the whole-pelvis + prostate boost group compared to either the conformal RT group or the prostate-boost-only RT group.

Beard, et al., (1997) studied fatigue in a prospective multi-institutional cohort treated with external beam irradiation techniques for prostate cancer. Twenty-five patients underwent whole pelvis RT; 60 patients underwent ‘small-field’ RT; thirty-four patients underwent conformal RT. They reported that whole pelvic fields fared significantly worse than small field or conformal RT delivery. They found trends against whole pelvic therapy in favor of conformal RT in patient reported outcomes of fatigue, energy, and vigor. The Danjoux and Beard studies suggested that smaller fields, and resulting small treatment volumes, are related to lower levels of treatment-induced fatigue observed during a course of RT.
Well established toxicities from ADT include lean weight loss, muscle weakness, fatigue, and reduced physical activity, among others (Higano 2003; Bylow 2007). A quality of life analysis of data from a randomized trial (n = 144) found that asymptomatic men with biochemical recurrence who received ADT had significantly worse fatigue severity than those who did not (Herr 2000). Combined androgen blockade (luprolide plus flutamide) was associated with greater fatigue than luprolide alone or orchiectomy. Likewise, a study of 91 men with lymph node-positive disease who received ADT had worse fatigue at 18-month follow-up than men who did not have this treatment (van Andel 2003). Two studies demonstrated that fatigue increased from the beginning to the end of a 3-month course of neoadjuvant hormone therapy prior to radiotherapy (Stephens 2007; Stone 2000).

Only two studies could be found that addressed fatigue associated with RT and/or ADT. Voerman, et al. (2006) conducted a cross-sectional study of 238 men who completed a quality of life questionnaire after completion of prostate cancer treatment (mean time after diagnosis = 44.3 months). In the sample, 38 had been treated with RT and 112 had received RT + ADT. Men receiving ADT reported considerably worse fatigue than those who received RT alone. In another study described earlier, Truong, et al. (2006) reported fatigue scores for men undergoing RT who had received neoadjuvant ADT. Fatigue increased significantly during RT and at the end of RT. After RT completion (median = 6.5 weeks after RT), fatigue improved but remained higher than baseline.

The etiology of fatigue, its correlates, and prevalence in the context of prostate cancer treatment are poorly understood. Past research suggests that irradiation of larger volumes was associated with worse fatigue (Monga 2005; Beard 1997; Danjoux 2007). Likewise, ADT has been associated with increased fatigue (Stephens 2007; Voerman 2006). Of note, in RTOG 0924, patients on both arms will similarly receive at least six months of ADT. Other fatigue correlates have been proposed: depression, poor sleep quality, and use of regular physical activity (Jereczek-Fossa 2001; Berger 2005; Mock 2000). Thus, we plan to address such confounding factors with brief and focused questions.

In order to minimize the potential impact of various confounding factors on fatigue, a secondary endpoint of this study, the following key information regarding potential confounds will also be collected at the time of the PROMIS-fatigue short form (using limited questions to minimize patient burden):

**Anxiety/Depression Item in EQ-5D**

Muscle weakness question (scale of 1-5, from none to very much)

Overall Sleep Quality: Item from Pittsburgh Sleep Quality Index (Buysse 1989):

Sleep quality will be measured by 1 item (Q3) of the Pittsburgh Sleep Quality Index (PSQI), a self-rated questionnaire which measures sleep quality and disturbances over a 1-week or 1-month time period.

<table>
<thead>
<tr>
<th>3. During the past week, how would you rate your sleep quality overall?</th>
<th>Very bad</th>
<th>Fairly bad</th>
<th>Fairly good</th>
<th>Very good</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Usual exercise (3 items):

Participants’ level of physical activity will be assessed using the Godin Leisure-Time Exercise Questionnaire (GLTEQ) [Godin 1986; Gionet 1989], which measures time spent per week in each of light, moderate, and vigorous activities. A score can be computed for each level of exercise. A total score is computed by summing the three levels weighted by their respective MET equivalents of 3, 5, and 9. The GLTEQ has good test-retest reliability and has shown convergent validity with both objective and other self-report measures of physical activity (Godin 1986; Gionet 1989).

The following questions are about your average weekly exercise. When answering the questions only count exercise that you do during free time (ignore exercise associated with your occupation and housework). Considering a typical week (7 days), how many times, on average, do you...
perform mild, moderate, or strenuous exercise? And when you engage in exercise, how long do you exercise, on average?

<table>
<thead>
<tr>
<th></th>
<th>Times Per Week (a)</th>
<th>Average Duration (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Mild exercise – that is, minimal effort exercise that did not make you perspire, such as easy walking, yoga, bowling, lawn bowling, shuffleboard, or golf</td>
<td>______</td>
<td>______ mins.</td>
</tr>
<tr>
<td>2. Moderate exercise – that is, exercise that is not exhausting and which made you perspire lightly, such as fast walking, tennis, easy bicycling, easy swimming, or popular and folk dancing</td>
<td>______</td>
<td>______ mins.</td>
</tr>
<tr>
<td>3. Strenuous exercise – that is, exercise that made your heart beat rapidly and made you sweat, such as running, aerobics classes, cross country skiing, vigorous swimming, or vigorous bicycling</td>
<td>______</td>
<td>______ mins.</td>
</tr>
</tbody>
</table>

1.5.2 Quality-Adjusted Survival and Failure Free Survival

In this study, the addition of prophylactic pelvic nodal radiotherapy is hypothesized to improve freedom from failure (FFF) and overall survival (OS), while having a negative impact on health related quality of life (HRQOL). As these are competing pros and cons of this strategy, it is useful to combine these factors into one equation to determine whether the potential benefits of this treatment (dose-escalated RT combined with short-term androgen deprivation), in terms of FFF and OS, outweigh the potential risks of this strategy, in terms of negatively impacting on global HRQOL, compared to RT alone. Such a quality adjusted survival (or failure free survival) analysis can be invaluable for assisting in the decisions of future patients faced with these treatment options as well as clinicians.

Quality-adjusted survival and freedom from progression can be defined by the weighted sum of different time episodes added up to a total quality-adjusted life-year or failure free survival-year [U= sum of quality (qi) of health states K times the duration (si) spent in each health state (Glasziou 1990)]

\[ U = \sum_{i=1}^{K} q_i s_i \]

The EQ-5D has been used across numerous disease sites (Milne 2006; Wildi 2004). The EQ-5D has been used to assess QALYs and the economic value of prostate cancer screening and treatment of pain related to prostate cancer metastasis (Essink-Bok 1998; Sandblom 2004). Further, the EQ-5D was used in a recent study to estimate the economic value of the welfare loss due to prostate cancer pain by estimating the extent to which pain affects HRQOL among patients with prostate cancer. Health status and economic outcomes were modeled among a well-defined population of 200,000 Swedish prostate cancer patients. Health utility ratings (using the EQ-5D) were obtained from a subset of 1,156 of the prostate cancer patients. A descriptive model showed that optimal treatment that would reduce pain to zero during the whole episode of disease would add on average 0.85 quality-adjusted life years (QALY) to every man with prostate cancer (Sennfalt 2004).

1.5.3 Health Related Quality of Life Assessments

The following instruments will be used to assess health related quality of life (HRQOL), including fatigue and quality adjusted survival: the Expanded Prostate Cancer Index (EPIC)-26, the Patient-Reported Outcome Measurement Information System (PROMIS)-fatigue short form, and the EuroQol (EQ-5D) instrument. These outcomes measurements will be limited to 230
consenting patients in each arm. Of note, these are essentially the same instruments (and time points) that are being studied in the “sister” study, RTOG 0815, which is currently accruing patients. In RTOG 0815, patients with “lower” intermediate risk prostate cancer all receive high dose RT and are randomized to +/- short term hormones. Ultimately, use of essentially the same instruments and time points in both studies (RTOG 0815 and RTOG 0924) will create a huge database of relevant information related to QOL, QAS, and fatigue issues in prostate cancer patients that will facilitate a large combined analysis in the future. The outcomes instruments in this study are as follows:

**Prostate Cancer-Specific Health-Related Quality of Life: EPIC-26**

The Expanded Prostate Cancer Index Composite (EPIC) is a prostate cancer health-related quality of life (HRQOL) patient self-administered instrument that measures a broad spectrum of urinary, bowel, sexual, and hormonal symptoms related to radiotherapy and hormonal therapy (van Andel 2003). Instrument development was based on advice from an expert panel and prostate cancer patients, which led to expanding the 20-item University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) to the 50-item EPIC. Summary and subscale scores were derived by content and factor analyses. Test-retest reliability and internal consistency were high for EPIC urinary, bowel, sexual, and hormonal domain summary scores (each r ≥0.80 and Cronbach's alpha ≥0.82) and for most domain-specific subscales. Correlations between function and bother subscales within domains were high (r >0.60). Correlations between different primary domains were consistently lower, indicating that these domains assess distinct HRQOL components. EPIC domains had weak to modest correlations with the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12), indicating rationale for their concurrent use. Moderate agreement was observed between EPIC domains relevant to the Functional Assessment of Cancer Therapy Prostate module (FACT-P) and the American Urological Association Symptom Index (AUA-SI), providing criterion validity without excessive overlap (Wei 2000).

Widespread implementation of health-related quality-of-life (HRQOL) measurement requires concise instruments. With 50 questions, the full-length Expanded Prostate Cancer Index Composite (EPIC) can be cumbersome to administer. To reduce patient burden, an abbreviated version of the EPIC (EPIC-26) was developed and validated (Szymanski 2010). The 50 questions that constitute the full-length EPIC-50 were evaluated to identify the items suitable for elimination while retaining the ability to measure the prostate cancer-specific HRQOL domains of the EPIC-50. The resulting abbreviated version (EPIC-26) was validated using question responses from 252 subjects who had undergone brachytherapy, external beam radiotherapy, or prostatectomy for prostate cancer. The EPIC-26 internal consistency was measured by Cronbach's alpha coefficient and reliability using test-retest correlation. Using the high item-scale correlations, clinically relevant content, and preservation of domain psychometrics, 26 items were retained in the EPIC-26 from the 50 questions in the full-length EPIC-50. A high correlation was observed between the EPIC-50 and EPIC-26 versions for the urinary incontinence, urinary irritation/obstruction, bowel, sexual, and vitality/hormonal domain scores (all r >0.96). The correlations between the different domains were low, confirming that EPIC-26 retained the ability to discern the distinct HRQOL domains. The internal consistency and test-retest reliability for EPIC-26 (Cronbach's alpha >/=0.70 and r >/=0.69, respectively for all HRQOL domains) supported its validity. EPIC-26 is a brief, valid, and reliable subjective measure of health quality among patients with prostate cancer. To reduce patient burden, this is the validated HRQOL instrument that will be used in this study.

**PROMIS-Fatigue Short Form**

The PROMIS Fatigue Scale (7 items) was developed by the Patient-Reported Outcome Measurement Information System (PROMIS), part of the NIH Roadmap Initiative, focused on developing a publicly available resource of standardized, accurate, and efficient PRO measures of symptoms, distress, and functioning. Two content domains of fatigue, experience and impact, were identified by a panel of experts. An item pool of 58 fatigue experience and 54 fatigue impact items were developed. The psychometric properties of these items were evaluated in a sample of 450 individuals from the general US population using classical test theory indices, monotonicity, and scalability. The expert panel selected the 10 best items in each domain. These 20 items were presented to a panel of clinical experts. Only one item was dropped because of redundancy. A preliminary fatigue short-
form measure of 7 items was created using items selected for consistency in the response scale, broad coverage across the fatigue continuum (i.e., high to low), and good precision of measurement (discrimination function).

**Quality-Adjusted Survival Analysis: EuroQol (EQ-5D)**

The EQ-5D is a patient self-administered questionnaire that takes approximately 5 minutes to complete (Schulz 2002). The first part consists of 5 items covering 5 dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension can be graded on 3 levels: 1-no problems, 2-moderate problems, and 3-extreme problems. Health states are defined by the combination of the leveled responses to the 5 dimensions, generating 243 (3^5) health states to which unconsciousness and death are added (Badia 1998).

The 5-item index score is transformed into a utility score between 0, “Worst health state,” and 1, “Best health state.” The index score or the cost-utility equation can be used in the quality adjusted survival analysis depending on the health state(s) of interest (Wu 2002). For this study we plan to report the multidimensional utilities for comparative purposes.

### 1.6 Correlation of Circulating Proinflammatory Cytokines to Fatigue

Plasma may be collected from patients enrolled on this protocol at baseline and during the last week of radiation treatment. The tissue specimens will be collected and processed according to the NRG Oncology specimen processing guidelines and must be clearly labeled with the patient identification number. Specimens from participating institutions will be banked in the NRG Oncology Biospecimen Bank for future translational analyses. Anticipated analyses for collected specimens include circulating markers that may correlate to patient reported outcomes. An example of one anticipated analysis is the evaluation of plasma cytokines for correlation to fatigue as measured by the PROMIS instrument in patients enrolled on this trial. Examples of cytokines that may be tested include CRP, TNF alpha, IL-1, IL-1ra, and IL-6.

Alterations in the circulating levels of the proinflammatory cytokines TNF alpha, IL-1, IL-1ra, IL-6 and the marker of inflammation C-reactive protein during radiotherapy for prostate cancer predict for the likelihood of developing fatigue as measured by the PROMIS instrument.

Pro-inflammatory cytokines have been found to play a role in cancer-related fatigue (CRF) and fatigue from other chronic illnesses (Schubert 2007). The most commonly implicated cytokines are IL-1, IL-6, TNF alpha, and IFN alpha (Ryan 2007). IL-1, IL-6, and TNF alpha are known to stimulate the hypothalamic pituitary axis, which is also implicated in CRF. TNF alpha also plays a role in modulating central neurotransmission, another potential central mechanism of CRF (Benzing 1999).

Because many of the therapies used to treat cancers can induce expression of these cytokines, it is possible that the cytokine release caused by these therapies also correlate with the occurrence of CRF. Several small studies have addressed the issue of cytokine levels and their correlation with fatigue in patients receiving radiotherapy. Ahlberg et al. (2004) evaluated 15 patients treated with pelvic radiotherapy to a dose of 46 Gy in 2 Gy fractions after hysterectomy. Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI-20). Cytokine levels were assessed before starting radiotherapy, after 30 Gy, and within one week of radiotherapy. Fatigue scores were elevated at the 30 Gy and completion of radiation time points. IL-1 remained undetectable at all time points. TNF alpha and IL-6 were increased in several patients at the time points during radiotherapy and at the completion of radiotherapy. IL-6 elevated in nearly half of patients, and levels decreased through radiotherapy in the remainder with a resultant negative correlation between serum IL-6 and fatigue in this small population. Unfortunately this is a small series of patients in whom surgical therapy was the primary therapy, which is known to alter cytokine levels such as IL-6, CRP, and TNF alpha postoperatively.

Geinitz et al. evaluated cytokine levels in 41 breast cancer patients that had undergone breast conserving therapy. Patients rated fatigue with the Fatigue Assessment Questionnaire and a visual analog scale of fatigue intensity before, during, and 2 months after radiation; and at long term follow up (Geinitz 2001; Geinitz 2004). Serum IL-1 beta, IL-6, and TNF alpha were also measured at these time points. Fatigue was elevated on the visual analogue scale during radiotherapy; however, no change was noted on the Fatigue Assessment Questionnaire. IL-1 beta, IL-6, and TNF alpha did not change during therapy and did not correlate with fatigue. Bower (2009) evaluated fatigue and cytokines in 20 men...
undergoing radiotherapy for prostate cancer and demonstrated that serum levels of C-reactive protein and IL-1 receptor agonist were positively associated with fatigue increases during treatment.

While several of the series that drew negative conclusions above found no increase in inflammatory cytokine levels with radiation, several series have found striking elevations. For example, Akmansu et al. (2005) found significant elevations in serum IL-6 and TNF alpha after five weeks of radiotherapy compared to pretreatment levels in 34 patients receiving radiotherapy for head and neck cancer. Greenberg et al. found significant elevations in IL-1 in the early weeks of radiotherapy for prostate cancer in 15 patients which correlated with an increase in fatigue (Greenberg 1993). Fatigue was assessed daily on a visual analogue scale. Patients were screened for depression during this study to rule out depression as a confounding factor.

In contrast, the effect of hormonal therapy on inflammatory markers is less well known. Small studies have shown altered cytokine expression by prostate tumors after hormonal therapy (Sugihara 1998), but levels of systemic cytokines after hormonal therapy for prostate cancer are not well described. Fatigue is a well-known complication of hormonal therapy for prostate cancer (Peters 2008). The combination of radiation and hormonal therapy for prostate cancer may result in a more persistent and prolonged fatigue compared to the series evaluating fatigue after radiation alone, with as many as 32% of patients experiencing fatigue at the completion of radiation and a substantial number experiencing fatigue as late as 6.5 weeks after completion of radiation (Stone 2000).

Correlation of inflammatory cytokines to fatigue may provide mechanistic information regarding the causes of fatigue in patients receiving radiation therapy and hormonal therapy and may provide a target for intervention in future studies. Blood collection is mandatory for patients consenting to the QOL portion of this study. An example of one anticipated analysis is the evaluation of plasma cytokines for correlation to fatigue as measured by the PROMIS instrument in patients enrolled on this trial. Examples of cytokines that may be tested include CRP, TNF alpha, IL-1, IL-1ra, and IL-6.

1.7 Genetic Predictors of Fatigue

It will be strongly recommended that patients consent to having a blood sample sent for storage to the NRG Oncology Biospecimen Bank. Theuffy coat will be isolated from each sample and the DNA extracted. The specimens will be collected and processed according to the NRG Oncology specimen processing guidelines. Anticipated analyses include evaluation of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) through screening DNA samples derived from case and matched control subjects using Affymetrix 6.0 microarrays. Case subjects will be patients that represent the 20% of patients in this study exhibiting the highest levels of fatigue as defined and measured by the PROMIS instrument used in this study while controls will be the 20% of patients who reported the lowest levels of fatigue as quantified using PROMIS. The goal of this study will be to identify SNPs and CNVs associated with the development of fatigue in prostate cancer patients following radiotherapy.

The hypothesis that forms the basis for this study is that SNPs and/or CNVs in certain genes are associated with the development of fatigue resulting from radiotherapy for prostate cancer. Evidence that possession of genetic variants is associated with the development of adverse effects resulting from radiotherapy comes from several studies. In one case/control study of 141 prostate cancer patients treated with radiotherapy, patients were screened for SNPs in TGFβ1 (Burri in press). Those subjects who possessed either the T/T genotype at position -509, the C/C genotype at position 869 or the G/C genotype at position 915 were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes. In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position. These subjects were also genotyped for SNPs in SOD2, XRCC1, and XRCC3 (Damaraju 2006). Patients possessing the XRCC1 rs25489 G/A genotype were more likely to develop erectile dysfunction following irradiation compared to patients who had the G/G genotype. The estimated CAG haplotype frequency for XRCC1 was significantly higher in men with late rectal bleeding than in men without late rectal bleeding. In addition, patients who possessed the SOD2 rs4880 C/T genotype exhibited a significant increase in grade 2 late rectal bleeding compared to patients who had either the C/C or T/T genotype for this SNP. Furthermore, patients possessing the combination of the SOD2 rs4880 C/T genotype and XRCC3 rs861539 C/T genotype experienced a significant increase in grade 2 late rectal bleeding compared to patients without this particular genotypic arrangement. Another important study reported that possession of SNPs in the Lig4, Ercc2, and
CYP2D6 was significantly associated with the development of clinical toxicity, including urinary morbidity, in patients treated with radiotherapy for prostate cancer (Dudbridge 2006). Taken together, the results of these studies provide a strong basis for the role of genetic factors in the ability to predict which prostate cancer patients will exhibit adverse radiotherapy responses.

1.8 Expression Signature to Predict Lymph Node Status
It will be strongly recommended that patients consent to having a tissue block sent for storage to the NRG Oncology Biospecimen Bank. Paraffin-embedded tissue blocks of diagnostic prostate biopsies will be obtained from participating institutions and banked in the NRG Oncology Biospecimen Bank for future translational analyses. This study is designed as a validation of previous work showing that a 3-6 gene signature from the primary tumor is able to predict lymph node status prospectively. If validated using tissue collected as part of this study, this signature will be applied in future protocols for patient stratification for whole pelvic radiotherapy.

1.8.1 Background
A 3 gene expression signature from the primary tumor has been developed at UCSF which is strongly associated with positive lymph node status (manuscript pending). This signature will be validated using biopsy tissues collected as part of RTOG 9413. Once that is accomplished, it will be further validated as part of this study protocol.

1.8.2 Design
Biopsy blocks will be collected from institutional sites as part of the tissue collection for translational studies. Three biopsy sections will be used for manual microdissection and extraction of RNA. RNA will then be quantitated for 3 genes of interest and 3 housekeeping genes to derive a signature lymph node metastatic index. This index will be tested for associations with lymph node status.

1.8.3 Other Studies
A number of other marker signatures have been developed for prediction of outcome in high grade prostate cancers, both by NRG Oncology investigators (Pollack et al.) and others. A standard set of these markers will be evaluated in the same biopsy samples to compare their outcome prediction with the lymph node signature already being tested.

2.0 OBJECTIVES
2.1 Primary Objective
Demonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.

2.2 Secondary Objectives
2.2.1 Demonstrate that prophylactic WPRT improves biochemical control (“Phoenix definition”). Patients not meeting these PSA criteria (Phoenix Definition) for failure who undergo salvage therapies (such as ADT, radical prostatectomy or brachytherapy, or Cryosurgery) should also be declared as failures at the time a positive biopsy is obtained or salvage therapy is administered, whichever comes first.

2.2.2 Distant metastasis (DM) free-survival, defined as imaging documented evidence of distant spread of disease;

2.2.3 Cause specific survival (CSS) will be defined as death from prostate cancer after biochemical failure followed by the development of metastatic disease followed by the development of castration resistant prostate cancer (CRPC);

2.2.4 Compare acute and late treatment adverse events between patients receiving NADT + WPRT versus NADT + P & SV RT;

2.2.5 Determine whether health related quality of life (HRQOL) as measured by the Expanded Prostate Cancer Index Composite (EPIC) significantly worsens with increasing aggressiveness of treatment (i.e. Arm 2, NADT + WPRT);

2.2.6 Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (PROMIS Fatigue Short Form) from baseline to last week of treatment and a greater increase in circulating inflammatory markers (IL-1, IL-1ra, IL-6, TNF-alpha, and C-reactive Protein);
2.2.7 Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression); this will be reported as the Quality Adjusted Freedom From Progression Year (QAFFPY) and as the Quality Adjusted Life Year (QALY);

2.2.8 Determine whether changes in fatigue from baseline to the next three time points (week prior to radiation therapy, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.

2.2.9 Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.

3.0 PATIENT SELECTION
NOTE: PER NCI GUIDELINES, EXCEPTIONS TO ELIGIBILITY ARE NOT PERMITTED

3.1 Conditions for Patient Eligibility (4/27/15)
For questions concerning eligibility, please contact the study data manager.

3.1.1 Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence as determined by one of the following combinations:
- Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
- Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/ml -OR-
  Gleason score 6 + ≥ 50% (positive) biopsies + PSA < 50 ng/ml;
- Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.
Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are re-biopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure.

3.1.2 History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.

3.1.3 Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), (but not by nodal sampling, or dissection) within 90 days prior to registration.
- Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm.

3.1.4 No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (Na F PET/CT is an acceptable substitute).
- Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis.

3.1.5 Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration.
- Study entry PSA should not be obtained during the following time frames: (1) 10-day period following prostate biopsy; (2) following initiation of hormonal therapy; (3) within 30 days after discontinuation of finasteride; (4) within 90 days after discontinuation of dutasteride.

3.1.6 Zubrod Performance Status 0-1 (unless otherwise specified);

3.1.7 Age ≥ 18;

3.1.8 CBC/differential obtained within 60 days prior to registration on study, with adequate bone marrow function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³;
- Platelets ≥ 100,000 cells/mm³;
- Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);

3.1.9 Patient must be able to provide study specific informed consent prior to study entry.

3.2 Conditions for Patient Ineligibility (2/26/14)
3.2.1 Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years (1095 days) not in the pelvis. (For example, carcinoma in situ of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed). Prior hematological (e.g., leukemia, lymphoma, myeloma) malignancy not allowed.
3.2.2 Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
3.2.3 Previous pelvic irradiation, prostate brachytherapy, or bilateral orchietomy
3.2.4 Previous hormonal therapy, such as LHRH agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., DES), or surgical castration (orchietomy)
   • Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 45 days prior to the date of registration. Please refer to Section 7.1.1 for timing of oral anti-androgen administration with the LHRH agonist.
3.2.5 Use of finasteride within 30 days prior to registration
3.2.6 Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration
3.2.7 Patients status post a negative lymph node dissection are not eligible
4.0 PRETREATMENT EVALUATIONS/MANAGEMENT
NOTE: This section lists baseline evaluations needed before the initiation of protocol treatment that do not affect eligibility.
4.1 Required Evaluations/Management (2/26/14)
4.1.1 Any patient undergoing brachytherapy must have imaging (transrectal ultrasound, CT or MRI) confirmation of prostatic volume <60 cc within 180 days prior to registration. Thus, the prostate volume measured at the time of transrectal ultrasound-guided biopsy confirmation may be used. If a patient is thought to be a poor brachytherapy candidate based on anatomy at the time of ultrasound, he may still participate in the study but must receive EBRT only per protocol guidelines. If a patient is deemed an inadequate brachytherapy candidate after he has already been enrolled on the protocol, he may be switched to EBRT administered per protocol guidelines, but this will result in a protocol deviation.
4.1.2 AST or ALT <2 x the upper limit of normal within 60 days prior to registration
4.2 Highly Recommended Evaluations/Management
4.2.1 Prior testosterone administration must have been last administered at least 90 days prior to registration.
4.3 Optional Online Completion of Patient Reported Outcome (PRO) Assessments (4/27/15)
   Note: The quality of life component closed to new patient accrual on 3/9/15.
   Missing data are a significant problem, particularly for PRO assessments. Unlike data for traditional endpoints, such as survival, PRO data can never be obtained retrospectively if it is not
provided by the patient at the appropriate time point. This limits researchers’ ability to accurately perform PRO statistical analyses and negatively impacts the clinical relevance of this effort. Typically, PRO forms are filled out in hardcopy (paper). To provide a more convenient method of completing PRO assessments, the Radiation Therapy Oncology Group (RTOG) is working with VisionTree Software, Inc., San Diego, CA. VisionTree offers patients on this study the option of completing their PRO forms online from any location that has a computer with Internet access, including the patient’s home, and provides reminders to patients to complete the assessments.

VisionTree has developed a new tool, VisionTree Optimal Care (VTOC), a HIPAA-secure, user friendly, web-based software system (Gorgulho 2005; Gorgulho 2007; Pedroso 2006). The VTOC tool contains a web-based system for global patient and trial administration access, which allows improved compliance and accuracy of data collection, validation, and reporting. It is compliant with the Title 21, Code of Federal Regulations, Part 11 statistical process control system and provides a mobile solution for clinical trials. PRO data are collected with Microsoft Excel and PDF export of reports. VTOC also has mobile messaging and e-mail reminders. Surveys can be “pushed” to patients for completion at timed intervals (see http://www.visiontree.com for details). VisionTree has many clinical partners and clients, including ASTRO, University of California-San Francisco, Baylor College of Medicine, Duke University, Emory University, Harvard Medical School, Henry Ford Hospital, and University of Pennsylvania. ASTRO utilizes VisionTree outcomes online for maintenance of certification and for capturing quality measures. This technology would allow consenting patients on this study to fill out their PRO forms online from any location and to receive e-mail reminders to complete assessments. E-mail reminders also can be sent to research associates (RAs) at the appropriate institutions to remind them that a PRO time point window is about to close so that a patient can be contacted to fill out PRO information on time, before it becomes “missing data”.

In a pilot RTOG study (RTOG 0828), the compliance rate of patients completing PRO assessments at 6 months significantly improved using electronic technology. Based on this pilot data, NRG Oncology is offering VisionTree as an option in other studies, including this one. Patients who prefer to complete hardcopy PRO assessments can do so.

To complete PRO forms online, patients must have an e-mail address that they consent to use so that e-mail reminders may be sent to them. The patient’s e-mail address also will be used for password-protected access to VTOC. Patients who are interested in participating but do not yet have an e-mail address can obtain one for free from a number of sources (e.g. Yahoo!, Hotmail, or AOL). Patients will receive a login card (either printed or sent via e-mail) with which to log in using the secure, web-based VTOC portal. VTOC meets all HIPAA guidelines and is encrypted (via 128-bit SSL) for the security, privacy, and confidentiality of PRO information. It is similar to the secure login commonly used when performing online banking. The login card can then be kept and maintained by the patient.

The patient’s e-mail address only will be used by NRG Oncology for this purpose. Patients will be sent e-mail reminders to complete PRO forms. A typical e-mail reminder would read: “Your Quality of Life forms for the study, RTOG 0924, are now due. Please go to http://www.optimalcare.com, use your secure login, and complete the online forms. If any questions make you feel uncomfortable, you may skip those questions and not give an answer. If you have any questions, please e-mail or call your research associate at [insert RA e-mail address] or [insert RA telephone number]. Thank you for participating in this study.” The reminders will be created by NRG Oncology and placed into a study template that will be sent to patients at customized intervals (at the time points when PRO forms are due). The first reminder will be sent at the beginning of the “window” to complete a PRO form, with a second reminder halfway through the window period if the PRO forms are not yet completed at that time point. A maximum of 3 reminders will be sent for each of the PRO time points. After a patient has completed all forms in the portal, a dialogue box will appear that says “Thank you for completing your Quality of Life forms,” and the patient will no longer receive any remaining notices for that time point. The site RA or study administrator will be informed through the VTOC “At-A-Glance” form management system when PRO forms have been completed.

25 RTOG 0924, Version Date: 4/20/16
If the patient declines participation in VisionTree, please document the reason in your source documentation.

See Section 11.4 for further details.

5.0 REGISTRATION PROCEDURES (2/11/14) (2/26/14)

Access requirements for OPEN and TRIAD
Site staff will need to be registered with CTEP and have a valid and active CTEP Identity and Access Management (IAM) account. This is the same account (user id and password) used for the CTSU members' web site. To obtain an active CTEP-IAM account, go to https://eapps-ctep.nci.nih.gov/iam.

Institutions that have been previously credentialed for prostate 3DCRT or IMRT on prior NRG Oncology protocols and that have successfully irradiated a phantom and been approved by IROC Houston [formerly the Radiological Physics Center (RPC)] need not perform additional credentialing for RTOG 0924. However, respective institutions may only administer treatment for which they have been previously credentialed (i.e., an institution credentialed for 3DCRT only may not administer IMRT on this study without completing the IMRT credentialing process). Credentialing requirements for IMRT and 3DCRT are specified in Sections 5.1 and 5.2 below.

5.1 Pre-Registration Requirements for Intensity Modulated Radiation Therapy (IMRT) Treatment Approach (4/27/15)

5.1.1 In order to utilize IMRT on this study, the institution must have met specific technology requirements and have provided baseline physics information. Instructions for completing these requirements or determining if they already have been met are available on the IROC Houston web site. Visit http://irochouston.mdanderson.org and select “Credentialing” and “Credentialing Status Inquiry”. The institution or investigator must complete the online Facility Questionnaire (available on the IROC Houston web site at http://irochouston.mdanderson.org) and submit it to IROC Houston for review prior to entering any cases.

Institutions that previously have been credentialed for one IMRT delivery technique (e.g., standard gantry mounted linear accelerator using fixed gantry angles) must repeat the credentialing process when they change to a different technology (e.g. tomotherapy).

An IMRT phantom study with IROC Houston must be successfully completed (if the institution has not previously met this IMRT credentialing requirement). Instructions for requesting and irradiating the phantom are available on the IROC Houston web site at http://irochouston.mdanderson.org; select “Credentialing”. Upon review and successful completion of the phantom irradiation, the IROC Houston will notify both the registering institution and NRG Oncology that the institution has completed this requirement. Subsequently, NRG Oncology will notify the institution that the IMRT credentialing requirement has been met.

5.2 Pre-Registration Requirements for 3-D Conformal Radiation Therapy (3DCRT) Treatment Approach (4/27/15)

5.2.1 Only institutions that have met the technology requirements and that have provided the baseline physics information that are described in 3D-CRT Quality Assurance Guidelines may enter patients onto this study.

5.2.2 The online Facility Questionnaire (available on the IROC Houston website at http://irochouston.mdanderson.org) is to be sent to IROC Houston for review prior to entering any cases. IROC Houston will notify both the registering institutions and NRG Oncology when all requirements have been met and the institution is RT credentialed to enter patients onto this study. Institutions that have previously enrolled patients on 3D-CRT trials of this same disease site may enroll patients on this study without further credentialing.

5.3 Pre-Registration Requirements for Brachytherapy Treatment Approach (4/27/15)

5.3.1 Institutions must be credentialed by IROC Houston prior to registering any cases to this study. The credentialing materials may be found on the IROC Houston website at http://irochouston.mdanderson.org under the “credentialing” tab. Upon review and successful
completion of the phantom irradiation, IROC Houston will notify both the registering institution and NRG Oncology that the institution has successfully met the IMRT credentialing requirements.

5.3.2 Brachytherapy Credentialing

Radiation Oncologists and Physicists are credentialed as a team for LDR brachytherapy (seed dependent), CT planned HDR brachytherapy, and TRUS planned HDR brachytherapy. The following can be found on IROC Houston’s website (http://irochouston.mdanderson.org) and must be completed for each technique and/or seed:

- Knowledge Assessment Questionnaire to be submitted to IROC Houston.
- Facility Questionnaire to be submitted to IROC Houston.
- 1 Benchmark Case to be submitted to IROC Houston.
- A recent clinical case treated per protocol and a completed Implant Dosimetry Data Form to be submitted to IROC Houston and electronically sent to TRIAD (see Section 12.2)

If an institution has been credentialed for a previous NRG Oncology LDR prostate brachytherapy trial (RTOG 0526, RTOG 0815), NRG Oncology HDR prostate brachytherapy trial for CT planned HDR, and/or NRG Oncology HDR prostate brachytherapy trial for TRUS planned HDR, and the radiation oncologist and physicist team are the same as on the approved credentialing request, and the institution is using the same seed model and planning system as on the approved credentialing request, then they do not have to be re-credentialed for that modality for this trial with the exception of completing the Knowledge Assessment Form specific to this protocol.

- A change of physician will require submission of the Knowledge Assessment Form and Clinical Test Case.
- A change in physicist will require submission of the Knowledge Assessment Form and the Benchmark Case.
- A change in either the treatment planning computer or brachytherapy source model will require resubmission of only the Benchmark Case.

Brachytherapy sources to be used on this protocol must be listed on the joint IROC Houston/AAPM source registry at http://irochouston.mdanderson.org; select “brachy sources”.

5.4 Digital RT Data Submission Using TRIAD (4/27/15)

TRIAD, the American College of Radiology’s (ACR) image exchange application that is used by NRG Oncology, will be used. TRIAD provides sites participating in NRG Oncology clinical trials a secure method to transmit DICOM RT and other objects. TRIAD anonymizes and validates the images as they are transferred.

TRIAD Access Requirements:

- Site physics staff who will submit images through TRIAD will need to be registered with The Cancer Therapy Evaluation Program (CTEP) and have a valid and active CTEP Identity and Access Management (IAM) account. Please refer to Section 5.0 of the protocol for instructions on how to request a CTEP-IAM account.
- To submit images, the site physics user must have been assigned the ‘TRIAD site user’ role on the relevant Group or CTSU roster. Users should contact your site Lead RA to be added to your site roster. Users from other cooperative groups should follow their procedures for assignment of roster roles.
- RAs are able to submit standard of care imaging through the same method.

TRIAD Installations:

When a user applies for a CTEP-IAM account with proper user role, he/she will need to have the TRIAD application installed on his/her workstation to be able to submit images. TRIAD installation documentation can be found on the RTOG/NRG Oncology website Core Lab tab.

This process can be done in parallel to obtaining your CTEP-IAM account username and password.

RTOG 0924, Version Date: 4/20/16
If you have any questions regarding this information, please send an e-mail to the TRIAD Support mailbox at TRIAD-Support@acr.org.

5.5 Regulatory Pre-Registration Requirements (4/27/15)

5.5.1 This study is supported by the NCI Cancer Trials Support Unit (CTSU).

Prior to the recruitment of a patient for this study, investigators must be registered members of a lead protocol organization. Each investigator must have an NCI investigator number and must maintain an “active” investigator registration status through the annual submission of a complete investigator registration packet (FDA Form 1572 with original signature, current CV, Supplemental Investigator Data Form with signature, and Financial Disclosure Form with original signature) to the Pharmaceutical Management Branch (PMB), CTEP, DCTD, NCI. These forms are available on the CTSU web site: http://ctep.cancer.gov/investigatorResources/investigator_registration.htm. For questions, please contact the CTEP Investigator Registration Help Desk by e-mail at pmbregpend@ctep.nci.nih.gov

The Cancer Therapy Evaluation Program (CTEP) Identity and Access Management (IAM) application is a web-based application intended for use by both Investigators (i.e., all physicians involved in the conduct of NCI-sponsored clinical trials) and Associates (i.e., all staff involved in the conduct of NCI-sponsored clinical trials). Associates will use the CTEP-IAM application to register (both initial registration and annual re-registration) with CTEP and to obtain a user account. Investigators will use the CTEP-IAM application to obtain a user account only. (See CTEP Investigator Registration Procedures above for information on registering with CTEP as an Investigator, which must be completed before a CTEP-IAM account can be requested.) An active CTEP-IAM user account will be needed to access all CTEP and CTSU (Cancer Trials Support Unit) web sites and applications, including the CTSU members’ web site. Additional information can be found on the CTEP web site at http://ctep.cancer.gov/branches/pmb/associate_registration.htm . For questions, please contact the CTEP Associate Registration Help Desk by email at ctepreghelp@ctep.nci.nih.gov.

Each investigator or group of investigators at a clinical site must obtain IRB approval for this protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office before they can enroll patients. Study centers can check the status of their registration packets by querying the Regulatory Support System (RSS) site registration status page of the CTSU member web site by entering credentials at https://www.ctsu.org . For sites under the CIRB initiative, IRB data will automatically load to RSS.

Site registration forms may be downloaded from the RTOG 0924 protocol page located on the CTSU members’ web site. Go to https://www.ctsu.org and log in to the members’ area using your CTEP-IAM username and password
- Click on the Protocols tab in the upper left of your screen
- Click on the (state organization type e.g. P2C, CITN, NCTN Groupname) link to expand, then select trial protocol, RTOG 0924
- Click on the Site Registration Documents link

Requirements for RTOG 0924 site registration:
- CTSU IRB Certification (for sites not participating via the NCI CIRB)
- CTSU IRB/Regulatory Approval Transmittal Sheet (for sites not participating via the NCI CIRB)
- CTSU RT Facilities Inventory Form (if applicable)

**NOTE:** Per NCI policy, all institutions that participate on protocols with a radiation therapy component must participate in the IROC Houston monitoring program. If this form has been previously submitted to CTSU, it does not need to be resubmitted unless updates have occurred at the RT facility.
- IRB/REB approval letter (for sites not participating via the NCI CIRB)
- IRB/REB approved consent (English and native language versions*)
  *Note: Institutions must provide certification of consent translation to NRG Oncology.
- IRB/REB assurance number renewal information, as appropriate
- See the additional pre-registration requirements in Section 5.1.

Non-English Speaking Canadian and Non-North American Participating Sites
*Translation of documents is critical. The institution is responsible for all translation costs. All regulatory documents, including the IRB/REB approved consent, must be provided in English and in the native
language. Certification of the translation is optimal but due to the prohibitive costs involved NRG Oncology will accept, at a minimum, a verified translation. A verified translation consists of the actual REB approved consent document in English and in the native language, along with a cover letter on organizational/letterhead stationery that includes the professional title, credentials, and signature of the translator as well as signed documentation of the review and verification of the translation by a neutral third party. The professional title and credentials of the neutral third party translator must be specified as well.

CTSU Regulatory Office, where they will be entered and tracked in the CTSU RSS.
CTSU Regulatory Office
1818 Market Street, Suite 1100
Philadelphia, PA 19103
Phone: 1-866-651-2878
Fax: 215-569-0206
E-mail: CTSUREgulatory@ctsu.coccg.org (for regulatory document submission only)

Check the status of your site’s registration packets by querying the RSS site registration status page of the members’ section of the CTSU web site. (Note: Sites will not receive formal notification of regulatory approval from the CTSU Regulatory Office.)

- Go to https://www.ctsu.org and log in to the members’ area using your CTEP-IAM username and password
- Click on the Regulatory tab at the top of your screen
- Click on the Site Registration tab
- Enter your 5-character CTEP Institution Code and click on Go

### 5.5.2 Pre-Registration Requirements FOR CANADIAN INSTITUTIONS
Prior to clinical trial commencement, Canadian institutions must complete and fax (215-569-0206) or e-mail (CTSUREgulatory@ctsu.coccg.org) to the CTSU Regulatory Office:
- Health Canada’s Therapeutic Products Directorates’ Clinical Trial Site Information Form,
- Qualified Investigator Undertaking Form, and
- Research Ethics Board Attestation Form.

### 5.5.3 Pre-Registration Requirements FOR INTERNATIONAL INSTITUTIONS

**For institutions that do not have an approved LOI for this protocol:**

International sites must submit an LOI to NRG Oncology to receive approval to participate in this trial. For more details see link below:
http://www.rtog.org/Researchers/InternationalMembers/LetterofIntent.aspx

**For institutions that have an approved LOI for this protocol:**

All requirements indicated in your LOI Approval Notification must be fulfilled prior to enrolling patients to this study.

### 5.6 Registration (4/27/15)

#### 5.6.1 OPEN Registration Instructions

Patient registration can occur only after evaluation for eligibility is complete, eligibility criteria have been met, and the study site is listed as ‘approved’ in the CTSU RSS. Patients must have signed and dated all applicable consents and authorization forms.

Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN). OPEN is a web-based registration system available on a 24/7 basis. To access OPEN, the site user must have an active CTEP-IAM account (check at https://eapps.ctep.nci.nih.gov/iam/index.jsp) and a ‘Registrar’ role on either the LPO or participating organization roster. See Section 5.0 for obtaining a CTEP-IAM account. All site staff will use OPEN to enroll patients to this study. It is integrated with the CTSU Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient position in the Rave database. OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on the CTSU members’ web site https://www.ctsu.org.

Prior to accessing OPEN site staff should verify the following:
All eligibility criteria have been met within the protocol stated timeframes. Site staff should use the registration forms provided on the group or CTSU web site as a tool to verify eligibility.

- All patients have signed an appropriate consent form and HIPPA authorization form (if applicable).

The OPEN system will provide the site with a printable confirmation of registration and treatment information. Please print this confirmation for your records.

Further instructional information is provided on the CTSU members’ web site OPEN tab or within the OPEN URL. For any additional questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com.

In the event that the OPEN system is not accessible, participating sites can contact web support for assistance with web registration: websupport@acr.org or call the Registration Desk at (215) 574-3191, Monday through Friday, 8:30 a.m. to 5:00 p.m. ET. The registrar will ask the site to fax in the eligibility checklist and will need the registering individual’s e-mail address and/or return fax number. This information is required to assure that mechanisms usually triggered by the OPEN web registration system (e.g. drug shipment and confirmation of registration) will occur.

6.0 RADIATION THERAPY (4/20/16)
In both arms, radiotherapy should begin 8-10 weeks after the date of the first LHRH agonist/antagonist injection.

Note: As this protocol allows for treatment with EBRT exclusively or EBRT + brachytherapy (at the discretion of the treating physician) this must be specified at the time of study enrollment. Should a patient who was originally intended to receive brachytherapy be found, post-enrollment, to be a poor brachytherapy candidate based on transrectal ultrasound examination, he may be switched to external beam radiotherapy administered per protocol guidelines, but this will result in a protocol deviation. Therefore, it is strongly recommended to obtain ultrasound assessment of prospective brachytherapy patients before enrollment on this study.

When an IMRT (rather than brachytherapy) boost is used to meet the dose constraints for the composite EBRT plan (see Sections 6.4 – 6.5) that includes Phases 1 and 2, both treatment plans must be generated and summed at the beginning of the patient’s treatment to verify adherence to the required dose constraints. In the case of an inability to meet normal tissue dose-constraints on the summed plan a decrease in PTV dose to achieve normal tissue sparing is recommended (see Section 6.5).

Note: For patients treated with EBRT + IMRT boost, the site must submit the Digital Data for both phase I and phase II in only one TRIAD submission.
6.1 Dose Specifications (4/20/16)

6.1.1 Phase 1: Sequential Boost Technique

- **Arm 1**: Treat prostate and seminal vesicles
  
  Acceptable Treatment Modalities: 3D-CRT or IMRT

  Prescribed Dose (See Table 1.1)
  
  45 Gy Rx to cover at least 98% of PTV\_4500

- Minimum dose within PTV\_4500 – 95% of prescribed dose and for a volume that is 0.03 cc

- Maximum dose within the PTV\_4500 – 107% of prescribed dose and for a volume that is 0.03 cc

**Table 1.1: 3D-CRT and IMRT Dose Objectives for Phase 1, Arm 1 – Prostate and Seminal Vesicles**

<table>
<thead>
<tr>
<th>Phase 1, Arm 1 PTV_4500</th>
<th>Dosimetric Parameter</th>
<th>Per Protocol</th>
<th>Variation Acceptable included in range of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage</td>
<td>D98%(%)</td>
<td>= 100%</td>
<td>98 to 102%</td>
</tr>
<tr>
<td>Minimum Dose</td>
<td>Dmin%(%)</td>
<td>≥ 95%</td>
<td>90 to 95%</td>
</tr>
<tr>
<td>Maximum Dose</td>
<td>Dmax%(%)</td>
<td>≤ 107%</td>
<td>107 to 110%</td>
</tr>
<tr>
<td>Homogeneity</td>
<td>V107%(%)</td>
<td>≤ 10%</td>
<td></td>
</tr>
<tr>
<td>DMax in Patient</td>
<td></td>
<td></td>
<td>In PTV_4500</td>
</tr>
</tbody>
</table>

**Note:** Dosimetric and/or volumetric parameters falling outside the Per Protocol and Variation Acceptable specifications are classified as Deviation Unacceptable. % Dose are normalized to Rx dose = 45 Gy. Dmin and Dmax are to 0.03 cc volume.

- **Arm 2**: Treat whole pelvis including prostate and seminal vesicles
  
  Acceptable Treatment Modalities: 3D-CRT or IMRT

  Prescription Dose (See Table 1.2)
  
  45 Gy Rx to cover at least 98% of PTV
- Minimum dose within PTV – 95% of prescribed dose and for a volume that is 0.03 cc
- Maximum dose within the PTV – 110% of prescribed dose and for a volume that is 0.03 cc

**Table 1.2: 3D-CRT and IMRT Dose Objectives for Phase 1, Arm 2 – Whole Pelvis including Prostate and Seminal Vesicles**

<table>
<thead>
<tr>
<th>Dosimetric Parameter</th>
<th>Per Protocol</th>
<th>Variation Acceptable included in range of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage D$_{98}$(%)</td>
<td>=100%</td>
<td>98 to 102%</td>
</tr>
<tr>
<td>Minimum Dose D$_{\text{min}}$(%)</td>
<td>≥ 95%</td>
<td>90 to 95%</td>
</tr>
<tr>
<td>Maximum Dose D$_{\text{max}}$(%)</td>
<td>≤ 110%</td>
<td>110 to 113%</td>
</tr>
<tr>
<td>Homogeneity V$_{110}$(%)</td>
<td>≤ 10%</td>
<td></td>
</tr>
</tbody>
</table>

D$_{\text{max}}$ in Patient in PTV_4500

Note: Dosimetric and/or volumetric parameters falling outside the Per Protocol and Variation Acceptable specifications are classified as Deviation Unacceptable. % Dose are normalized to Rx dose = 45 Gy. D$_{\text{min}}$ and D$_{\text{max}}$ are to 0.03 cc volume.

6.1.2 Phase 2: Sequential Boost Technique

- **Arms 1 and 2: Reduce volume to boost prostate and proximal seminal vesicles**

  Acceptable Treatment Modalities: IMRT or permanent prostate implant (PPI) brachytherapy or HDR brachytherapy

  Prescribed Dose (See Table 2)
  34.2 Gy Rx for IMRT to cover at least 98% of the PTV_7920
  - Prescribed dose may be reduced to 32.4 Gy or to 30.6 Gy (see Section 6.5)
  - Minimum dose within PTV_7920 – 95% of prescribed dose and for a volume that is 0.03 cc
  - Maximum dose within the PTV_7920 – 107% of prescribed dose and for a volume that is 0.03 cc
  100 Gy for low dose rate PPI with Pd-103
  110 Gy for low dose rate PPI with I-125
  15 Gy in one fraction for HDR

**Table 2: IMRT Dose Objectives for Phase 2, Arms 1 and 2 – Prostate and Proximal Seminal Vesicle Boost**

<table>
<thead>
<tr>
<th>Dosimetric Parameter</th>
<th>Per Protocol</th>
<th>Variation Acceptable included in range of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage D$_{98}$(%)</td>
<td>= 100%</td>
<td>98 to 102%</td>
</tr>
<tr>
<td>Minimum Dose D$_{\text{min}}$(%)</td>
<td>≥ 95%</td>
<td>90 to 95%</td>
</tr>
<tr>
<td>Maximum Dose D$_{\text{max}}$(%)</td>
<td>≤ 107%</td>
<td>107 to 110%</td>
</tr>
<tr>
<td>Homogeneity V$_{107}$(%)</td>
<td>≤ 10%</td>
<td></td>
</tr>
</tbody>
</table>

D$_{\text{max}}$ in Patient in PTV_7920, PTV_7740 or PTV_7560

Note: Dosimetric and/or volumetric parameters falling outside the Per Protocol and Variation Acceptable specifications are classified as Deviation Unacceptable. % Dose are normalized to Rx dose = 34.2 Gy for PTV_7920 or 32.4 Gy, 30.6 Gy for PTV_7740, PTV_7560 respectively. D$_{\text{min}}$ and D$_{\text{max}}$ are to 0.03 cc volume. PTV_?? can be one of PTV_7920, PTV_7740, PTV_7560

6.1.3 CT Slice Thickness, Dose Matrix Spatial Resolution, and DVH Fidelity

A CT slice thickness of 3mm with a linear dose matrix spatial resolution of 3mm, provides an dose voxel of 0.027cc, just sufficient to determine doses in Vcc = 0.03cc for compliance assessment via DVH analyses. Higher spatial resolution in imaging and in dose matrices improve the DVH analyses in the point-dose surrogate volume, Vcc = 0.03cc.
For planning systems that calculate DVH by super-sampling of the dose matrix data, planners may find it useful to set the secondary DVH resolution in number of points sampling an object volume (i.e., PTV, OAR, …) to obtain a planning_DVH_Vcc smaller than 0.03cc. The lower bound on the number of sampling points is given by Object_Volume(cc)/0.03cc. A factor of two to three increasing this number improves the fidelity of the DVH derived from the calculated dose matrix.

6.2 Technical Factors
6.2.1 Either 3DCRT or IMRT may be used for phase 1 of either Arm 1 or 2. For 3DCRT treating the whole pelvis (WPRT), a minimum of 4-fields should be used and a 4 field plan is recommended. More than 4 conformal fields can be used for the Arm 1 prostate plus seminal vesicle treatments. For IMRT, no specific field arrangement is required. For the prostate conedown boost in phase 2, IMRT must be used for patients designated for EBRT boost. RT will be delivered with megavoltage equipment at energies ≥ 6 MV. Typically, except for tomotherapy and VMAT techniques, 5 to 9 gantry angles are employed for the boost EBRT treatment. Patients who receive brachytherapy as a boost component of their RT will undergo EBRT for Phase 1 implementing either 3DCRT or IMRT as described. The prostate and seminal vesicles will be treated to a dose of 45 Gy in 1.8 Gy fractions prescribed to a PTV dose as above.

6.3 EBRT Localization, Simulation, and Immobilization (2/26/14)
Simulation will be CT-based in all cases. The use of urethral contrast at the time of simulation is not required to help identify the apex of the prostate. Rectal contrast is discouraged because it may distort the rectum and artificially displace the prostate in the anterior direction. IV contrast is permitted to assist in identifying the pelvic vessels. Patients will be positioned supine or prone on a flat tabletop and a customized thermoplastic immobilization cast or a molded foam cradle or similar immobilization for stabilization and setup reproducibility is suggested. Rectal balloons for planning and treatment are permitted on this study. The degree of bladder fullness should be made to duplicate the degree of fullness anticipated for daily treatment, i.e., if the patient is instructed to maintain a full bladder for treatment, he should be simulated as such (especially for cases in which image guidance or adaptive treatments are not implemented). The rectum should be kept as empty as possible; consider an enema 1-2 hours prior to simulation. CT images should be acquired at a slice thickness of ≤3 mm from the top of the iliac crests inferiorly. Target volumes (Section 6.4) and normal critical structures (Section 6.4.4) will be defined in the slices in which they are visualized. The 3DCRT cases (Phase 1) must utilize “beam’s eye view” representations to define final beam aperture.

6.4 Treatment Planning/Target Volumes (4/20/16)
6.4.1 Patients treated with an IMRT boost (Phase 2) should have a composite treatment plan generated at the beginning of Phase 1 so that the final EBRT dose to critical structures is evaluated before any dose delivery has begun.

Dose for Phase 1 (CTV_4500/PTV_4500) will be 45.0 Gy at 1.8 Gy per fraction in both arms. Once Phase 1 is completed, a cone down boost to the prostate will be delivered in Phase 2 by any one of the three acceptable methods: IMRT, HDR or LDR permanent prostate implant. If an IMRT boost is planned, the prostate will receive 34.2 Gy at 1.8 Gy per fraction, for a total prostate dose of 79.2 Gy. For pelvic 3D-CRT, a 4-field technique, using opposed anterior-posterior and opposed lateral fields, is recommended. All fields should conform to the beam’s eye-view of the target. No specific field arrangement is required for IMRT, although typically 5-9 fields are used for fixed gantry treatment. Tomotherapy and VMAT are also allowed for IMRT treatment on this protocol.

6.4.2 The definition of GTV, CTV and PTV will be in accordance with the ICRU Report #50: Prescribing, Recording, and Reporting Photon Beam Therapy.
- **Phase 1 Prostate and Seminal Vesicle (Arm 1)**
  - **Gross Target Volume (GTV)**
  - The GTV is defined by the physician as all known disease as defined by the planning CT, urethrogram, and clinical information. If a urethrogram is used, the GTV will encompass a
volume inferiorly 5 mm superior to the tip of the dye and no less than the entire prostate. Prostate dimensions should be defined as visualized on CT scan.

**Clinical Target Volume (CTV 4500)**

The CTV 4500 will include the prostate and entire seminal vesicles.

**Planning Target Volume**

The PTV 4500 margins should be a minimum of 0.5 cm and a maximum of 1.5 cm in all dimensions. Individual selection of a PTV margin should be based on the institutions’ level of confidence in patient set-up and availability of image guidance. The maximum dose heterogeneity allowable in the PTV1 will be 7%; a variation acceptable and a deviation unacceptable are defined in the Compliance Criteria subsection (6.7.1) of the Quality Assurance section and are summarized in the table below.

- **Phase 1 Pelvic Field (Arm 2)**
  **Clinical Target Volume (CTV 4500)**
  The CTV 4500 will include the prostate and entire seminal vesicles and the pelvic nodes (CTVn), which include, the obturator, external iliac, proximal internal iliac and common iliac nodes, using the vascular structures, up to a level corresponding to the top of L4-L5 so that the entire common iliac nodes are included. For those patients with significant small bowel adjacent the common iliac nodes, the superior contour may be reduced to the top of L5-S1. Please refer to the pelvic nodal atlas at the RTOG/NRG Oncology Web site (Pelvic Lymph Node Volumes for Prostate Cancer Atlas; [http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx](http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx)). The presacral nodes from L5-S1 to S3 may be included if desired depending on whether the dose constraints to the rectum are achievable (see Table 3). The CTV 4500 will extend superiorly from at least L5-S1 (L4-L5 if feasible) to 0.5 cm below the tip of the urethral contrast dye (if used) and no less than the entire prostate gland. The inferior extent of the external iliac lymph nodes is at the top of the femoral heads. The inferior extent of the obturator lymph nodes is at the top of the symphysis pubis. The CTV 4500 will include a 7 mm margin in 3-dimensions to the contoured iliac vessels, but not extend outside of the true pelvis, into the pelvic musculature nor into adjacent identifiable organs, such as the bladder, rectum or other bowel. Extension of the CTV 4500 into adjacent bone may be carved out.

If using 3DCRT, lateral borders will be at least 1 cm from the pelvic brim. In the lateral fields, the external and internal iliac lymph nodes below the SI joints, and the posterior extension of the seminal vesicles should be covered. The usual posterior border is approximately S2-3 and anterior border at the anterior aspect of the pubic synthesis, but CT anatomy should take precedence. The superior border should be L5-S1 and inferior border should be 0.5 cm below the tip of the urethral contrast dye (if used) and no less than the entire prostate gland.

**Planning Target Volume (PTV 4500)**

The PTV 4500 margins should be a minimum of 0.5 cm and a maximum of 1.5 cm in all dimensions.

- **Phase 2 Prostate and Proximal Seminal Vesicles Boost with IMRT (Arm 1 and 2)**
  **Gross Target Volume (GTV)**
  The GTV is defined by the physician as all known disease as defined by the planning CT, urethrogram, and clinical information. (see Section 6.4.2).

  **Clinical Target Volume (CTV 7920)**
  The CTV 7920 is the GTV (prostate) plus areas at risk for microscopic disease extension plus the proximal bilateral seminal vesicles (ProxSV). Only the proximal 1.0 cm of seminal vesicle tissue adjacent to the prostate shall be included in the clinical target volume. This 1.0 cm of seminal vesicles refers to both radial (in plane) and superior (out of plane) extent. If both prostate and seminal vesicle are visualized in the same CT slice, this seminal vesicle tissue will contribute to the 1.0 cm of tissue.

  **Planning Target Volume (PTV 7920)**
  The PTV 7920 will provide a margin around the CTV 7920 to compensate for the variability of treatment set up and internal organ motion. A range of 5-10 mm around the CTV is required to define each respective PTV. Individual selection of a PTV margin
should be based on the institution’s level of confidence in patient set-up and the availability of image guidance. Superior and inferior margins (capping) should be 5-10 mm cm depending on the thickness and spacing of the planning CT scan. Careful consideration should be made when defining the 5-10 mm margin in 3 dimensions.

### 6.4.3 Normal Critical Structures

Normal critical structures to be defined on the treatment planning CT scan will include the following: bladder, rectum (from its origin at the rectosigmoid flexure superiorly or the bottom of the SI joints, whichever is more inferior to the inferior-most extent of the ischial tuberosities), bilateral femora (to the level of ischial tuberosity), penile bulb, and skin. Any small bowel within the primary beam aperture should be defined as well. The normal tissues will be contoured and considered as solid organs. The bladder should be contoured from its base to the dome, and the rectum from the anus (at the level of the ischial tuberosities) for a length of 15 cm or to the rectosigmoid flexure. This generally is below the bottom of the sacroiliac joints. If IMRT is being used to treat the pelvic nodes, the potential bowel space (not just individual loops of bowel) where the small and large bowel may fall should be outlined. The borders are the abdominal wall anteriorly, pelvic sidewalls laterally (excluding the pelvic lymph node regions), superiorly to one cut above the last axial CT image on which the lymph nodes are outlined and inferiorly from the level of the top of CTV_4500 (outlining around the sides of the bladder near the top of the bladder to encompass the bowel that may fall into these regions).

See the RTOG/NRG Oncology web site [http://www.rtog.org/CoreLab/ContouringAtlases/MaleRTOGNormalPelvisAtlas.aspx](http://www.rtog.org/CoreLab/ContouringAtlases/MaleRTOGNormalPelvisAtlas.aspx) to view the normal pelvis atlas for examples of target and normal tissue contours.

The following table summarizes the naming of targets and critical structures for submission of data via TRIAD.

<table>
<thead>
<tr>
<th>Standard DICOM Name</th>
<th>Description</th>
<th>Validation Profile</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EBRT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTV</td>
<td>Gross tumor volume (prostate)</td>
<td>Required</td>
</tr>
<tr>
<td>CTV_7920</td>
<td>Phase 2 clinical target volume (GTV + SemVes_Prox)</td>
<td>Required for IMRT Boost Cases</td>
</tr>
<tr>
<td>CTV_4500</td>
<td>Phase 1 clinical target volume (GTV + SeminalVesicle +/- CTVn)</td>
<td>Required</td>
</tr>
<tr>
<td>PTV_7920</td>
<td>Phase 2 planning target volume</td>
<td>Required for IMRT Boost Cases</td>
</tr>
<tr>
<td>PTV_4500</td>
<td>Phase 1 planning target volume</td>
<td>Required</td>
</tr>
<tr>
<td>NonPTV4500</td>
<td>External minus PTV_4500</td>
<td>Required</td>
</tr>
<tr>
<td>NonPTV7920</td>
<td>External minus PTV_7920</td>
<td>Required for IMRT Boost Cases</td>
</tr>
<tr>
<td>Femur_L</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>Femur_R</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>PenileBulb</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>External</td>
<td>External Patient Contour</td>
<td>Required</td>
</tr>
<tr>
<td>SeminalVesicle</td>
<td>Entire seminal vesicles (for CTV_4500)</td>
<td>Required</td>
</tr>
<tr>
<td>SemVes_Prox</td>
<td>Proximal seminal vesicles (for CTV_7920)</td>
<td>Required for IMRT Boost Cases</td>
</tr>
<tr>
<td>BowelSpace</td>
<td>Required for Arm 2 Cases</td>
<td></td>
</tr>
<tr>
<td>CTVn</td>
<td>CTV pelvic nodes as per RTOG/NRG Oncology pelvic atlas</td>
<td>Required for Arm 2 Cases</td>
</tr>
<tr>
<td>Urethra</td>
<td>Optional</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** All required structures must be labeled as listed in the table below for digital RT data submission. Resubmission of data may be required if labeling of structures does not conform to the standard DICOM name listed.

---

**Note:** For EBRT + IMRT Boost cases treated with a Total Dose reduced by 1 or 2 fractions, the required PTV_7920 and NonPTV7920 structures must reflect the decreased Total Dose for submission to TRIAD.
6.4.4 The PTV forms the entire target as described. No extension of fields to specifically treat regional lymph nodes is permitted. 3D conformal beams will be shaped to include the entire PTV and minimize dose to surrounding critical structures as described. IMRT using inverse planning is permitted with constraints placed to adhere to critical structure dose limitations as defined below.

6.5 Critical Structures (2/26/14)
Critical structure dose constraints shall remain consistent with those represented in prior NRG Oncology 3DCRT/IMRT prostate protocols (see Table 3 below). Of note, the penile bulb constraint is to be regarded as a guideline, and adherence to this should not, in any way, result in compromised coverage of the dose delivery to the target volume.

Table 3: Critical Structure Dose Constraints

<table>
<thead>
<tr>
<th>Normal organ limit†</th>
<th>No more than 15% volume receives dose that exceeds</th>
<th>No more than 25% volume receives dose that exceeds</th>
<th>No more than 35% volume receives dose that exceeds</th>
<th>No more than 50% volume receives dose that exceeds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder Constraint</td>
<td>80 Gy</td>
<td>75 Gy</td>
<td>70 Gy</td>
<td>65 Gy</td>
</tr>
<tr>
<td>Rectum Constraint</td>
<td>75 Gy</td>
<td>70 Gy</td>
<td>65 Gy</td>
<td>60 Gy</td>
</tr>
<tr>
<td>Penile Bulb</td>
<td>Mean dose less than or equal to 52.5 Gy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Normal organ limit refers to the volume of that organ that should not exceed the dose limit.

While every effort should be made to deliver prescription doses to the PTV as specified while adhering to these constraints, it is recognized that certain anatomical factors may prevent this. As mentioned in Section 6.0, a prescription dose reduction to a level of 77.4 Gy or 75.6 Gy is permitted if constraints cannot be met at a prescription dose of 79.2 Gy. For purposes of compliance, up to a 5% absolute increase in the volume of critical structure receiving greater than the specified dose will be considered “variation acceptable,” e.g. up to 20% of the rectum may receive a dose of > 75 Gy without a protocol deviation. Any increase in critical structure volume greater than 5% receiving more than the specified dose will be considered a “deviation unacceptable.” It is at this point that a dose reduction to 77.4 Gy or 75.6 Gy should be implemented. The prescription dose should be the maximum deliverable up to 79.2 Gy while respecting the critical normal structure constraints. Of note, the penile bulb constraint is to be regarded as a guideline, and adherence to this should not, in any way, result in a reduction of the prescription dose or compromised dose coverage of the target volume.
6.6 Treatment Verification (2/26/14)

6.6.1 For 3DCRT, first day port films or portal images of each field along with orthogonal isocenter verification films (or images) must be obtained. If modifications are made in field shaping or design, a port film/image of each modified field along with orthogonal isocenter verification films (or images) is required on the first day’s treatment of that field. Thereafter, weekly verification films or images of orthogonal isocenter views (anterior to posterior and lateral projection) are required.

For IMRT, the intensity profiles of each beam must be independently verified and compared to the planned field intensity. Detailed quality assurance measurements of dose distributions delivered by the planned treatment fields should be performed and verified by direct comparison with planned dose distributions. This must be done prior to treatment of the first fraction of any fresh IMRT course. Portal images are not required for IMRT but orthogonal verification images are required, just as for 3DCRT. Real-time ultrasound localization and online cone beam CT image guidance are important complements to conventional port films or portal imaging and should be used when available. When not available, weekly port filming/imaging is required in this study.

When CT image guidance is used in daily treatment set-up, and where daily CT quality assurance includes imaging and treatment coordinate coincidence test(s), then weekly verification films or images are optional.

For any x-ray imaging modalities used for verification, routine quality assurance should follow the guidelines found in Table VI of the report of Task Group 142 of the American Association of Physicists in Medicine (Klein, et al., 2009).

Ultrasound quality assurance should be informed by the report of Task Group 65 of the American Association of Physicists in Medicine (Goodsitt, et al., 2009).

6.6.2 Daily on-line target localization (kV or MV imaging with fiducials, trans-abdominal ultrasound, or other) or off-line adaptive approaches to account for interfraction organ motion and setup variability are permitted on this study but not required.

6.7 Quality Assurance (2/26/14)

6.7.1 Compliance Criteria for Cases Treated with EBRT

Cases that are treated entirely with external beam radiation therapy must meet the criteria as stated in Sections 6.1.1 and 6.1.2 (see also Tables 1 and 2) to be scored as per protocol. That is, each case will have to meet the requirements in these sections depending on the particular arm of the study selected during randomization. Both the Phase 1 and 2 requirements for a particular arm must be met in order to be scored as per protocol. If only one phase of treatment meets the requirement, the case will be scored with the lower score of either variation acceptable or deviation unacceptable. In addition, the critical structure dose constraints of Section 6.5 and Table 3 must be met. In this case also, the patient’s treatment will be scored lower when the critical structure score is lower.

The compliance criteria for the situation where the Phase 2 boost is accomplished with brachytherapy is given in Sections 6.8 and 6.9 below.

- Acceptable dose heterogeneity for external beam treatment is summarized in Tables 1 and 2. The treating physician must carefully consider the tolerance dose/volume to each critical normal structure and unspecified tissue.
- **Dose Distribution**
  IROC-Philadelphia-RT (formerly RTOG RT Quality Assurance) will display, and compare with isodose distributions for the axial and coronal planes through the planning target volume to verify correct digital submission and conversion. The submitted DVHs for the PTV will then be compared with those generated by IROC-Philadelphia-RT. Per protocol scoring will be considered for those cases in which 98% of the PTV receives the prescription dose.
- **Elapsed Days During Radiotherapy**
  Per Protocol: 1 to 7 break days
Variation Acceptable: 8 to 14 days
Deviation Unacceptable: > 14 days

6.8 Dose Specifications/Technical Considerations: LDR Brachytherapy Boost (4/20/16)

Note: As this protocol allows for treatment with exclusively EBRT or EBRT + brachytherapy (at the discretion of the treating physician) this must be specified at the time of study enrollment. Should a patient who was originally intended to receive brachytherapy be found, post-enrollment, to be a poor brachytherapy candidate based on transrectal ultrasound examination, he may be switched to external beam radiotherapy administered per protocol guidelines, but this will result in a protocol deviation. Therefore, it is strongly recommended to obtain ultrasound assessment of prospective brachytherapy patients before enrollment on this study.

6.8.1 LDR, permanent seed, brachytherapy boost is permitted at the discretion of the treating radiation oncologist in conjunction with EBRT as described in Section 6.2.3. Implants will only be offered to patients with a prostate volume documented to be <60 cc by transrectal ultrasound examination or MRI, and no large TURP defects. The implant may be performed under either general or spinal anesthesia and will be performed following the EBRT portion of treatment no more than 4 weeks after its completion.

6.8.2 Preplanning
This will be carried out prior to the procedure or intra-operatively via transrectal ultrasound examination. The prostate will be defined from base to apex in the axial plane at 5 mm slice intervals. The treatment length and prostate volume will be recorded. The CTV is the prostate gland plus any visualized extracapsular extension of tumor. The PTV may be the same as the CTV or a 2-3 mm margin may be added anteriorly and laterally and up to 5 mm craniocaudally at the discretion of the treating physician.

6.8.3 Isotope Selection
Iodine-125 or Palladium-103 seeds may be used. The sources will be received and inventoried in accordance with state and federal regulations. If nonsterile loose sources or cartridges are used, at least 10% of the sources will be assayed in such a manner that direct traceability to either the National Institute of Standards and Technology (NIST), an Accredited Dosimetry Calibration Lab (ADCL) or for international participants, the national standards laboratory in their respective country, is maintained. NIST 1999 standards will be used. If sterile source assemblies or strands are used, alternatively non-stranded loose seeds equal to 5% of the total, or five seeds, whichever is fewer, may be ordered and assayed. Agreement of the average measured source strength shall agree with that indicated in the vendor’s calibration certificate to within 5%. No measured source strengths should fall outside 10% of that indicated in the vendor’s calibration certificate.

- For I-125, the allowable source strength for each seed is 0.277 U to .650 U (NIST 99 or later). For Pd-103 sources, this range is 1.29 U to 2.61 U (NIST 99 or later).
- The vendor’s stated source strength shall be used in all dosimetry calculations. Calculations will be performed in accordance with NIST 1999 calibration standards, the point source formalism described in the report generated by AAPM Task Group 43 and subsequent published AAPM Subcommittee Reports. The AAPM’s recommendations for Pd-103 dose specifications and prescription are being followed.

6.8.4 Prescription Doses
The prescription dose for permanent seed interstitial boost will be 110 Gy for I-125 and 100 Gy for Pd-103. Doses will be prescribed as minimal peripheral dose to the PTV.

6.8.5 Postimplant Imaging
A pelvic x-ray with seed count verification will be obtained immediately postimplant. If the seed count does not match the number of seeds implanted, PA and lateral chest x-rays will be obtained to rule out pulmonary seed migration. CT scan for postimplant dosimetric analysis will be obtained following implant completion. Use of a Foley catheter for this test is encouraged for accurate urethral dosimetry but not required. This may be obtained immediately postoperative on the day of the implant if desired but no later than 5 weeks postimplant. The use of intravesical contrast is encouraged. CT slices should be acquired at ≤3 mm thickness and should encompass the pelvis from, at minimum, the bottom of the sacroiliac joints superiorly to 2 cm caudal to the prostatic apex.

- Structures defined will include the prostate, bladder, and rectum. The rectum will be defined from the bottom of the sacroiliac joints to the ischial tuberosity and will extend to the outer
surface of the visualized rectal wall. The postimplant, CT-defined prostate will be defined as the “evaluated target volume” (ETV) and will form the basis for dosimetric analysis.

6.6.6 Dosimetry

Postimplant evaluation will be performed on equipment capable of providing structural and volume-based dosimetric assessment on both the target and critical structures. Volume acquisition will be based on contiguous axial CT slices as described above. Both target volume and critical structures will be contoured on each applicable axial slice. Isodose line displays and dose-volume histograms for all structures will be generated.

- The calculation grid should be set no larger than (2 mm x 2 mm x axial slice width).
- The planning system shall be capable of transmitting data in DICOM format to TRIAD electronically.
- Guidelines established by the American Brachytherapy Society (Nag 2000) are to be followed. DVH-based analysis must be used in the postplan evaluation. The following values shall be reported. Vn is the percentage of the ETV that received at least n% of the prescription dose. Dm is the minimum dose received by m% of the ETV.
- Target coverage will be documented in terms of V100, V90, V80, D90.
- Dose uniformity will be expressed in terms of V150.
- The rectum will be defined from the bottom of the SI joints to the ischial tuberosity. The maximum rectal dose as well as the volume and percentage of rectum receiving >100% of the prescription dose will be recorded.

**Note:** All required LDR Brachytherapy Boost structures must be labeled as listed in the table in Section 6.4.3 for digital RT data submission. Resubmission of data may be required if labeling of structures does not conform to the standard DICOM name listed.

6.6.7 Compliance Criteria

- **Per protocol:** D90 for the ETV is greater than 90% of the prescription dose but less than 130% of the prescription dose.
- **Variation acceptable:** D90 for the ETV is greater than 80% of the prescription dose, but less than 90% of the prescription dose, or greater than 130% of the prescription dose.
- **Deviation unacceptable:** D90 for the ETV is less than 80% of the prescription dose.

6.6.8 Dosimetric Data to be Submitted to TRIAD

- Copies of preimplant TRUS images with CTV and PTV annotated
- A copy of the implant record generated during the procedure
- A copy of the image taken after the procedure and a copy of the image or scout taken during the post implant CT
- A copy of the postimplant CT scan, ETV and bladder and rectum delineation and dosimetry calculations (must be submitted electronically)
- A copy of the postimplant dosimetry report that contains the information required in Section 6.6.6 above.

6.6.9 Quality Assurance

Individual case review will be performed by the LDR brachytherapy study co-chair overseeing this subgroup of patients enrolled on this protocol, as specified below in Section 6.10.

6.9 Dose Specifications/Technical Considerations: HDR Brachytherapy Boost (4/20/16)

**Note:** As this protocol allows for treatment with exclusively EBRT or EBRT + brachytherapy (at the discretion of the treating physician) this must be specified at the time of study enrollment. Should a patient who was originally intended to receive brachytherapy be found, post-enrollment, to be a poor brachytherapy candidate based on transrectal ultrasound examination, he may be switched to external beam radiotherapy administered per protocol guidelines, but this will result in a protocol deviation. Therefore, it is strongly recommended to obtain ultrasound assessment of prospective brachytherapy patients before enrollment on this study.

Type of HDR planning (CT or TRUS) must be specified at the time of enrollment. Any change of HDR planning technique must be reported to the HDR study co-chair in writing prior to the implant.

6.9.1 HDR brachytherapy boost is permitted at the discretion of the treating radiation oncologist in conjunction with EBRT as described in Section 6.2.3. Implants will only be offered to patients with a prostate volume documented to be <60 cc by transrectal ultrasound or MRI examination
and no TURP defects. The implant may be performed during the EBRT portion of the treatment or within 2 weeks prior to its initiation or following its completion. For patients receiving HDR brachytherapy boost, RT should begin, as for other modalities, 8-10 weeks following the first LHRH administration. The date of the HDR brachytherapy implant will constitute the start of RT for those patients receiving the implant prior to EBRT.

6.9.2 CT Based HDR Brachytherapy

- All implants will be performed under transrectal ultrasound guidance. Epidural, spinal, or general anesthesia may be used. A 12-16 French Foley catheter should be inserted to allow visualization of the urethra. Posterior rows of catheters may be advanced into the seminal vesicles under TRUS guidance.
- At least 14 treatment catheters should be used to ensure adequate CTV (see below) coverage with acceptable dose heterogeneity. The implant catheters must be CT compatible; do not use metal catheters.
- Fiducial markers identifying the prostatic base and apex should be placed at the time of the implant procedure unless previously placed for guidance of EBRT.
- The use of intraoperative cystoscopy is required to ensure the absence of treatment catheters within the urethra or bladder. The cystoscope should be retroflexed within the bladder for visualization of the bladder neck. Light pressure on the treatment catheters should result in mucosal tenting confirming adequate coverage at the prostatic base.
- All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure.
- The treatment planning CT scan must be performed with the patient in the supine position with the Foley catheter in place. Metallic obturators, dummy ribbons and rectal tube or marker must be removed prior to the CT scan. If contrast material is used in the bladder, rectum or urethra, it should be diluted to 10% or less to minimize CT artifact. The scan must include all of the CTV (see below) with at least 9 mm superior and inferior margin, and the scan must include the tips of all the implanted catheters. The scan thickness must be ≤0.3 cm and the slices must be contiguous. The field of view (FOV) of axial CT slice should include all the critical structures and target volume on that slice while minimized the overall FOV size to approximately 20 x 20 cm. FOV does not need to include the contour of pelvis. The brachytherapy target volume (see below) and normal critical structures (see below) must be outlined on all CT slices including the prostate, penile bulb, urethra, bladder, and rectum.
- The evaluation of the quality of the implant will be based on the CT using criteria defined below (see “Compliance Criteria”)
- Dwell times in positions located outside of the PTV (see below) should be turned down or off to minimize normal tissue irradiated. A dwell time optimization program based on implant geometry or an inverse planning algorithm may be used. Manual optimization is also accepted.
- The Clinical Target Volume (CTV) is defined by the physician on the treatment planning CT scan. The CTV is the prostate gland plus any visualized extracapsular extension of tumor. The brachytherapy Planning Target Volume (PTV) is identical to the CTV.
- Critical structures to be defined using CT planning include the bladder, rectum, urethra, and penile bulb within the volume of interest defined above. The outermost extent of the bladder/rectal wall will define those structures. The urethra is defined by the outer surface of the Foley catheter.
- The volume of bladder and rectum receiving 75% of the prescription dose must be kept to less than 1 cc (V75 <1 cc) and the volume of urethra receiving 125% of the prescription dose must be kept to less than 1 cc (V125 <1 cc) and urethral V150 should be 0 cc (V150 = 0 cc). If the dose to normal critical structures cannot be kept below the specified level, we recommend readjusting the implant or repeating the implant procedure until a more optimal implant is obtained.

**Note:** All required HDR Brachytherapy Boost structures must be labeled as listed in the table in Section 6.4.3 for digital RT data submission. Resubmission of data may be required if labeling of structures does not conform to the standard DICOM name listed.
- Compliance Criteria
A prescription dose of 15 Gy in one fraction will be delivered to the PTV. Ninety percent coverage of the PTV with the prescription dose is considered per protocol, ≥85% but <90% is considered variation acceptable, and <85% coverage is considered deviation unacceptable. Urethral dose above limits (V125 ≥ 1cc and V150 > 0 cc) is considered deviation unacceptable.

- **Catheter Position Verification**
  - Visual inspection of the catheters prior to delivery of treatment is required. The physician may adjust the catheters if catheter displacement is identified prior to the treatment. If readjustment is needed, the CT planning should be repeated.

- **Catheter Removal**
  - After completion of the treatment all implant catheters will be removed.

- **Brachytherapy Data Submission**
  - All data will be digitally submitted to TRIAD and include CT data, normal critical structures, PTV contours, and digital DVH data for all normal critical structures, and the PTV for dose plan.

- **Quality Assurance**
  - Individual case review will be overseen by the brachytherapy study co-chairs overseeing this subgroup of patients enrolled on this protocol, as specified in Section 6.10.

### 6.9.3 TRUS Based HDR Brachytherapy

- All implants will be performed under transrectal ultrasound guidance. Epidural, spinal, or general anesthesia may be used.
- At least 14 treatment catheters should be used to ensure adequate CTV (see below) coverage with acceptable dose heterogeneity.
- All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure.
- The treatment planning TRUS must be performed with the patient in the supine position with the 12-16 French Foley catheter in place. Two sets of TRUS images are taken. The first set will be done prior to the insertion of implant catheters when the target volume and the urethra are visible. The second set of images is done after the insertion of the implant catheters and is used for treatment planning. The scan must include all of the CTV (see below) with at least 1 cm superior and inferior margin, and the scan must include the tips of all the implanted catheters. The scan thickness must be ≤0.3 cm and the slices must be contiguous. The brachytherapy target volume (see below) and normal critical structures (see below) must be outlined on all slices including the CTV, urethra and rectum.
- Both transrectal ultrasound scans, one prior to implant catheter insertion and one with catheters in place must be submitted for each patient.
- Dwell times in positions located outside of the PTV (see below) should be turned down or off to minimize normal tissue irradiated. A dwell time optimization program based on implant geometry or an inverse planning algorithm may be used. Manual optimization is also accepted.
- The Clinical Target Volume (CTV) is defined by the physician on the trans-rectal ultrasound. The CTV is the prostate gland plus any visualized extracapsular extension of tumor. The brachytherapy Planning Target Volume (PTV) is identical to the CTV.
- Critical structures to be defined using TRUS planning include the rectum, and urethra within the volume of interest defined above. The rectum is defined as the outermost extent of the rectal wall from the TRUS probe, the lateral boarders extends to the edge of the TRUS image. The urethra is defined by the outer surface of the Foley catheter and it is contoured as a solid structure.
- The volume of rectum receiving 80% of the prescription dose must be kept to less than 0.5 cc (V80 <0.5 cc) and the volume of urethra receiving 130% of the prescription dose should be 0 cc and the urethra the D10 should be < 118%.
- All TRUS based HDR treatment should be delivered with TRUS probe in the patient so the dosimetry may be accurately reproduced.
- **Note:** All required HDR Brachytherapy Boost structures must be labeled as listed in the table in Section 6.4.3 for digital RT data submission. Resubmission of data may be required if labeling of structures does not conform to the standard DICOM name listed.

- **Compliance Criteria**
A prescription dose of 15 Gy in one fraction will be delivered to the PTV. Ninety percent coverage of the PTV with the prescription dose is considered per protocol, 85% but <90% is considered variation acceptable, and <85% coverage is considered deviation unacceptable. Urethral dose above limits (V130 > 0 cc and D10 < 118%) is considered deviation unacceptable.

- **Catheter Removal**
  After completion of the treatment all implant catheters will be removed.
- **Brachytherapy Data Submission**
  All data will be digitally submitted to TRIAD and include both TRUS scans (with/without implant catheter), normal critical structures (urethra and rectum), all PTV contours, and digital DVH data for all normal critical structures, and the PTV for dose plan. Seminal vesicle and bladder contours do not need to be submitted.
- **Quality Assurance**
  Individual case review will be overseen by the brachytherapy study co-chairs overseeing this subgroup of patients enrolled on this protocol, as specified in Section 6.10.

6.10 **R.T. Quality Assurance Reviews (2/26/14)**
The study co-chairs for the respective RT modalities offered in this trial will oversee quality assurance reviews for patients treated in those respective fashions. These reviews will be ongoing and performed remotely. RT quality assurance reviews will be facilitated by IROC Philadelphia-RT (formerly RTOG RT Quality Assurance).

6.11 **Radiation Therapy Adverse Events**
6.11.1 All patients will be seen weekly by their treating radiation oncologist while undergoing EBRT. Any observations with respect to the following symptoms/side effects will be recorded:
- Bowel/rectal irritation manifesting as cramping, diarrhea, urgency, proctitis, or hematochezia
- Urinary frequency, urgency, dysuria, hematuria, urinary tract infection, or incontinence
- Radiation dermatitis
6.11.2 Clinical discretion may be used in managing radiotherapy-related side effects. Diarrhea/rectal frequency/urgency may be managed with diphenoxylate or loperamide. Bladder irritation may be mitigated with phenazopyridine. Urinary frequency/urgency can be managed with anticholinergic agents or alpha-blockers such as tamsulosin. Erectile dysfunction can be managed with phosphodiesterase (PDE) inhibitors such as sildenafil.

6.12 **Radiation Therapy Adverse Event Reporting**
See Section 7.5.

7.0 **DRUG THERAPY (2/26/14)**
All eligible patients receive NADT (neoadjuvant androgen deprivation therapy) consisting of an antiandrogen combined with an LHRH (lutetinizing hormone releasing hormone) agent. Use of both drugs is considered combined androgen blockade (CAB). **Protocol treatment must begin within 6 weeks after randomization (if protocol hormone therapy did not start prior to registration).** Radiotherapy should begin 8-10 weeks after starting LHRH agonist/antagonist injection.

7.1 **Anti-Androgen Therapy: Casodex (Bicalutamide) (4/20/16)**
For further information, consult the package insert.
7.1.1 **Timing:** Oral anti-androgen therapy will begin within 0-14 days (can begin before, same day as, or after) of the date of the first LHRH agonist/antagonist administration and continue for a total duration of 6 months if receiving LHRH agonist/antagonist for 6 or 32 months. If receiving 4 months of LHRH agonist/antagonist, the duration of anti-androgen therapy is 4 months. The total duration of administered anti-androgen therapy must be documented and submitted to NRG Oncology.
7.1.2 **Description:** Bicalutamide is a nonsteroidal anti-androgen, which has no androgenic or progestational properties. The chemical name is propanamide, N-[4-cyano-3(trifluoromethyl)phenyl]- 3-[(4-fluorophenyl)sulphonyl]- 2- hydroxy- 2- methyl, (+,-). Bicalutamide is a racemic mixture with the antiandrogen activity residing exclusively in the (-) or R-enantiomer. Bicalutamide has a long half-life compatible with once-daily dosing.
Bicalutamide is well tolerated and has good response rates in phase II trials (Kinnealey 1991; Tyrrell 1994).

7.1.3 Supply: Commercially available.
7.1.4 Storage: Bicalutamide should be stored in a dry place at room temperature between 68°-77°F.
7.1.5 Administration: Bicalutamide is administered orally at a dose of one 50 mg tablet per day. Administration will be suspended only if there is an apparent or suspected reaction to the drug. During RT interruptions, bicalutamide will be continued. Any treatment interruptions or failure of the patient to comply with the prescribed medication schedule must be documented and reported to NRG Oncology.
7.1.6 Toxicity: Consult the package insert for comprehensive toxicity information. In animal experiments, birth defects (abnormal genitalia, hypospadias) were found in male offspring from female animals dosed with bicalutamide during pregnancy. Although offspring from male animals dosed with bicalutamide did not show any birth defects, patients enrolled in this trial are advised not to cause pregnancy nor donate sperm while receiving protocol therapy or during the first 3 months after cessation of therapy. The use of barrier contraceptives is advised. The most frequent adverse events reported among subjects receiving bicalutamide therapy are breast tenderness, breast swelling, and hot flashes. When bicalutamide 50 mg was given in combination with an LHRH analog, the LHRH analog adverse event profile predominated with a high incidence of hot flashes (53%) and relatively low incidences of gynecomastia (4.7%) and breast pain (3.2%). Other side effects include impotence and loss of libido, fatigue, and rarely, photosensitivity and diarrhea.

7.1.7 Dose Modifications: AST or ALT together with the CBC and differential will be measured pretreatment and as clinically indicated during radiotherapy (see Appendix I). If the AST or ALT rises to ≥ 2x the institutional upper limit of normal, bicalutamide must be discontinued. Elevated AST/ALT values to < 2x the institutional upper limit of normal are subject to dose modifications or discontinuation of anti-androgen at the discretion of the treating physician.

7.2 Anti-Androgen Therapy: Eulexin (Flutamide) (2/26/14)
For further information, consult the package insert.
7.2.1 Timing: See Section 7.1.1.
7.2.2 Description: Flutamide is a substituted anilide. It is a fine, light, yellow powder, insoluble in water but soluble in common organic solvents such as aromatic or halogenated hydrocarbons. Its concentration in plasma can be determined by gas chromatography. Flutamide is a nonsteroidal antiandrogen that is metabolized into a hydroxylated derivative, which effectively competes with the hydrotestosterone for androgen receptor sites.
7.2.3 Supply: Commercially available.
7.2.4 Storage: Flutamide should be stored at temperatures ranging from 20-30°C (68-86°F) and protected from excessive moisture.
7.2.5 Administration: Flutamide is administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg. Administration will be suspended only if there is an apparent or suspected reaction to the drug. During RT interruptions, flutamide will be continued. Any treatment interruptions or failure of the patient to comply with the prescribed medication schedule must be documented and reported to NRG Oncology.
7.2.6 Toxicity: Consult the package insert for comprehensive toxicity information. The reported side effects of treatment include diarrhea and anemia. A high percentage of patients treated with flutamide alone developed gynecomastia within 2 to 8 months. There have been post-marketing reports of hospitalization, and, rarely, death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after prompt discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide. Other side effects include impotence and loss of libido, fatigue, and rarely, photosensitivity.
7.2.7 Dose Modifications: If gastrointestinal disturbances (cramps, diarrhea) occur prior to initiation of radiotherapy, flutamide will be withheld until the side effects subside; the drug will then be reintroduced at a dose of 250 mg/day and increased (at 3-day intervals) to 500 mg/day and then to 750 mg/day as tolerated. If gastrointestinal disturbances occur after administration of radiotherapy, it might be difficult to identify their cause. However, if severity of diarrhea exceeds the level commonly observed during prostate irradiation, the toxicity will be ascribed to flutamide and the drug will be permanently discontinued. AST or ALT together with the CBC
and differential will be measured pretreatment and as clinically indicated during radiotherapy (see Appendix I). If AST or ALT increase ≥ 2x the institutional upper limit of normal, flutamide must be discontinued. Elevated AST/ALT values to < 2x the institutional upper limit of normal are subject to dose modifications or discontinuation of anti-androgen at the discretion of the treating physician.

7.3 LHRH Agonist/Antagonist Therapy (leuprolide, goserelin, buserelin, triptorelin/degareliz) (4/20/16)

For additional information, consult the package inserts.

7.3.1 Timing: The first LHRH agonist/antagonist administration will occur within 0-14 days (can begin before, same day as, or after) of the start of anti-androgen treatment (see Sections 7.1 and 7.2). The radiotherapy should begin 8-10 weeks after the date of the first LHRH agonist/antagonist injection. The total duration of LHRH therapy will be 4 or 6 months (short term) or 32 months (long term) of total cumulative administered dose, at the treating physician’s discretion. The total administered duration as well as the specific agent used must be documented and submitted to NRG Oncology.

7.3.2 Description: LHRH agonists/antagonists are long-acting analogs of the native LHRH peptide and are effective at reducing serum testosterone. Analogs approved by the FDA (or by Health Canada for Canadian institutions) can be used in this study.

7.3.3 Supply: Commercially available. (Note: Buserelin is not commercially available in the United States. It is commercially available for use in Canada and other countries.)

7.3.4 Storage: LHRH analogs should be stored as directed by the commercial supplier.

7.3.5 Administration: LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall (Zoladex), intramuscular injection (Lupron), or subcutaneous injection (Eligard). Any duration formulation (1, 3, 4, or 6-month based on the manufacturer) is permitted to allow the duration of hormonal therapy to total 4 or 6 months or 32 months. The manufacturer's instructions should be followed.

7.3.6 Toxicity: Consult the package insert for comprehensive toxicity information. Class-related toxicity is generally a manifestation of the mechanism of action and related to low testosterone levels. In the majority of patients testosterone levels increase above normal in the first week, declining thereafter to baseline levels or below by the end of the second week of treatment. The most common side effect of LHRH analogs is vasomotor hot flashes; edema, gynecomastia, bone pain, thrombosis, and gastrointestinal disturbances have occurred. Potential exacerbations of signs and symptoms during the first few weeks of treatment is a concern in patients with vertebral metastases and/or urinary obstruction or hematuria which, if aggravated, may lead to neurological problems such as temporary weakness and/or paresthesia of the lower limbs or worsening of urinary symptoms. Other side effects include impotence and loss of libido, weight gain, depression, dizziness, loss of bone density, anemia, increased thirst and urination, unusual taste in the mouth, skin redness or hives, pain at injection site, and muscle mass and strength loss, hair changes, penile length and testicular volume loss, increased cholesterol, hypertension, diabetes exacerbation, emotional lability, nausea, vomiting, and rarely, allergic generalized rash and difficulty breathing.

7.4 Adverse Events (2/26/14)

This study will utilize the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4 for adverse event (AE) reporting. The CTCAE version 4 is identified and located on the CTEP web site at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. All appropriate treatment areas should have access to a copy of the CTCAE version 4.

Adverse events (AEs) that meet expedited reporting criteria defined in the table(s) below will be reported via the CTEP Adverse Event Reporting System (CTEP-AERS) application accessed via the CTEP web site (https://eapps-ctep.nci.nih.gov/ctepaers/pages/task?rand=1389817585865).

7.4.1 Adverse Events (AEs)

Definition of an AE: Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product (attribution of unrelated, unlikely, possible, probable, or definite). (International Conference on Harmonisation [ICH], E2A, E6).
7.4.2 Serious Adverse Events (SAEs) — Serious adverse events (SAEs) that meet expedited reporting criteria defined in the table in Section 7.5 will be reported via CTEP-AERS. SAEs that require 24 hour CTEP-AERS notification are defined in the expedited reporting table in Section 7.5. Contact the CTEP-AERS Help Desk if assistance is required.

Definition of an SAE: Any adverse drug event (experience) occurring at any dose that results in any of the following outcomes:
- Death;
- A life-threatening adverse drug experience;
- Inpatient hospitalization or prolongation of existing hospitalization;
- A persistent or significant disability/incapacity;
- A congenital anomaly/birth defect;
- Important medical events (IME) that may not result in death, be life threatening, or require hospitalization may be considered an SAE, when, based upon medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definition.

7.4.3 Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
AML or MDS that is diagnosed as a secondary malignancy during or subsequent to treatment in patients on NCI/CTEP-sponsored clinical trials must be reported via the CTEP-AERS system within 30 days of AML/MDS diagnosis.

Secondary Malignancy
A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g., treatment with investigational agent/intervention, radiation or chemotherapy). A secondary malignancy is not considered a metastasis of the initial neoplasm.

CTEP requires all secondary malignancies that occur following treatment with an agent under an NCI IND/IDE be reported via CTEP-AERS. Three options are available to describe the event:
- Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia [AML])
- Myelodysplastic syndrome (MDS)
- Treatment-related secondary malignancy

Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported via the routine reporting mechanisms outlined in each protocol.

Second Malignancy
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a metastasis from the initial malignancy). Second malignancies require ONLY routine reporting via CDUS unless otherwise specified.

7.5 CTEP-AERS Adverse Event Reporting Requirements (2/26/14)
All serious adverse events that meet expedited reporting criteria defined in the reporting table below will be reported via CTEP-AERS, the CTEP Adverse Event Reporting System, accessed via the CTEP web site, https://eapps-ctep.nci.nih.gov/ctepaers/pages/task?rand=1389817585865.

Submitting a report via CTEP-AERS serves as notification to NRG Oncology and satisfies NRG Oncology requirements for expedited adverse event reporting.

CTEP-AERS provides a radiation therapy-only pathway for events experienced that involve radiation therapy only. These events must be reported via the CTEP-AERS radiation therapy-only pathway.
In the rare event when Internet connectivity is disrupted, a 24-hour notification must be made to the NRG Oncology Operations Office at 1-800-227-5463, ext. 4189, for instances when Internet fails. Once internet connectivity is restored, an AE report submitted by phone must be entered electronically into CTEP-AERS.

- **CTEP-AERS-24 Hour Notification** requires that a CTEP-AERS 24-hour notification is electronically submitted within 24 hours of learning of the adverse event. Each CTEP-AERS 24-hour notification must be followed by a CTEP-AERS 5 Calendar Day Report. Serious adverse events that require 24 hour CTEP-AERS notification are defined in the expedited reporting table below.

- Supporting source document is not mandatory. However, if the CTEP-AERS report indicates in the *Additional Information* section that source documentation will be provided, then it is expected. If supporting source documentation accompanies a CTEP-AERS report, include the protocol number, patient ID number, and CTEP-AERS ticket number on each page, and fax supporting documentation to the NRG Oncology dedicated SAE FAX, 215-717-0990.

- A serious adverse event that meets expedited reporting criteria outlined in the following table but is assessed by the CTEP-AERS System as "expedited reporting NOT required" must still be reported to fulfill NRG Oncology safety reporting obligations. Sites must bypass the "NOT Required" assessment; the CTEP-AERS System allows submission of all reports regardless of the results of the assessment.

CTEP defines expedited AE reporting requirements for phase 2 and 3 trials as described in the table below. **Important:** All AEs reported via CTEP-AERS also must be reported on the AE section of the appropriate case report form (see Section 12.1).
**Late Phase 2 and Phase 3 Studies: Expedited Reporting Requirements for Adverse Events that Occur within 30 Days of the Last Administration of the Commercially Available Agent**

**FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)**

**NOTE:** Investigators **MUST** immediately report to the sponsor (NCI) **ANY** Serious Adverse Events, whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)

An adverse event is considered serious if it results in **ANY** of the following outcomes:

1. Death
2. A life-threatening adverse event
3. An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for ≥ 24 hours
4. A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
5. A congenital anomaly/birth defect.
6. Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).

**ALL SERIOUS** adverse events that meet the above criteria **MUST** be immediately reported to the NCI via CTEP-AERS within the timeframes detailed in the table below.

<table>
<thead>
<tr>
<th>Hospitalization</th>
<th>Grade 1 Timeframes</th>
<th>Grade 2 Timeframes</th>
<th>Grade 3 Timeframes</th>
<th>Grade 4 &amp; 5 Timeframes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resulting in Hospitalization ≥ 24 hrs</td>
<td>10 Calendar Days</td>
<td></td>
<td></td>
<td>24-Hour 5 Calendar Days</td>
</tr>
<tr>
<td>Not resulting in Hospitalization ≥ 24 hrs</td>
<td>Not required</td>
<td>10 Calendar Days</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR

**Expedited AE reporting timelines are defined as:**

- **"24-Hour; 5 Calendar Days"** - The AE must initially be reported via CTEP-AERS within 24 hours of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.
- **"10 Calendar Days"** - A complete expedited report on the AE must be submitted within 10 calendar days of learning of the AE.

1. Serious adverse events that occur more than 30 days after the last administration of commercially available agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:
   - **Expedited 24-hour notification followed by complete report within 5 calendar days for:**
     - All Grade 4, and Grade 5 AEs
   - **Expedited 10 calendar day reports for:**
     - Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization
     - Grade 3 adverse events

2. For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded UP to the nearest whole day, after the agent/intervention was last administered. Footnote “1” above applies after this reporting period.

**Effective Date:** May 5, 2011

---

**8.0 SURGERY**

Not applicable to this study.

**9.0 OTHER THERAPY**

Not applicable to this study.
10.0 TISSUE/SPECIMEN SUBMISSION

Patients must be offered the opportunity to participate in the correlative components of the study, such as tissue/specimen submission or quality of life assessment. If the patient consents to participate in the tissue/specimen component of the study, the site is required to submit the patient’s specimens as specified in Section 10.0 of the protocol. Note: Sites are not permitted to delete the tissue/specimen component from the protocol or from the sample consent.

10.1 Tissue/Specimen Submission

The NRG Oncology Biospecimen Bank-San Francisco, located at the University of California San Francisco acquires and maintains high quality specimens from NRG Oncology trials. Tissue from each block is preserved through careful block storage and processing. The NRG Oncology encourages participants in protocol studies to consent to the banking of their tissue. The NRG Oncology Biospecimen Bank provides tissue specimens to investigators for translational research studies. Translational research studies integrate the newest research findings into current protocols to investigate important biologic questions. The NRG Oncology Biospecimen Bank also collects tissue for Central Review of pathology. Central Review of tissue can be for eligibility and/or analysis.

10.1.1 In this study, tissue, blood, and urine will be submitted to the NRG Oncology Biospecimen Bank for the purpose of tissue banking and translational research (recommended).

- Anticipated analysis for collected tissue includes a validation of previous work showing that a 3-6 gene signature from the primary tumor is able to predict lymph node status prospectively. If validated using tissue collected as part of this study, this signature will be applied in future protocols for patient stratification for whole pelvic radiotherapy.
- Anticipated analyses for collected plasma include circulating markers that may correlate to patient reported outcomes. An example of one anticipated analysis is the evaluation of plasma cytokines for correlation to fatigue as measured by the PROMIS instrument in patients enrolled on this trial. Examples of cytokines that may be tested include CRP, TNF alpha, IL-1, IL-1ra, and IL-6.
- Anticipated analyses for collected blood include evaluation of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) through screening DNA samples derived from case and matched control subjects using Affymetrix 6.0 microarrays. Case subjects will be patients that represent the 20% of patients in this study exhibiting the highest levels of fatigue as defined and measured by the PROMIS instrument used in this study while controls will be the 20% of patients who reported the lowest levels of fatigue as quantified using PROMIS. The goal will be to identify SNPs and CNVs associated with the development of fatigue in prostate cancer patients following radiotherapy.

10.2 Specimen Collection for Tissue Banking and Translational Research (Recommended)

(4/20/16)

For patients who have consented to participate in the tissue/blood component of the study (See sample consent).

Blood collection is mandatory for patients who consented for the quality of life (QOL) portion of this study and is optional for other participants. Note: The QOL portion of the study is closed to new accrual.

The following must be provided in order for the case to be evaluable for the Biospecimen Bank:

10.2.1 One H&E stained slide (slide can be a duplicate cut stained H&E of the diagnostic slide [block]; it does not have to be the diagnostic slide itself)

10.2.2 A corresponding paraffin-embedded tissue block of the tumor (the block must match the H&E being submitted) or 10-15 unstained slides (5 micron cut onto positive charged slides) of tumor tissue. Block or slides must come from the same block and be clearly labeled with the pathology identification number and block number that corresponds to the Pathology Report.

10.2.3 A Pathology Report documenting that the submitted block or slides contain tumor. The report must include the NRG Oncology protocol number and patient’s case number. The patient’s name and/or other identifying information should be removed from the report. The surgical pathology numbers and information must NOT be removed from the report.

- The submitted material must be from malignant tumor, not necrotic or fibrotic tissue. If the submitted material is reviewed and is not tumor, the site may be assessed a protocol violation.

10.2.4 A Specimen Transmittal Form clearly stating that tissue is being submitted for the NRG Oncology Biospecimen Bank; if for translational research, this should be stated on the form.
The form must include a label with the NRG Oncology protocol number, patient’s case number, institution name and NRG Oncology institution number.

### 10.2.5 Serum, plasma, whole blood cells, and urine

See Appendix IV for the blood and urine collection kits and instructions. Note: Kits include a label for batch shipping. The following materials must be provided in order for the case to be evaluable by the NRG Oncology Biospecimen Bank: A Specimen Transmittal Form documenting the date of collection of the biospecimen; the NRG Oncology protocol number, the patient’s case number, institution's NRG ID and name, time point of study, and method of storage, for example, stored at -80°C, must be included.

### 10.2.6 Storage Conditions

Store frozen specimens at -80°C (-70°C to -90°C) until ready to ship. If a -80°C freezer is not available:

- Samples can be stored short term in a -20°C freezer (non-frost free preferred) for up to one week (please ship out Monday-Wednesday only; Canada: Monday-Tuesday).

**OR:**

- Samples can be stored in plenty of dry ice for up to one week, replenishing daily (ship out Monday-Wednesday only; Canada: Monday-Tuesday).

**OR:**

- Samples can be stored in liquid nitrogen vapor phase (ship out Monday-Wednesday only; Canada: Monday-Tuesday).

Please indicate on Specimen Transmittal Form the storage conditions used and time stored.

### 10.2.7 Specimen Collection Summary

<table>
<thead>
<tr>
<th>Specimens for Tissue Banking/Translational Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimens taken from patient:</td>
</tr>
<tr>
<td>Collected when:</td>
</tr>
<tr>
<td>Submitted as:</td>
</tr>
<tr>
<td>Shipped:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Representative H&amp;E stained slides of the primary tumor</th>
<th>Pre-treatment</th>
<th>H&amp;E stained slide</th>
<th>Slide shipped ambient</th>
</tr>
</thead>
<tbody>
<tr>
<td>A corresponding paraffin-embedded tissue block of the primary tumor taken before initiation of treatment</td>
<td>Pre-treatment</td>
<td>Paraffin-embedded tissue block (must match the H&amp;E slide being submitted). For sites unable to provide the block then or 10-15 unstained slides are an acceptable alternative (5 micron cut onto positively charged slides)</td>
<td>Block or slides shipped ambient. Use of a cold pack is recommended during warm weather.</td>
</tr>
<tr>
<td>SERUM: 5-10 mL of whole blood in 1 red-top tube and centrifuge</td>
<td>Pre-treatment</td>
<td>Frozen serum samples containing minimum <strong>0.5 mL</strong> per aliquot in 1 mL cryovials (five). Store frozen at -80°C until ready to ship</td>
<td>Serum sent frozen on dry ice via overnight carrier</td>
</tr>
<tr>
<td>PLASMA: 5-10 mL of anticoagulated whole blood in EDTA tube #1 (purple/lavender top) and centrifuge</td>
<td>Prior to RT and last week of RT</td>
<td>Frozen plasma samples containing <strong>0.5 mL</strong> per aliquot in 1 mL cryovials (five). Store frozen at -80°C until ready to ship</td>
<td>Plasma sent frozen on dry ice via overnight carrier</td>
</tr>
<tr>
<td>DNA: 5-10 mL of</td>
<td>Pre-treatment</td>
<td>Frozen whole blood</td>
<td>Whole blood sent</td>
</tr>
</tbody>
</table>
anticoagulated whole blood in EDTA tube #2 (purple/lavender top) and mix

<table>
<thead>
<tr>
<th>Note: If this collection is missed, the site can collect whole blood for DNA at any time point. The timepoint must be noted on the Specimen Transmittal Form</th>
<th>samples containing 1 mL per aliquot in 1ml cryovials (three to five). Store frozen at -80°C until ready to ship</th>
<th>frozen on dry ice via overnight carrier</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-20 mL clean-catch urine</td>
<td>Pre-treatment</td>
<td>Two 5-10 mL urine aliquots in 2 sterile 15 ml polypropylene centrifuge tubes. Store frozen at -80°C. (-20°C is allowed for short term storage)</td>
</tr>
</tbody>
</table>

10.2.8 Submit materials for Tissue Banking and Translational Research as follows:

**U. S. Postal Service Mailing Address:** For Non-frozen Specimens Only
NRG Oncology Biospecimen Bank - San Francisco
University of California San Francisco
Department of Radiation Oncology - Box 18002340 Sutter Street, Room S341
San Francisco, CA 94143

**Courier Address (FedEx, UPS, etc.):** For Trackable FFPE and ALL Frozen Specimens
NRG Oncology Biospecimen Bank - San Francisco
University of California San Francisco
2340 Sutter Street, Room S341
San Francisco, CA 94115

Questions: 415-476-7864/FAX 415-476-5271; NRGBB@ucsf.edu

10.3 Reimbursement (4/27/15)
NCI funds for reimbursement for protocol-specified biospecimen materials will be distributed per the requirements/methods specified by the new NCTN Program. This information will be made available with the other registration materials in the Oncology Patient Enrollment Network (OPEN) portal system. OPEN will serve as the registration system for all patient enrollments onto NCI-sponsored NCTN trials, including this study, which will be transitioned into the new Program from the NCI-sponsored Cooperative Group Clinical Trials Program.

10.4 Confidentiality/Storage

10.4.1 Upon receipt, the specimen is labeled with the RTOG protocol number and the patient's case number only. The NRG Oncology Biospecimen Bank database only includes the following information: the number of specimens received, the date the specimens were received, documentation of material sent to a qualified investigator, type of material sent, and the date the specimens were sent to the investigator. No clinical information is kept in the database.

10.4.2 Specimens for tissue banking will be stored for an indefinite period of time. Specimens for the translational research component of this protocol will be retained until the study is terminated, unless the patient has consented to storage for future studies. If at any time the patient withdraws consent to store and use specimens, the material will be returned to the institution that submitted it.

11.0 PATIENT ASSESSMENTS

11.1 Study Parameters: See Appendix I for a summary of patient assessments.

11.2 Criteria for Discontinuation of Protocol Treatment
- Progression of disease;
- A delay in protocol treatment, as specified in Sections 6.0 and/or 7.0.
If protocol treatment is discontinued, follow up and data collection will continue as specified in the protocol.

11.3 Quality of Life Assessments (4/27/15)

NOTE: The quality of life (QOL) component of this study closed to patient accrual on 3/9/15. If the patient provided consent to participate in the quality of life component of this study, the site is required to administer the QOL assessments specified below. **Blood collection is mandatory for patients who have provided consent to the QOL portion of this study** (see **Section 10.0**).

The following instruments will be used to assess health related quality of life (HRQOL), including fatigue and quality adjusted survival: the Expanded Prostate Cancer Index (EPIC)-26, the Patient-Reported Outcome Measurement Information System (PROMIS)-fatigue short form, and the EuroQol (EQ-5D) instrument. The EPIC-26, PROMIS-fatigue short form, and EQ-5D will be collected at pretreatment (baseline), the week prior to starting RT *(EPIC and EQ-5D only)*, and 6 months, 1 year and 5 years after therapy starts. At the same time points, the QL form (i.e., one item from the PSQI, 3 items from the GLTEQ, and one question regarding general muscle weakness) will be collected. In addition, in order to correlate fatigue with the cytokine changes, the PROMIS-fatigue short form (and the associated questions) also will be collected at the following time points: the last week of RT, and 3 months post RT.

11.3.1 The Expanded Prostate Cancer Index Composite (EPIC)

The EPIC is a prostate cancer health-related quality of life (HRQOL) patient self-administered instrument that measures a broad spectrum of urinary, bowel, sexual, and hormonal symptoms related to radiotherapy and hormonal therapy. To reduce patient burden, an abbreviated version of the EPIC (EPIC-26) was developed and validated.

11.3.2 PROMIS-Fatigue Short Form

The PROMIS Fatigue Scale of 7 items was created using items selected for consistency in the response scale, broad coverage across the fatigue continuum (i.e., high to low), and good precision of measurement (discrimination function).

11.3.3 EuroQol (EQ-5D)

The EQ-5D is a patient self-administered questionnaire that takes approximately 5 minutes to complete. The first part consists of 5 items covering 5 dimensions including: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension can be graded on 3 levels: 1-no problems, 2-moderate problems, and 3-extreme problems. The EQ-5D has been translated into most major languages, with the EuroQol Group closely monitoring the translation process; translations can be accessed at [http://www.euroqol.org/](http://www.euroqol.org/).

11.4 Optional Online Completion of PRO Assessments (4/27/15)

NOTE: The quality of life (QOL) component of this study closed to patient accrual on 3/9/15.

11.4.1 Patients who consent to participate in the PRO data completion have the option of completing PRO forms online from any location, including home, via VisionTree Optimal Care (VTOC). Patients without e-mail or Internet access can participate in the PRO component of the study by completing hardcopy (paper) forms. Indeed, at any time, any patient may choose to fill out their PRO form using the hardcopy form. The PRO forms completed via VTOC are identical to the hardcopy forms; this technology does not add to or change the PRO assessments in this study.

11.4.2 If the patient wishes to complete PRO assessments online, the patient must have an e-mail address that they consent to use for this purpose. Patients’ e-mail addresses are necessary so that e-mail reminders may be sent to them to remind them to fill out PRO forms that are due. The patient's e-mail address also will be used for password-protected access to VisionTree Optimal Care (VTOC). Patients who are interested in participating but do not yet have an e-mail address can obtain one for free from a number of sources (e.g., Yahoo!, Hotmail, or AOL).

11.4.3 VTOC will send patients e-mail reminders to complete PRO forms. The first reminder will be sent at the beginning of the window for completion of the form, with a second reminder sent halfway through the window, if the form has not yet been completed. A maximum of 3 reminders will be sent for each of the PRO assessment time points. After the patient has completed all forms, a dialogue box will appear thanking the patient for completing the PRO form(s), and the patient will no longer receive reminders for that time point.

11.4.4 Site Research Associates (RAs) will receive training in the use of VTOC via NRG Oncology webinars and educational sessions. The RA or study administrator will be informed via the VTOC “At a Glance” form management system when PRO forms have been completed or when the window for a particular form has closed. If the site RA receives a notice that forms
have not been completed, she or he will contact the patient to remind the patient to fill out the PRO form or inquire why the forms have not been completed. The RA will complete the cover page for each form that was not completed (either via VTOC or in hardcopy) and will submit the cover page to NRG Oncology (see Section 12.1). All pretreatment QOL assessments (EPIC-26, PROMIS-fatigue, EQ-5D) are to be completed at the site regardless of the patient’s consent to use VTOC. Patients who consent to use VTOC will complete all follow-up assessments using the VTOC software only.

12.0 DATA COLLECTION

Data should be submitted to:

NRG Oncology*
1818 Market Street, Suite 1720
Philadelphia, PA 19103

*If a data form is available for web entry, it must be submitted electronically.

Patients will be identified by initials only (first middle last); if there is no middle initial, a hyphen will be used (first-last). Last names with apostrophes will be identified by the first letter of the last name.

12.1 Summary of Data Submission

<table>
<thead>
<tr>
<th>Item</th>
<th>Due</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic Form (A5)</td>
<td>Within 1 week of registration</td>
</tr>
<tr>
<td>Initial Evaluation Form (I1)</td>
<td>Within 1 week of registration</td>
</tr>
<tr>
<td>Pathology Report (P1) (copy of diagnostic report)</td>
<td></td>
</tr>
<tr>
<td>EPIC (FA)</td>
<td>During the week prior to the start of RT</td>
</tr>
<tr>
<td>EQ-5D (QF)</td>
<td>During the last week of RT, and then 3 months post RT</td>
</tr>
<tr>
<td>PROMIS (HP)</td>
<td></td>
</tr>
<tr>
<td>PSQI/GLTEQ form (QL)</td>
<td>6 months, 1 year and 5 years post RT</td>
</tr>
<tr>
<td>EPIC (FA)</td>
<td>Short term NADT: Prior to the start of RT, 3 months post RT</td>
</tr>
<tr>
<td>EQ-5D (QF)</td>
<td>Long term NADT: Prior to the start of RT, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months post RT</td>
</tr>
<tr>
<td>PROMIS (HP)</td>
<td></td>
</tr>
<tr>
<td>PSQI/GLTEQ form (QL)</td>
<td>Short term NADT: Starting at 6 months post RT, then 9 months and 12 months post RT for year 1; every 6 months for years 2-5; then annually.</td>
</tr>
<tr>
<td>PROMIS (HP)</td>
<td>Long term NADT: Starting at 42 months post RT, then every 6 months for years 4 and 5; then annually.</td>
</tr>
<tr>
<td>Interim follow-up form (F0)</td>
<td></td>
</tr>
<tr>
<td>Follow-up form (F1)</td>
<td></td>
</tr>
</tbody>
</table>
## 12.2 Summary of Dosimetry Digital Data Submission (4/27/15)
Submit to TRIAD; see Section 5.0 for account access and installation instructions. Hardcopies should be sent to:

IROC Houston  
ATTN: Dosimetry  
8060 El Rio Street  
Houston, TX 77054  
Phone: 713-745-8989; Fax: 713-794-1364  
E-mail: irochouston@mdanderson.org

<table>
<thead>
<tr>
<th>Data Submission Requirements</th>
<th>DUE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITEM</strong></td>
<td></td>
</tr>
<tr>
<td>Note: For patients treated with EBRT + IMRT boost, the site must submit the Digital Data for both phase I and phase II in only one TRIAD submission.</td>
<td></td>
</tr>
<tr>
<td><strong>Arm 1 &amp; Arm 2 Phase 1 EBRT</strong></td>
<td></td>
</tr>
<tr>
<td>DICOM Items</td>
<td>DICOM CT Image</td>
</tr>
<tr>
<td></td>
<td>DICOM Structure</td>
</tr>
<tr>
<td></td>
<td>DICOM Dose</td>
</tr>
<tr>
<td></td>
<td>DICOM RT Plan</td>
</tr>
<tr>
<td>Contour and DVH Analysis Worksheet (DV)</td>
<td></td>
</tr>
<tr>
<td>Digital Data Submission Information Form (DDSI)</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx">http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx</a></td>
<td></td>
</tr>
<tr>
<td><strong>Arm 1 &amp; Arm 2 Phase 2 EBRT</strong></td>
<td></td>
</tr>
<tr>
<td>DICOM Items</td>
<td>DICOM CT Image</td>
</tr>
<tr>
<td></td>
<td>DICOM Structure</td>
</tr>
<tr>
<td></td>
<td>DICOM Dose (Phase 2)</td>
</tr>
<tr>
<td></td>
<td>DICOM RT Plan (Phase 2)</td>
</tr>
<tr>
<td></td>
<td>DICOM Dose (Composite)*</td>
</tr>
<tr>
<td></td>
<td>DICOM RT Plan (Composite)*</td>
</tr>
<tr>
<td>*Composite data is a required submission, if data can be exported from planning system</td>
<td></td>
</tr>
<tr>
<td>Contour and DVH Analysis Worksheet (DV)</td>
<td></td>
</tr>
<tr>
<td>Digital Data Submission Information Form (DDSI)</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx">http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx</a></td>
<td></td>
</tr>
<tr>
<td><strong>Arm 1 &amp; Arm 2 Phase 2 LDR/HDR Brachy Boost</strong></td>
<td></td>
</tr>
<tr>
<td>DICOM Items</td>
<td>DICOM CT Image</td>
</tr>
<tr>
<td></td>
<td>DICOM Structure</td>
</tr>
<tr>
<td></td>
<td>DICOM Dose</td>
</tr>
<tr>
<td></td>
<td>DICOM RT Plan</td>
</tr>
<tr>
<td></td>
<td>TRUS Scans (2 sets-pre/post insertion)</td>
</tr>
<tr>
<td></td>
<td>TRUS Based HDR Brachytherapy only</td>
</tr>
<tr>
<td>Contour and DVH Analysis Worksheet (DV)</td>
<td></td>
</tr>
<tr>
<td>Digital Data Submission Information Form (DDSI)</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx">http://www.rtog.org/CoreLab/RTQASubmissionInformation.aspx</a></td>
<td></td>
</tr>
<tr>
<td>NRG Oncology Prostate Brachytherapy Protocol Compliance Form-Available on the RPC website, <a href="http://irochouston.mdanderson.org">http://irochouston.mdanderson.org</a></td>
<td></td>
</tr>
</tbody>
</table>
13.0 STATISTICAL CONSIDERATIONS

13.1 Primary Endpoint
13.1.1 Overall survival (OS): death due to any cause

13.2 Secondary Endpoints (4/27/15)
13.2.1 Cause-specific survival (CSS): The event for CSS will be death due to prostate cancer;
13.2.2 Distant metastasis (DM);
13.2.3 Biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the nadir PSA) [Roach 2006];
13.2.4 Incidence of “acute” adverse events (based on the current version of CTCAE): The acute adverse events will be the first occurrence of worst severity of the adverse event ≤ 30 days of the completion of RT;
13.2.5 Time to “late” grade 3+ adverse events (based on the current version of CTCAE): The time of a first late grade 3+ adverse event, defined as > 30 days from the completion of RT;
13.2.6 Comparison of prostate cancer-specific health related quality of life (HRQOL) change as measured by the EPIC-26 (bowel or urinary domain);
13.2.7 Comparison of fatigue status as measured by the Patient-Reported Outcome Measurement Information System (PROMIS) fatigue domain change score (from baseline to the last week of treatment);
13.2.8 Assessment and comparison of Quality Adjusted Life Years (QALYs)
13.2.9 Collect paraffin-embedded tissue blocks, plasma, whole blood, serum, and urine for planned and future translational research analyses.

13.3 Sample Size and Accrual (4/20/16)

13.3.1 Sample Size
In our prior study (RTOG 9413) we showed that WPRT was associated with an improvement in progression free survival (PFS) and no statistically significant increase in grade 3 morbidity or mortality. Given our findings we believe it is appropriate to launch a Phase III Trial with the primary endpoint of OS. A patient subset of the PORT+NADT arm of 9413 with similar characteristics to Arm 1 (NADT+P&SV) of this study yielded a 10-year OS of 53%. It is hypothesized for there to be a 6.5% increase in absolute OS in the NADT+WPRT arm (Arm 2), i.e., 10-year OS of 59.5%. This corresponds to an 18% relative reduction in yearly mortality.

Assuming an exponential distribution for OS (each arm) with five planned efficacy analyses (four interim, one final), 10-year OS for Arm 1 of 53% (yearly hazard 0.0635), and 59.5% for Arm 2 (yearly hazard 0.0519), then 1,044 deaths are required to detect an 18.2% relative reduction in yearly hazard rate with 90% power, employing a one-sided log-rank test at the 0.025 level of significance. With 2,400 patients accrued over 8 years, definitive analysis would occur at approximately 16 years from commencement of accrual. Interim analysis efficacy testing will be based on the alpha spending approach (Lan 1983), using a boundary function suggested by Jennison and Turnbull (2000). The futility testing is based on the Freidlin and Korn method (Freidlin 2002) at a nominal significance level of 0.005. Adjustment to the final alpha level to accommodate the efficacy rule requires a nominal increase to 1087 for the required number of events. Guarding against an ineligibility or lack-of-data rate of up to 7.5% among patients enrolled, the final targeted accrual for this study will be 2,580 patients. Patients will be randomized to 1 of 2 treatment arms (ratio 1:1) based on the permuted block randomization.

13.3.2 Accrual and Duration
The proposed trial, RTOG 0924, builds on the experience obtained in five prior NRG Oncology trials including RTOG 9406 (dose escalation with external beam radiotherapy (EBRT), 9413 (PORT vs WPRT), 9202 (long term vs short term ADT), 0321 (EBRT + high dose rate (HDR) brachytherapy, and 0019 (EBRT and permanent prostate implant (PPI). Many of the patients...
treated on these trials were similar to the groups of patients proposed RTOG 0924. Based on the number of patients treated to these studies and our broader eligibility and choice of boost techniques we conservatively expect RTOG 0924 to complete accrual in approximately 9 years. Based on patient accrual in previous NRG Oncology randomized prostate studies, it is expected that there will be no entries during the initial 6 months while institutions are obtaining IRB approval. The total duration of the study is expected to be approximately 16 years from the time the study opens to the time of the final analysis, with at least 7 years of follow-up for each patient, and an average uniform accrual rate of ~300 patients per year, or approximately 25 patients per month.

13.4 Analysis Plans (4/27/15)

13.4.1 Analysis of the Primary Endpoint

The primary endpoint is overall survival (OS). The time to failure will be measured from the date of randomization to the date of documented death. The OS function will be estimated by the Kaplan-Meier method (1958). We want to test whether or not the OS rate in Arm 2 is higher than that of Arm 1. The null and alternative hypotheses are:

\[ H_0: \lambda_1 \leq \lambda_2 \quad \text{vs.} \quad H_\lambda: \lambda_1 > \lambda_2 \]

where, \( \lambda_1 \) and \( \lambda_2 \) are yearly death rate for Arm 1 and Arm 2, respectively. We will use the log-rank test (Mantel 1966; Kim 1990) with a nominal significance level of 0.025 (interim analysis-adjusted level 0.02) at the final analysis to test this hypothesis. In addition, the Cox (1972) proportional hazard regression model will be used to compare the treatment differences, computing both unadjusted and covariate adjusted hazard ratios with respective 95% confidence interval. The risk group (high vs. intermediate), RT modality (IMRT boost vs. HDR+PPI brachytherapy boost), age, and race (as appropriate) will be adjusted for in this latter analysis.

13.4.2 Biochemical Failure by Phoenix Definition

The biochemical failure (BF) rate by 5 years is defined as the proportion of patients with the event of BF by 5 years from randomization among all eligible patients at baseline. BF is defined by the Phoenix definition (PSA ≥2 ng/ml over the nadir PSA) [Roach 2006]. Patients who receive any salvage therapy (e.g., salvage androgen deprivation, vaccine therapy, biologic/small molecule therapy, or chemotherapy) prior to BF will be treated as failures. The salvage ADT is defined as the first administration of subsequent ADT (either LHRH agonist/antagonist or anti-androgen). The rate of salvage ADT is defined as the proportion of patients who have salvage ADT by 5 years among all eligible patients at baseline. The endpoint BF rate by 5 years will be estimated by the cause-specific hazard rate approach (Kalbfleisch and Ross, 1980; Gaynor et al, 1993).

The Z-test statistic for the difference between the two rates with the standard errors estimated by Greenwood’s method will be used, with a significance level of 0.025. The following test statistics (T.S.) will be used for testing between the two arms:

\[
T.S. = \frac{(1 - \hat{p}_1) - (1 - \hat{p}_2)}{\sqrt{\hat{p}_1^2 \sum_{i=1}^{n_1} f_i (r_i - f_i)} + \hat{p}_2^2 \sum_{j=1}^{n_2} f_j (r_j - f_j)} = \frac{\hat{p}_2 - \hat{p}_1}{\sqrt{\hat{p}_1^2 \sum_{i=1}^{n_1} f_i (r_i - f_i)} + \hat{p}_2^2 \sum_{j=1}^{n_2} f_j (r_j - f_j)}
\]

where \( p \) and \( q \) are the BF or the salvage ADT rate of Arm 1 and Arm 2, respectively, estimated by the cumulative incidence method, \( r_i \) is the number of patients who are at risk and \( f_i \) is the number of patients who have BF or the salvage ADT failure events \((i=1,2)\). If \( H_0 \) is rejected, then we conclude that Arm 2 is better than Arm 1. If \( H_0 \) is not rejected, then we conclude that Arm 2 is not better than Arm 1.

In addition, logistic regression (Agresti 1990) will be used to compare the treatment differences in the hypothesis with and without adjustment for at least the following covariates: risk group (high vs. intermediate), RT modality (IMRT boost vs. HDR+PPI brachytherapy boost), age, and
race (as appropriate). Odds ratios and the respective 95% confidence intervals will be computed.

13.4.3 Time to Failure of Secondary Survival Endpoints

CSS will be measured from the date of randomization to the date of death due to prostate cancer. DM will be measured from the date of randomization to the date of documented distant metastasis/clinical and/or radiographic appearance of disseminated disease. Both endpoints will be estimated by the cause-specific hazard rate approach (Kalbfleisch and Ross, 1980; Gaynor et al., 1993). Fine and Gray's regression (Gray 1988; Fine 1999) also will be used for both CSS and DM. Both unadjusted and adjusted hazard ratios and the respective 95% confidence interval will be computed. The stratification variables (risk group, RT modality), age, and race (as appropriate), and possibly other covariates, will be adjusted for in this analysis.

13.4.4 Comparison of the Incidence of Acute Adverse Events and Time to Late Grade 3+ Adverse Events

Adverse events will be scored according to the CTEP active version of the CTCAE. An acute adverse event will be defined as the first occurrence of worst severity of the adverse event occurring less than or equal to 30 days after the completion of RT. Univariate logistic regression (Agresti 1990) will be used to model the distribution of acute adverse events. Multiple logistic regression (Agresti 1990) will be used to model the distribution of acute adverse events adjusted for covariates. Both unadjusted and adjusted odds ratios and the respective 95% confidence interval will be computed and tested using a one-sided Chi-Square test statistic with the significance level of 0.025. Late grade 3+ adverse events will be defined as grade 3+ adverse events occurring more than 30 days after the completion of RT. The time to late grade 3+ adverse events will be measured from the time protocol treatment started to the time of the worst late grade 3+ adverse event. If no such late adverse event is observed until the time of the analysis, the patient will be censored at the time of the analysis. Death without late adverse event will be considered as the competing risk for late adverse events and the distribution of time to late grade 3+ adverse events will be estimated using the cause-specific hazard rate approach (Kalbfleisch and Ross, 1980; Gaynor et al., 1993) and tested using a significance level of 0.025. A Fine and Gray’s regression model (Fine 1999) will be used to compare the treatment differences of time to late adverse event with and without adjusting for other covariates. Both unadjusted and adjusted hazard ratios and the respective 95% confidence interval will be computed. At least the treatment arm, the stratification variables (risk group RT modality), age, and race (as appropriate) will be considered when it is adjusted in the analysis.

13.4.5 Group Sequential Testing for Early Termination and Reporting of Efficacy and Futility

A group sequential test with four planned interim analyses and a final analysis will be performed. The interim analysis will be carried out when the cumulative deaths are met. At each planned interim analysis, the p-value from the log-rank test statistic assessing treatment efficacy and futility with respect to the primary endpoint, OS, will be compared to the nominal significance level. The efficacy testing is based on the Lan-DeMets alpha-spending approach (Lan 1983) that is similar to boundaries suggested by Jennison and Turnbull (2000) [see Table 5 for nominal significance level for efficacy testing] and for the futility testing boundary we will use a less aggressive boundary, Rule C (at a nominal significance level of 0.005) in Freidlin and Korn (2002). The following hypotheses are tested:

\[ H_0: \lambda_1 \leq \lambda_2 \ \text{ vs. } \ H_A: \lambda_1 > \lambda_2 \]

where \( \lambda_1 \) and \( \lambda_2 \) are the hazard rate for Arm 1 and Arm 2, respectively. If the \( H_0 \) is rejected, then we conclude that the OS rate of Arm 2 will be better than Arm 1 and stop accrual if applicable.

**Table 5: Schedule for the Planned Interim Analysis**

<table>
<thead>
<tr>
<th>Information Time</th>
<th>Estimated Analysis Time*</th>
<th>Cumulative Number of Deaths in the Two Arms</th>
<th>Z-value to Reject for Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.20</td>
<td>5.4 years</td>
<td>217</td>
<td>≥3.322</td>
</tr>
<tr>
<td>0.40</td>
<td>7.6 years</td>
<td>435</td>
<td>≥2.843</td>
</tr>
<tr>
<td>0.60</td>
<td>9.7 years</td>
<td>652</td>
<td>≥2.535</td>
</tr>
<tr>
<td>0.80</td>
<td>12.0 years</td>
<td>870</td>
<td>≥2.288</td>
</tr>
<tr>
<td>1.00</td>
<td>14.6 years</td>
<td>1087</td>
<td>≥2.074</td>
</tr>
</tbody>
</table>
*Time to the interim analysis from the first patient entry without considering ineligibility or lack-of-data rate and under the null hypothesis

For futility testing, the alternative hypotheses, $H_A (\lambda_1 / \lambda_2 = 1.224)$ will be tested at 0.005 level (the futility nominal significance level). If the computed p-value is less than 0.005 then we will consider stopping the trial in favor of the $H_0$ and conclude that the overall survival rate of Arm 1 will be better than Arm 2. Otherwise, we will continue the trial.

Phase III trials are required by NCI Cooperative Group Program Guidelines to be reviewed by a Data and Safety Monitoring Committee (DSMC). This study will be reviewed by the NRG Oncology Data Monitoring Committee (DMC) on a semi-annual basis in January and June. Based on the results of each interim analysis, the following action will be taken and the responsible statistician will recommend to the NRG Oncology DMC that the randomization be discontinued, if applicable, and the study be considered for early publication. Before making such a recommendation, the accrual rate, treatment compliance, safety of the treatments, and the importance of the study are taken into consideration along with the p-value. The NRG Oncology DMC will then make a recommendation about the trial to the NRG Oncology Group Chair.

13.4.6 Interim Report to Monitor the Study Progress
Interim reports with descriptive statistics will be prepared twice per year until the initial paper reporting the treatment results has been submitted. In general, the interim reports will contain information about the patient accrual rate with a projected completion date for the accrual phase, compliance rate of treatment delivery with the distributions of important prognostic baseline variables, and the frequencies and severity of the adverse event by treatment arm. The interim reports will not contain the results of the treatment comparisons with respect to the primary endpoint and secondary endpoints.

This study will be monitored by the Clinical Data Update System (CDUS) version 3.0. Cumulative CDUS data will be submitted quarterly by electronic means. Reports are due January 31, April 30, July 31, and October 31.

13.4.7 Reporting the Initial Treatment Analysis
The analysis reporting the treatment results will be carried out after the criteria for early stopping/reporting are met. Five interim analyses and one final analysis will be performed for efficacy and futility of the experimental treatment and will be carried out as described in Section 13.4.5. It will include tabulation of all cases entered and those excluded from the analyses; the distribution of the important prognostic baseline variables; safety treatments; treatment compliance; and observed results with respect to the primary and secondary endpoints will be shown. All eligible patients randomized will be included in the comparison and will be grouped by assigned treatment in the analysis (intent-to-treat analysis). In addition, exploratory analyses of treatment comparisons of the primary and secondary survival endpoints will be tested using the Cox or Fine and Gray’s proportional hazard model that includes treatment arms, the stratification factors (risk group and RT modality), age, and race (as appropriate).

13.4.8 Analysis for Endpoints Related to Quality of Life (QOL)
**Patient accrual for the QOL measurements will be limited to 230 cases in each arm.** Note: The quality of life (QOL) component of this study closed to patient accrual on 3/9/15. We will have 2 co-primary QOL endpoints of EPIC-26 bowel/rectal and urinary/irritative domains, analyzed at 6 months post-RT. From the EPIC home page: http://roadrunner.cancer.med.umich.edu/epic/, for 1 domain as the primary endpoint (significance level 0.05 and 90% power), the required sample size is 86 patients (per arm). Since there will be 2 domains used, a 20% adjustment for multiplicity is employed, so that the required sample size for 2 domains is 108 patients (per arm). A current analysis of EPIC numbers from RTOG 0415 indicated that, of 971 patients consenting to the QOL portion of the study, 886 patients (91%) completed both the bowel and urinary irritative domains at baseline. Additionally, of these 886 patients, only 464 patients (52%) completed the same domains at 6 months (this is the first time point past baseline). Using these numbers as an expectation of missing data for RTOG 0924, the projected sample size would need to be about 230 patients (per arm) to achieve 90% power. Differences in EPIC domains between NHT+RT and RT will be based on the minimally important difference (MID). In Dunn et al. (2009), the upper limit MID...
values were determined to be 6 points and 7 points for the bowel and urinary irritative EPIC-26 domains, respectively. These differences correspond to \( \frac{1}{2} \) SD (effect size 0.5).

Quality of life will be assessed via the following instruments: the Expanded Prostate Cancer Index (EPIC), the Patient-Reported Outcome Measurement Information System (PROMIS) fatigue domain, and the EuroQol (EQ-5D).

Information regarding potential confounds will also be collected in a short form (QL) using limited questions to minimize patient burden. This information can be used to evaluate the potential impact of these confounding factors on fatigue. Patient responses to the following will be collected in the QL form: muscle weakness (one item), overall sleep quality as measured by one item from the Pittsburgh Sleep Quality Index (PSQI) [Buysse 1989] and level of physical activity as measured by the Godin Leisure-Time Exercise Questionnaire (GLTEQ) [Godin 1986; Gionet 1989]. Anxiety/depression is also a potential confound with fatigue and patient responses to the anxiety/depression item in the EQ-5D can be used.

Protocol-eligible patients will be included in the QOL analysis only if they agree to participate in the QOL portion of this study. All the QOL instruments (EPIC-26, PROMIS fatigue domain, EQ-5D) will be collected on all cases participating in this portion of the trial. Patients will complete the EPIC-26, PROMIS fatigue domain, and the EQ-5D at pretreatment (baseline), the week prior to starting RT, and 6 months, 1 year and 5 years after therapy starts. At the same time points, the QL form (i.e., one item from the PSQI, 3 items from the GLTEQ, and one question regarding general muscle weakness) will be collected. In addition, in order to correlate fatigue with the cytokine changes, the PROMIS-fatigue short form (and the associated questions) also will be collected at the following time points: the last week of RT, and 3 months post RT. NRG Oncology provides individualized patient calendars available to Investigators and Research Associates 24/7 on the RTOG/NRG Oncology web site.

We will describe the distributions of QOL data collection patterns over all collection points in each treatment arm. Longitudinal data analysis, specifically the general linear mixed-effect model (Verbeke 2000) will be performed to describe the change trend of the EPIC-26, PROMIS fatigue domain, and the EQ-5D across the 2 treatments. The primary objective in HRQOL analysis is to determine the QOL differences. The response will be the change of measurement from baseline for each measurement. The model will include the baseline and stratification variables (risk group, comorbidity score, and RT modality).

The PROMIS fatigue domain consists of 7 questions to quantify the fatigue continuum (i.e., high to low), and good precision of measurement (discrimination function). Each question has a 5-point Likert scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). The EQ-5D is a 2-part self-assessment questionnaire and only the first part will be used. This consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a 3-point Likert scale (1=no problems, 2-moderate problems, and 3-extreme problems). There are 243 \( (=3^5) \) health states. We will transform the 5-item index score into a utility score between 0 (worst health state) and 1 (best health state) for comparative purposes. We hypothesize that the measurements from the GI or GU domains of the EPIC-26 instrument will be worse in Arm 2 than Arm 1 (at 6 months) because of the aggressiveness of treatment. We also hypothesize that measurements from the PROMIS fatigue domain will be higher in Arm 2 than in Arm 1.

To address the non-ignorable missing data caused by censoring survival time, the data analysis also will include patients who have not died. To examine trade-offs between survival time and QOL, we will combine them for each patient into a single measurement: Quality Adjusted Life Year (QALY). If (and only if) the primary endpoint hypothesis is substantiated, we will conduct a cost-utility analysis. The cost-utility analysis will not be done until after the primary endpoint results are published. QALY is defined by the weighted sum of different time episodes added up to a total quality-adjusted survival time. These health state-based methods of quality-adjusted survival analysis are known as the quality-adjusted time without symptoms and toxicity method (Q-TwiST) [Glasziou 1990].
\[
\text{Q-TwiST} = \sum_{i=1}^{k} q_i s_i
\]

where \( q_i \) is the quality (the utility coefficient) of health state \( i \), \( s_i \) is the duration spent in each health state, and \( k \) is the number of health states. We will use Glasziou’s multiple health-state (Q-TwiST) models to use the repeated measures of EQ-5D. Because Glasziou’s method incorporates longitudinal QOL data into an analysis of quality-adjusted survival, the health-stated model must be constructed on the following assumptions:

A1) QOL is independent from treatment.
A2) A health state is independent from previous states.
A3) Proportionality of quality-adjusted duration and duration of the actual state of health

Assumption A1 can be checked by plotting QOL over time according to treatment, and the t test can be used to compare the mean QOL scores of each treatment arm. Assumption A2 can be checked by comparing the QOL for patient groups in a given health state where the groups are defined by duration of previous health state experience using a regression model. Suitable checks for assumption A3 at minimum would be a simple plot. If data does not support these assumptions, we will use a method which uses the longitudinal QOL data directly. Cost-utility will be analyzed at 2 time points: at 1 year and 5 years posttherapy. We will use the 5-item utility score in EQ-5D for the cost-utility analysis. We will use the Z-test to test the hypothesis that the cost-utility in the 2 treatment arms is the same with a significance level of 0.05 and a 2-sided test.

To inspect the missing data mechanism, we will use at least a graphical method. A missing completely at random (MCAR) mechanism exists when missing values are randomly distributed across all observations. A missing at random (MAR) mechanism exists when values are not randomly distributed across all observations, rather than one or more sub-samples. If the cause of missing data is MCAR, listwise deletion (complete case analysis) will be done. If the MAR assumption is supported by the data, then an imputation method such as multiple imputation will be applied to impute missing data. If the MAR assumption is not supported by the data, then adjusting for covariates (such as the baseline QOL score) might reduce the conditional association between outcomes and missing values. If missing data patterns look similar when stratified by such covariate(s), then an analysis that adjusts for such covariate(s) will be conducted and an imputation method such as multiple imputation will be applied. If approximate conditional independence cannot be obtained with any set of covariates, then MNAR (missing not at random) must be addressed by an explicit model for the missing data mechanism and then an imputation method such as multiple imputation will be applied. All results from the imputed analysis using the multiple imputation will be compared to the complete case analysis results to assess any potential biases. We will conduct a sensitivity analysis using various assumptions on the missing data to determine what impact missing data and imputation methods have on the study conclusions. Imputation methods when prescribed by validated instrument developers will be employed first. Additional methods or methods used when none are described for a given instrument may include linear mixed-effects models to obtain separate estimates for the QOL outcome within strata based on missing data patterns (Donaldson 2005). NRG Oncology recognizes that all options are subject to bias and analysis with more than one method for consistency across methods is prudent.

13.4.9 Analysis for Translational Research

The feasibility of proposed translational studies will be assessed following completion of accrual and sample collection. These studies are intentionally similar in design to those included on RTOG 0815 to facilitate combined analysis. In the next few years, it is anticipated that DNA samples from independent work already in progress will be used in genome wide association studies (GWAS) to discover SNPs associated with the development of fatigue following radiotherapy for prostate cancer. DNA samples from both 0815 and 0924 will therefore serve as a critical replication cohort to validate the SNPs that will be identified through the GWAS.
### 13.5 Gender and Minorities

#### Projected Distribution of Gender and Minorities

<table>
<thead>
<tr>
<th>Ethnic Category: Total of all subjects</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hispanic or Latino</td>
<td>N/A</td>
<td>81</td>
<td>81</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>N/A</td>
<td>2,499</td>
<td>2,499</td>
</tr>
<tr>
<td><strong>Ethnic Category: Total of all subjects</strong></td>
<td>N/A</td>
<td>2,580</td>
<td>2,580</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Racial Category: Total of all subjects</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Indian or Alaskan Native</td>
<td>N/A</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Asian</td>
<td>N/A</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Black or African American</td>
<td>N/A</td>
<td>661</td>
<td>661</td>
</tr>
<tr>
<td>Native Hawaiian or other Pacific Islander</td>
<td>N/A</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>White</td>
<td>N/A</td>
<td>1887</td>
<td>1887</td>
</tr>
<tr>
<td><strong>Racial Category: Total of all subjects</strong></td>
<td>N/A</td>
<td>2,580</td>
<td>2,580</td>
</tr>
</tbody>
</table>
REFERENCES (4/20/16)


Dunn, RL, Sandra, MG, Wei, JT. Minimally important difference for the expanded prostate cancer index composite (EPIC). *ISOQOL*, 2009.


### APPENDIX I, STUDY PARAMETER TABLE: PRE-TREATMENT ASSESSMENTS (4/27/15)

<table>
<thead>
<tr>
<th>Pre-Treatment Assessments (may be required for eligibility)</th>
<th>Within 180 days prior to registration</th>
<th>Within 120 days prior to registration</th>
<th>Within 90 days prior to registration</th>
<th>Within 60 days prior to registration</th>
<th>Week prior to RT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histo/cyto eval</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History/physical; DRE</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic +/- abdominal CT or MR</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone scan</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status</td>
<td>Pre-treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC w/ diff</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate volume measurement</td>
<td></td>
<td>For patients undergoing brachytherapy only</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST or ALT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>QOL assess**: EPIC, PROMIS, EQ5D, PSQI/GLTEQ <em>(if patient consents)</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-treatment</td>
</tr>
<tr>
<td>Tissue, blood for plasma*, serum, DNA, and urine <em>(if patient consents)</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-treatment</td>
</tr>
</tbody>
</table>

*Collection of plasma prior to RT and during the last week of RT is mandatory for patients consenting to the QOL portion of the study.*

---Continued on next page---
APPENDIX I, STUDY PARAMETER TABLE: ASSESSMENTS DURING RADIATION TREATMENT (4/27/15)

<table>
<thead>
<tr>
<th>Assessments During RT</th>
<th>Weekly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weekly physical</td>
<td>X</td>
</tr>
<tr>
<td>Performance status</td>
<td>X</td>
</tr>
<tr>
<td>CBC w/ diff</td>
<td></td>
</tr>
<tr>
<td>AST or ALT</td>
<td>As clinically indicated during radiation therapy</td>
</tr>
<tr>
<td>Tumor response evaluation; DRE</td>
<td>As clinically indicated</td>
</tr>
<tr>
<td>Adverse event evaluation</td>
<td>X</td>
</tr>
<tr>
<td>QOL assess**: PROMIS, PSQI/GLTEQ only (if patient consents)</td>
<td>Last week of radiation therapy</td>
</tr>
<tr>
<td>Plasma* (if patient consents)</td>
<td></td>
</tr>
</tbody>
</table>

*Collection of plasma prior to RT and during the last week of RT is mandatory for patients consenting to the QOL portion of the study.

-Continued on next page-
APPENDIX I, STUDY PARAMETER TABLE: ASSESSMENTS IN FOLLOW-UP (2/26/14)

<table>
<thead>
<tr>
<th>Assessments</th>
<th>3 months post RT</th>
<th>6 months post RT</th>
<th>q 3 mos for year 1</th>
<th>q 6 mos years 2 through 5</th>
<th>1 year post RT</th>
<th>5 years post RT</th>
<th>Annually after year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic +/- abdominal CT or MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As clinically indicated during follow up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Performance status</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>CBC w/ diff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>As clinically indicated during follow up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor response evaluation; DRE</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Adverse event evaluation</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QOL assess*: EPIC, PROMIS, EQ5D, PSQI/GLTEQ (if patient consents)</td>
<td>PROMIS + PSQI/ GLTEQ only</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>


APPENDIX II
ZUBROD PERFORMANCE SCALE

0  Fully active, able to carry on all predisease activities without restriction

1  Restricted in physically strenuous activity but ambulatory and able to carry work of a light or sedentary nature. For example, light housework, office work

2  Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours

3  Capable of only limited self-care, confined to bed or chair 50% or more of waking hours

4  Completely disabled. Cannot carry on self-care. Totally confined to bed

5  Death
### APPENDIX III
### AJCC STAGING SYSTEM
### PROSTATE, 7th Edition
### DEFINITIONS OF TNM

#### Primary Tumor, Clinical (T)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>T1</td>
<td>Clinically inapparent tumor neither palpable nor visible by imaging</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor incidental histologic finding in 5% or less of tissue resected</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor incidental histologic finding in more than 5% of tissue resected</td>
</tr>
<tr>
<td>T1c</td>
<td>Tumor identified by needle biopsy (e.g., because of elevated PSA)</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor confined with prostate*</td>
</tr>
<tr>
<td>T2a</td>
<td>Tumor involves one-half of one lobe or less</td>
</tr>
<tr>
<td>T2b</td>
<td>Tumor involves more than one-half of one lobe but not both lobes</td>
</tr>
<tr>
<td>T2c</td>
<td>Tumor involves both lobes</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor extends through the prostate capsule**</td>
</tr>
<tr>
<td>T3a</td>
<td>Extracapsular extension (unilateral or bilateral)</td>
</tr>
<tr>
<td>T3b</td>
<td>Tumor involves the seminal vesicle(s)</td>
</tr>
<tr>
<td>T4</td>
<td>Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles and/or pelvic wall</td>
</tr>
</tbody>
</table>

*Note: Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c

**Note: Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified not as T3 but as T2.

#### Primary Tumor, Pathologic (pT) *

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pT2</td>
<td>Organ confined</td>
</tr>
<tr>
<td>pT2a</td>
<td>Unilateral, one-half of one side or less</td>
</tr>
<tr>
<td>pT2b</td>
<td>Unilateral, involving more than one-half of side but not both sides</td>
</tr>
<tr>
<td>pT2c</td>
<td>Bilateral disease</td>
</tr>
<tr>
<td>pT3</td>
<td>Extraprostatic extension</td>
</tr>
<tr>
<td>pT3a</td>
<td>Extraprostatic extension or microscopic invasion of bladder neck**</td>
</tr>
<tr>
<td>pT3b</td>
<td>Seminal vesicle invasion</td>
</tr>
<tr>
<td>pT4</td>
<td>Invasion of rectum, levator muscles, and/or pelvic wall</td>
</tr>
</tbody>
</table>

*Note: There is no pathologic T1 classification

**Note: Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease).

#### Regional Lymph Nodes (N)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes were not assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in regional lymph node(s)</td>
</tr>
</tbody>
</table>

*Pathologic*

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pNX</td>
<td>Regional nodes not sampled</td>
</tr>
<tr>
<td>pN0</td>
<td>No positive regional nodes</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastases in regional node(s)</td>
</tr>
</tbody>
</table>
### Distant Metastasis (M)*
- **M0** No distant metastasis
- **M1** Distant metastasis
  - **M1a** Nonregional lymph node(s)
  - **M1b** Bone(s)
  - **M1c** Other site(s) with or without bone disease

*Note: When more than one site of metastasis is present, the most advanced category is used; pM1c is most advanced.

### Histologic Grade (G)
- **Gleason X** Gleason score cannot be processed
- **Gleason ≤6** Well-differentiated (slight anaplasia)
- **Gleason 7** Moderately differentiated (moderate anaplasia)
- **Gleason 8-10** Poorly differentiated/undifferentiated (marked anaplasia)

### Anatomic Stage/Prognostic Groups*

<table>
<thead>
<tr>
<th>Stage</th>
<th>T1a-c</th>
<th>N0</th>
<th>M0</th>
<th>PSA &lt;10</th>
<th>Gleason ≤6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>PSA &lt;10</td>
<td>Gleason ≤6</td>
</tr>
<tr>
<td></td>
<td>T1-2a</td>
<td>N0</td>
<td>M0</td>
<td>PSA X</td>
<td>Gleason X</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T1a-c</td>
<td>N0</td>
<td>M0</td>
<td>PSA &lt;20</td>
<td>Gleason 7</td>
</tr>
<tr>
<td></td>
<td>T1a-c</td>
<td>N0</td>
<td>M0</td>
<td>PSA ≥10&lt;20</td>
<td>Gleason ≤6</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>PSA &lt;20</td>
<td>Gleason ≤7</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
<td>PSA &lt;20</td>
<td>Gleason ≤7</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
<td>PSA X</td>
<td>Gleason X</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2c</td>
<td>N0</td>
<td>M0</td>
<td>Any PSA</td>
<td>Any Gleason</td>
</tr>
<tr>
<td></td>
<td>T1-2</td>
<td>N0</td>
<td>M0</td>
<td>PSA ≥20</td>
<td>Any Gleason</td>
</tr>
<tr>
<td></td>
<td>T1-2</td>
<td>N0</td>
<td>M0</td>
<td>Any PSA</td>
<td>Gleason ≥8</td>
</tr>
<tr>
<td>Stage III</td>
<td>T3a-b</td>
<td>N0</td>
<td>M0</td>
<td>Any PSA</td>
<td>Any Gleason</td>
</tr>
<tr>
<td>Stage IV</td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>Any PSA</td>
<td>Any Gleason</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td>Any PSA</td>
<td>Any Gleason</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>Any PSA</td>
<td>Any Gleason</td>
</tr>
</tbody>
</table>

*Note: When either PSA or Gleason is not available, grouping should be determined by T stage and/or either PSA or Gleason as available.

---

Shipping Instructions:

U.S. Postal Service Mailing Address: For FFPE or Non-frozen Specimens Only
NRG Oncology Biospecimen Bank
University of California San Francisco
Department Of Radiation Oncology- Box 1800
2340 Sutter Street, Room S341
San Francisco, CA 94143

Courier Address (FedEx, UPS, etc.): For ALL Frozen or Trackable Specimens
NRG Oncology Biospecimen Bank
University of California San Francisco
2340 Sutter Street, Room S341
San Francisco, CA 94115

- Include all NRG Oncology paperwork in pocket of biohazard bag.
- Check that the Specimen Transmittal Form (STF) has the consent boxes checked off, and has an RTOG label with study, case number, institution name, institution number and patient initials.
- Check that all samples are labeled with the NRG Oncology study and case number, and include date of collection as well as collection time point (e.g., pretreatment, post-treatment).

FFPE Specimens:
- Slides should be shipped in a plastic slide holder/slide box. Place a small wad of padding in top of the container. If you can hear the slides shaking it is likely that they will break during shipping.
- FFPE Blocks can be wrapped with paper towel, or placed in a cardboard box with padding. Do not wrap blocks with bubble wrap or gauze. Place padding in top of container so that if you shake the container the blocks are not shaking. If you can hear the block shaking it might break during shipping.
- Slides, Blocks, or Plugs can be shipped ambient or with a cold pack either by United States Postal Service (USPS) to the USPS address (94143) or by Courier to the Street Address (94115). Do NOT ship on Dry Ice.

Frozen Specimens:
- Multiple cases may be shipped in the same cooler, but make sure each one is in a separate bag and clearly identified. If possible keep Serum, Plasma, and Whole Bloods in separate bags.
- Place specimens and absorbent shipping material in Styrofoam cooler filled with dry ice (at least 7 lbs). There should be plenty of dry ice under and above the specimens. If the volume of specimens is greater than the volume of dry ice then ship in a larger Styrofoam box, or two separate boxes. Any Styrofoam box can be used, as long as it is big enough.
- Specimens received thawed due to insufficient dry ice or shipping delays will be discarded and the site will be notified.
- Send frozen specimens on dry ice via overnight courier to the address above. Specimens should only be shipped Monday through Wednesday (Monday-Tuesday for Canada) to prevent thawing due to delivery delays. Saturday or holiday deliveries cannot be accepted. Samples can be stored frozen at -80°C until ready to ship.

For Questions regarding collection kits/shipping please contact the NRG Oncology Biospecimen Bank by e-mail: NRGBB@ucsf.edu or phone: 415-476-7864 or Fax: 415-476-5271
APPENDIX IV (continued)
NRG ONCOLOGY BLOOD COLLECTION KIT INSTRUCTIONS

This Kit is for collection, processing, storage, and shipping of serum, plasma and whole blood:

**Kit contents**: Sites are required to supply the blood draw tubes.
- Twenty (20) 1 ml cryovials for all time points and draws
- Biohazard bags and Absorbent shipping material
- One Styrofoam container (inner) and Cardboard shipping (outer) box per case
- UN1845 DRY Ice Sticker and UN3373 Biological Substance Category B Stickers
- Specimen Transmittal Form (ST Form) and Kit Instructions

**PREPARATION AND PROCESSING OF SERUM, PLASMA AND WHOLE BLOOD:**

(A) **Serum (if requested): Red Top Tube (two 5 ml tubes or one 10 ml tube)**
- Label Five (5) 1ml cryovials for the serum collected. Label them with the RTOG/NRG study and case number, collection date, time, and time point, and clearly mark cryovials “serum”.

**Process:**
1. Allow one red top tube to clot for 30 minutes at room temperature.
2. Spin in a standard clinical centrifuge at ~2500 RPM for 10 minutes at 4°C (preferred). If sites are unable to process samples at 4°C then spinning at room temperature is acceptable if done within 2 hours of draw but must be noted on the STF.
3. Aliquot 0.5 ml serum into as many cryovials as are necessary for the serum collected (up to 5) labeled with RTOG/NRG study and case numbers, collection date/time, protocol time-point collected (e.g. pretreatment, post-treatment), and clearly mark specimen as “serum”.
4. Place cryovials into biohazard bag and immediately freeze tubes upright at -70 to -90°C, and store frozen until ready to ship. See below for storage conditions.
5. Store serum at -70 to -90°C until ready to ship on dry ice. See below for storage conditions.

(B) **Plasma (If requested): Purple Top EDTA tube #1 (two 5 ml tubes or one 10 ml tube)**
- Label Five (5) 1ml cryovials for the plasma collected. Label them with the NRG Oncology study and case number, collection date/time, time point collected and clearly mark cryovials “plasma”.

**Process:**
1. After collection, invert tube(s) multiple times to ensure adequate mixing of EDTA.
2. Centrifuge specimen(s) within one hour of collection in a standard clinical centrifuge at ~2500 RPM for 10 minutes at 4°C (preferred). If sites are unable to process samples at 4°C then spinning at room temperature is acceptable if done within 2 hours of draw but must be noted on the STF.
3. If the interval between specimen collection and processing is anticipated to be more than one hour, keep specimen on ice until centrifuging is performed.
4. Carefully pipette and aliquot 0.5 ml plasma into up to 5 cryovials as are necessary for the plasma collected labeled with NRG Oncology study and case numbers, collection date/time, time point collected and clearly mark specimen as “plasma”. Avoid pipetting up the buffy coat layer.
5. Place cryovials into biohazard bag and immediately freeze tubes upright at -70 to -90°C.
6. Store frozen plasma until ready to ship on dry ice.
7. See below for storage conditions.

**PLEASE MAKE SURE THAT EVERY SPECIMEN IS LABELED and include collection time point on the STF.**

(continued on next page)
APPENDIX IV (continued)
NRG ONCOLOGY BLOOD COLLECTION KIT INSTRUCTIONS

(C) Whole Blood for DNA (if requested): Purple Top EDTA tube #2 (one 5 ml tube or one 10 ml tube)
☐ Label as many 1ml cryovials (three to 5) as necessary for the whole blood collected. Label them with the NRG Oncology study and case number, collection date/time, and time point, and clearly mark cryovials "blood".

Process:
1. After collection, invert tube(s) multiple times to ensure adequate mixing of EDTA. Blood can also be mixed for 5 minutes on a mixer at room temperature.
2. Carefully pipette and aliquot 1.0 ml blood into as many cryovials as are necessary for the blood collected (3 to 5) labeled with NRG Oncology study and case numbers, collection date/time, time point collected and clearly mark specimen as “blood”.
3. Place cryovials into biohazard bag and freeze tubes upright immediately at -70 to -80 °Celsius.
4. Store blood samples frozen until ready to ship on dry ice.
5. See below for storage conditions.

PLEASE MAKE SURE THAT EVERY SPECIMEN IS LABELED and include collection time point on STF.

Freezing and Storage:
☐ Freeze Blood samples in a -80°C Freezer or on Dry Ice or snap freeze in liquid nitrogen.
☐ Store at -80°C (-70°C to -90°C) until ready to ship.
If a -80°C Freezer is not available,
   ▪ Samples can be stored short term in a -20°C freezer (non-frost free preferred) for up to one week (please ship out Monday-Wednesday only; Canada: Monday-Tuesday only).
   OR:
   ▪ Samples can be stored in plenty of dry ice for up to one week, replenishing daily (please ship out on Monday-Wednesday only; Canada: Monday-Tuesday only).
   OR:
   ▪ Samples can be stored in liquid nitrogen vapor phase (ship out Monday-Wednesday only; Canada: Monday-Tuesday only).
☐ Please indicate on Specimen Transmittal Form the storage conditions used and time stored.

Shipping/Mailing:
☐ Ship specimens on Dry Ice overnight Monday-Wednesday (Monday-Tuesday from Canada) to prevent thawing due to delivery delays. Saturday and holiday deliveries cannot be accepted.
☐ Include all NRG Oncology paperwork in a sealed plastic bag and tape to the outside top of the Styrofoam box.
☐ Wrap frozen specimens of same type (i.e., all plasma together and whole bloods together) in absorbent shipping material and place each specimen type in a separate biohazard bag. Place specimen bags into the Styrofoam cooler and fill with plenty of dry ice (7-10 lbs/3.5kg minimum). Add padding to avoid the dry ice from breaking the tubes.
☐ Place Styrofoam coolers into outer cardboard box, and attach shipping label and UN3373 and UN1895 stickers to outer cardboard box.(continued on next page)
Multiple cases may be shipped in the same cooler, but make sure each one is in a separate bag and that there is enough room for plenty of dry ice. There should always be more dry ice than samples. Add padding to avoid the dry ice from breaking the tubes.

For questions regarding collection, shipping or to order a Blood Collection Kit, please e-mail NRGBB@ucsf.edu or call (415)476-7864.

**Shipping Address:**
Courier Address (FedEx, UPS, etc.): For ALL Frozen Specimens
NRG Oncology Biospecimen Bank
University of California San Francisco
2340 Sutter Street, Room S341
San Francisco, CA 94115
For questions, call 415-476-7864 or e-mail: NRGBB@ucsf.edu
This Kit is for collection, processing, storage, and shipping of urine specimens.

Kit Contents:
- One (1) Sterile Urine collection cup
- Two 7 ml disposable pipettes
- Absorbent paper towel
- Two 15 ml polypropylene centrifuge tubes
- Biohazard bags
- Parafilm for sealing outside of tubes

Preparation and Processing of Urine Specimens:

Process:
- A clean catch urine specimen will be collected. To collect the specimen, use the following instructions:
  - Males should wipe clean the head of the penis and females need to wipe between the labia with soapy water/cleansing wipes to remove any contaminants.
  - After urinating a small amount into the toilet bowl to clear the urethra of contaminants, collect a sample of urine in the collection cup.
  - After 10-25 mL urine has been collected, remove the container from the urine stream without stopping the flow of urine.
  - Finish voiding the bladder into the toilet bowl.
- Aliquot 5-10 mls of Urine into each of two 15 ml polypropylene centrifuge tubes (disposable pipets are provided in the kit). Do not fill with more than 10 mls to avoid cracking of tubes due to expansion during freezing. Replace the cap and tighten on the outside rim of the urine tube to prevent leakage.
- Use parafilm to seal the cap around the outside rim of the urine tube to prevent leakage.
- Discard remaining Urine and collection cup.
- Label the specimen with the NRG Oncology study and case number, collection date and time, point of collection, and clearly mark specimens as “urine”.
- Wrap Urine Tubes with absorbent material (paper towels) and place into biohazard bag and seal the bag. Freeze and store Urine samples in a -20°C or -80°C freezer until ready to ship.

PLEASE MAKE SURE THAT EVERY SPECIMEN IS LABELED with NRG Oncology study and case numbers, collection date/time, and time point collected (e.g. pretreatment, post-treatment).

Storage and Shipping:

Freezing and Storage:
- Urine specimens may be sent in batches or with other frozen biospecimens, if within 30-60 days of collection. Store at -20°C or -80°C (-70°C to -90°C) until ready to ship. If a -80°C Freezer is not available:
  - Samples can be stored short term in a -20°C freezer (non-frost free preferred) for up to one week (please ship out Monday-Wednesday only; Canada: Monday-Tuesday only).

OR:
  - Samples can be stored in plenty of Dry Ice for up to one week, replenishing daily (please ship out Monday-Wednesday only; Canada: Monday-Tuesday only).
  - Please indicate on Specimen Transmittal Form the storage conditions used and time stored.

Shipping/Mailing:
- Ship specimens on Dry Ice overnight Monday-Wednesday (Monday-Tuesday from Canada) to prevent thawing due to delivery delays. Saturday and holiday deliveries cannot be accepted.
- Include all NRG Oncology paperwork in a sealed plastic bag and tape to the outside top of the Styrofoam box.
- Place sealed specimen bags into the Styrofoam cooler and fill with plenty of dry ice (7-10 lbs/3.5kg minimum). **Add padding to avoid the dry ice from breaking the tubes.**
- Place Styrofoam coolers into outer cardboard box, and attach shipping label and UN3373 and UN1895 stickers to outer cardboard box.
- Multiple cases may be shipped in the same cooler, but make sure each one is in a separate bag and that there is enough room for plenty of dry ice. **Add padding to avoid the dry ice from breaking the tubes.**
- Samples received thawed will be discarded, and a notification will be sent immediately to the Principal Investigator and Clinical Research Assistant of the submitting institution. The institution should send a subsequent sample, collected as close as possible to the original planned collection date.
- For questions regarding ordering, collection, or shipping of a Urine Collection Kit, please e-mail NRGGB@ucsf.edu or call (415) 476-7864 or fax (415) 476-5271.

Shipping Address: FedEx/UPS/Courier address (For all frozen samples)
NRG Oncology Biospecimen Bank at UCSF
2340 Sutter Street, Room S341, San Francisco, CA 94115
Contact Phone: (415) 476-7864

RTOG 0924, Version Date: 4/20/16